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ABSTRACT OF DISSERTATION

PHASE BEHAVIOR OF AMORPHOUS SOLID DISPERSIONS: MISCIBILITY AND
MOLECULAR INTERACTIONS

Over the past few decades, amorphous solid dispersions (ASDs) have been of
great interest to pharmaceutical scientists to address bioavailability issues associated with
poorly water-soluble drugs. ASDs consist of an active pharmaceutical ingredient (API)
that is typically dispersed in an inert polymeric matrix. Despite promising advantages, a
major concern that has resulted in limited marketed formulations is the physical
instability of these complex formulations. Physical instability is often manifested as
phase heterogeneity, where the drug and carrier migrate and generate distinct phases,
which can be a prelude to recrystallization. One important factor that dictates the physical
stability of ASDs is the spatial distribution of API in the polymeric matrix. It is generally
agreed that intimate mixing of the drug and polymer is necessary to achieve maximum
stabilization, and thus understanding the factors controlling phase mixing and nanodomain structure of ASDs is crucial to rational formulation design. The focus of this
thesis work is to better understand the factors involved in phase mixing on the nanometric
level and get insights on the role of excipients on overall stabilization of these systems.
The central hypothesis of this research is that an intimately mixed ASD will have better
physical stability as compared to a partially homogeneous or a non-homogeneous system.
Our approach is to probe and correlate phase homogeneity and intermolecular drugexcipient interactions to better understand the physical stability of ASDs primarily using
solid-state nuclear magnetic resonance (SSNMR) spectroscopy and other solid-state
characterization tools. A detailed investigation was carried out to understand the role of
hydrogen bonding on compositional homogeneity on different model systems. A
comprehensive characterization of ternary ASDs in terms of molecular interactions and
physical stability was studied. Finally, long-term physical stability studies were
conducted in order to understand the impact of different grades of a cellulosic polymer on
phase homogeneity for two sets of samples prepared via different methods. Overall,
through this research an attempt has been made to address some relevant questions
pertaining to nano-phase heterogeneity in ASDs and provide a molecular level
understanding of these complex systems to enable rational formulation design.

KEYWORDS: Amorphous solid dispersions, Solid-state nuclear magnetic resonance
spectroscopy, Drug-polymer miscibility, Hydrogen bonding, Physical
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CHAPTER 1. INTRODUCTION: FUNDAMENTALS OF AMORPHOUS SOLID DISPERSIONS
1.1

Introduction
Oral route for drug delivery is considered the most preferred for its ease of

administration, high patient compliance, cost effectiveness and flexible dosage design.1
After oral ingestion of the solid dosage form, the drug is released in gastrointestinal (GI)
tract, dissolved in GI fluids, then absorbed across the intestinal mucosa and passed
through the liver to systemic circulation to reach its site of action.2 For the drug to
dissolve in GI medium, appreciable aqueous solubility is required for adequate
absorption and oral bioavailability. Thus, the two key properties of drug candidates that
govern their extent of oral bioavailability are aqueous solubility and intestinal
permeability. Based on these two properties, Amidon et al., proposed the
biopharmaceutics classification system (BCS) in the year 1995.3 According to BCS, drug
substances are classified into four classes based on their aqueous solubility and intestinal
permeability (Figure 1.1). These four categories include drugs with high solubility/high
permeability (class I), low solubility/high permeability (class II), high solubility/low
permeability (class III), and low solubility/low permeability (class IV). A drug substance
is considered “highly soluble” when the highest dosage strength is soluble in 250 mL or
less in aqueous media (pH 1-7.5) whereas the drug is considered “highly permeable”
when ≥ 90% of the administered dose is absorbed across GI barrier.4
Combinatorial chemistry and high-throughput screening employed in drug
discovery have significantly increased the number of poorly water soluble drug
candidates.5,6 Poor aqueous solubility is responsible for a large number of attritions with
the majority of new chemical entities (NCEs) with challenging physicochemical
1

properties. This has emerged as a major obstacle in drug discovery and development.7 It
is estimated that approximately over 75 % of drug candidates, 60 % of NCEs, and 90 %
of marketed drugs belong to either BCS class II or class IV.7-10 Thus, there is an
increased interest in developing efficient formulation strategies for such drug candidates.
This has resulted in progress of BCS class II compounds further along the drug
development stages and several have become successful marketed drugs.2,5
Some approaches that have been utilized successfully to address low drug
solubility include salt formation, crystal modification, pH modification, cyclodextrin
complexation, particle size reduction, lipid based systems, and amorphization.11,12
Among the approaches stated above, amorphization is a prominent solubilization
strategy. Amorphous solids are characterized by short range order and high internal
energy.13 Generally, amorphous drugs have higher solubility than the corresponding
crystalline form since the need of overcoming the lattice energy for the solubilization
process is waived off.14 Studies point out that an amorphous form of a drug can generate
1.1 to 1000 fold increase in solubility of the same drug compared to its crystalline
form.15,16 These benefits come with a cost and the enhanced thermodynamic properties
also accounts for higher chemical reactivity and crystallization tendency that can occur
during manufacturing, storage or dissolution.17 Hence, an amorphous form of drug is
seldom used alone.
An important strategy for stabilizing an amorphous drug against crystallization is
to disperse it into a polymer matrix, forming a solid dispersion.18,19 A solid dispersion
can potentially enhance the physical stability by reducing the molecular mobility of a
drug and increasing the diffusion length for the assembly of drug molecules into a drug
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rich phase or recrystallization.20,21 In spite of the benefits offered by this formulation
technology, developing a robust solid dispersion formulation still remains a daunting
task for pharmaceutical scientists. Therefore, a significant part of pharmaceutical
academic and industrial research is directed towards understanding the critical factors for
physical stabilization of amorphous drugs. In this chapter, we will discuss the
characteristics of amorphous state and factors affecting the physical stability and
physicochemical properties of amorphous solid dispersion. In addition, preparation
methods and the characterization techniques are also reviewed. Last but not least, a
comprehensive overview of available literature on amorphous solid dispersions (ASDs)
is presented here.

1.2

The Amorphous State
A convenient way to visualize the energetics of the amorphous state can be

achieved through drawing the schematic representation of enthalpy (or volume)
variations as a function of temperature (Figure 1.2). If we consider a situation where
molten drug is cooled to the melting point (Tm) of the crystalline phase, which is a firstorder transition and leads to a decrease in free volume and enthalpy. However, if
crystallization is not allowed to occur then the material enters the “supercooled” liquid
state without depicting any discontinuity in H and V. The “supercooled” liquid state is
often called a rubbery state due to the high viscosity of the material. Further cooling will
result in substantial increase in viscosity and produce a glass at the glass transition state
(Tg), accompanied by a change of slope. It should be noted that the “glassy state” is a
non-equilibrium state and Tg can fluctuate with processing conditions and as a function
of the history of the sample, which implies that Tg is a thermal event affected by kinetic
3

factors.13 At temperatures below Tg, the material becomes brittle and extremely viscous
(>1012 Pa s).22 Moreover at temperatures below Tg, the real glass relaxes to reach
asymptotically the equilibrium state and when the material is re-heated to the Tg, the lost
enthalpy is recovered again.17 If the supercooled liquid curve is traced below Tg, there
comes a point where it meets the crystal curve at temperature known as the Kauzmann
temperature (TK). At TK, the configurational entropy of the system reaches zero and is
believed to be a temperature with zero mobility ensuring sufficient physical stability for
the sample.13
The amorphous state is characterized by the absence of long-range three
dimensional order and has enhanced thermodynamic properties in comparison to their
crystalline counterparts as a result possess higher apparent solubility. Since the
amorphous state is thermodynamically unstable, there is a tendency to approach a lower
energy level through a process of relaxation.23 In theory, three types of relaxations are
observed (α, β and γ relaxations). The slower, primary and universal motions involving
Tg belong to α relaxations while β relaxations represent faster, secondary local motions
of specific chemical groups or sequences and are dominant below the Tg. It is suggested
that α relaxations are the key kinetic factor for crystallization, whereas β relaxations are
responsible for crystallization below Tg for many systems.24 Besides these two relaxation
processes, γ relaxations are closely related to β relaxations but occur at lower
temperatures.23

1.3

Amorphous Solid Dispersions
Historically the term “solid dispersion” was first used by Chiou and Riegelmann

in 1971 who defined it as “a dispersion of one or more active ingredients in an inert
4

carrier at the solid state, prepared either by the melting, the solvent or the combined
melting solvent methods”.25 However, the concept was first used earlier where the drug
was delivered with a carrier as a eutectic mixture but it was Chiou and Riegelmann who
first proposed a classification system for solid dispersions.25,26 Since then, this
technology has been used as a viable formulation strategy to overcome the low oralbioavailability of BCS class II compounds. Before we discuss the other topics related to
this important platform technology, it is relevant to study briefly its classification system.

Figure 1.1. Biopharmaceutics classification system (BCS) and formulation approaches
applicable for different classes. Adapted from reference.12
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Figure 1.2. Schematic representation of thermodynamic relationship of amorphous and
crystalline states. The green curve represents Tg curve of a solid dispersion. TK:
Kauzmann temperature, Tg: glass transition, Tm: melting temperature. Modified from the
reference.17
1.3.1

Classification of Solid Dispersions
Depending on the molecular structure of active pharmaceutical ingredient (API)

in the carrier, the solid dispersions can be divided into crystalline solid dispersion and
amorphous solid dispersion (ASD). Furthermore, within crystalline solid dispersion two
classes exist: solid solution and eutectic mixture. Likewise, ASD group can be further
divided into two sub-groups: glass solutions and glass suspensions. Here, we restrict
ourselves to the ASD group, consisting of amorphous API and the carrier. The
classification system for solid dispersions is shown in Table 1.1.
6

In the case of glass solutions, the carrier is amorphous while the drug molecules
are molecularly dispersed in the amorphous matrix forming a homogenous single-phase
system. These days polymers such as synthetic poly(vinylpyrrolidone) (PVP),
semisynthetic hydroxypropyl methyl cellulose (HPMC) are employed as amorphous
carriers.27 An intimate mixing between the drug and polymer ensures a physically stable
system provided solubility of the drug in the polymer does not exceed. However, if drug
is present at supersaturated concentration, recrystallization may occur. For a system to
classify as a glass suspension, the drug is no longer dispersed molecularly within the
amorphous polymer and multiple phases exist. In such system, the drug usually exists as
a separate drug rich amorphous phase and may have higher tendency to recrystallize.
More recently a different system of classification has been proposed based on the
complexity of solid dispersions and their evolution over the time.19 Based on this
classification system, solid dispersions can be categorized into four generations (Figure
1.3). The generations highlight the advancement of knowledge and their composition.

Figure 1.3. Classification of solid dispersions and their properties. Adapted from
references.19,27
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Table 1.1. Classification of solid dispersions.
Number of Phases
State of API
1

2

Crystalline

Solid solution

Eutectic mixture

Amorphous

Glass solution

Glass suspension

1.3.2

Preparation Methods
Broadly, the preparation methods for ASDs can be classified into two major

groups: solvent based or fusion based.27 Each group encompasses many technologies
under it and the same is shown as a schematic in Figure 1.4.
1.3.2.1 Fusion Based Technologies
In general, fusion based approach involves heating the drug and carrier mixture
above their melting point or Tg and then cooling the mixture to kinetically trap the
amorphous form of the drug. The resultant solid sample is then crushed, pulverized and
sieved to reduce the particle size. Even though this approach is solvent-free and
frequently used, this method has some limitations such as thermolability of the drug and
carrier at high temperatures.27 In addition, the drug and carrier need be to miscible at
high temperatures as any immiscibility can potentially lead to phase separation from
inhomogeneous distribution of drug in the matrix.
Hot-melt extrusion (HME) is a popular fusion based technique that has been used
for manufacturing ASDs on an industrial scale. The technique has its origin in plastic
industry and known for its high scalability and applicability. In this method, the drug and
carrier are mixed together and pumped through a heated barrel by one or two screws
8

under pressure and then discharging the extrudate through a die to get product in a
specific shape such as a rod, pellet or tablet.28 The intense mixing and agitation forced by
rotating screws ensure homogenous mixing and also make the process continuous.29 In
order to lower the processing temperature or reduce the melt viscosity, low molecular
weight additives such as plasticizers are added.23 This technique offers many advantages
like solvent free method, efficient process, easy scale up and continuous manufacturing.
Moreover, another important advantage of HME in comparison with other fusion based
methods is the low residence time of the drug-polymer melt at higher temperature which
diminishes the risk of degradation in the case of thermolabile drug. This technology has
been successfully used for manufacturing marketed products like Kaletra, Onmel,
Rezuin, Norvir, and Zoladex.30
Other fusion based technologies that have been developed for ASDs include
KinetiSol®. KinetiSol® is a new upcoming technology that is specifically suitable for
thermolabile compounds as it uses shorter residence time than a regular HME process.30
It can work better with viscous melts and thus the use of plasticizers can be avoided.31
This technology is being developed for industrial manufacturing and there are no
marketed products yet being manufactured via this process.
1.3.2.2 Solvent Based Technologies
The solvent based technologies include spray drying, freeze drying, rotary
evaporation, supercritical fluid technology, fluid bed granulation, coprecipitation, spray
freeze drying and electrospining.27 With solvent based technologies, the common steps
involve preparation of drug carrier solution in a common solvent followed by
evaporation of the solvent to produce a solid sample. This approach is devoid of any
9

melting at elevated temperature and hence most suited for thermolabile APIs. An
important requirement for this approach is the sufficient solubility of API and the carrier
in a common solvent, which can be challenging at times. Solvent like methanol, ethanol,
methylene chloride, acetone, water or their mixtures have been employed and sometimes
surfactants are also incorporated to aid in solubilization. The main disadvantage of this
method is the issue of residual solvent, which is nearly impossible to remove completely
and may pose toxicity based on solvent(s) used.30 Also, the residual solvent can act like a
plasticizer and promote potential phase separation.32 Other challenges that are associated
with this approach are high production cost, extra infrastructure for solvent removal,
environmental concerns and potential explosion hazards.
Spray drying is the most industrially applicable technique based on solvent based
approach to be employed for ASDs manufacturing. It has been used in the field of
pharmaceuticals since 1970s and is known for its efficient processing.33 This unit
operation consists of drug-carrier solution or suspension that is atomized into fine
droplets and evaporating the droplets rapidly using a drying hot gas inside the drying
chamber followed by collection of solid particles in a cyclone. This technique has proven
to be effective method for preparation of ASDs and offers better process control with
desired particle properties.34 Compared to traditional solvent based methods like rotary
evaporation, this approach ensure better mixing and hence molecularly dispersed ASDs
are produced. It has been shown that phase separation in the final product can be
controlled through processing conditions.35 A typical schematic of spray drying process
is presented in Figure 1.5. Several marketed products prepared by this technology
include InCivek, Kalydeco, Intelence and Torcetrapib.30
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Figure 1.4. Commonly used methods in preparation of ASDs.

Figure 1.5. Schematic representation of spray-drying equipment. Taken from source.82

1.3.3

Characterization of Amorphous Solid Dispersions
The characterization of ASDs is very crucial in order to study their phase

behavior and require in-depth comprehensive characterization. A variety of
characterization tools are available and multiple analytical techniques are used in
conjunction to provide qualitative and quantitative information on crystallinity, phase
11

mixing, molecular mobility, intermolecular interactions, residual moisture/solvent
content etc. In this section, the focus is given to techniques that are most widely applied
such as differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD),
thermogravimetric analysis (TGA) and fourier transform infrared spectroscopy (FTIR).
A comparative analysis of commonly employed technique is presented in Table 1.2. For
this thesis work, special focus is given to solid-state nuclear magnetic resonance
(SSNMR) spectroscopy, which is covered in-depth in Chapter 2.
1.3.3.1 Differential Scanning Calorimetry
DSC has been used as a very important technique for examining the thermal
properties of ASDs like melting point, Tg event, enthalpy recovery, crystallinity,
polymorphic transitions etc.36 The operating principle involves heating the sample and
the empty reference pan inside the furnace and measuring the temperature difference
between them. The total heat flow can be described by:
𝑑𝑄
𝑑𝑇
= 𝐶𝑝 .
+ 𝑓(𝑡, 𝑇)
𝑑𝑡
𝑑𝑡

(1.1)

where dQ/dt is the total heat flow, Cp is the heat capacity of the sample, dT/dt is the
heating rate and f(t, T) is the kinetic heat flow. It can be seen from the equation 1.1 that
total heat flow contains two components: a specific heat component (non kinetic) and a
kinetic component, which is a function of time and temperature.37 In a standard DSC
setup, it is not possible to resolve these two components and hence modulated DSC
(mDSC) is used. In mDSC experiments, a nonlinear waveform is superimposed on the
linear heating rate. Thus, it possible to deconvolute the total heat flow into the reversing
(Cp related ) and non reversing (kinetic) contributions, where non reversing heat flow
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signal is the difference between the total and reversing heat flow as shown in equation
1.2.38
𝑄𝑡𝑜𝑡𝑎𝑙 = 𝑄𝑟𝑒𝑣𝑒𝑟𝑠𝑖𝑛𝑔 + 𝑄𝑛𝑜𝑛𝑟𝑒𝑣𝑒𝑟𝑠𝑖𝑛𝑔

(1.2)

mDSC improves the sensitivity and permits the investigation of important signals like T g
separately, which is usually depicted as a step change in heat capacity with a baseline
shift in the thermogram. Reversing heat flow includes transitions like heat capacity, Tg,
and melting, while non reversing heat flow includes transitions like enthalpic relaxation,
cold crystallization, thermal decomposition, evaporation, etc.39 Since Tg is a kinetic
phenomenon, it is strongly dependent on scanning rate and the thermal history of the
sample.36 In practice, Tg is normally measured as the mid-point temperature at the half
height of the step change. A typical mDSC thermogram is depicted in Figure 1.6.
Another important piece of information that can be obtained from mDSC
measurements is the phase homogeneity in ASDs. In multicomponent systems such as
ASDs, it is important to assess phase mixing, which can be confirmed from the number
of Tg events observed in a thermogram. In general, the presence of a single Tg is
indicative of a homogenous sample, whereas multiple Tg events are consistent with
possible phase separation.36 In addition, detecting phase mixing with mDSC requires
individual Tg’s to be 10 °C apart and domains larger than 30 nm.23,40 Theoretical Tg
values can also be compared with the predicted Tg values based on number empirical
mathematical models available. Among them, Gordon-Taylor relationship has been
widely used and any deviation from the predicted Tg behavior is suggestive of the
presence of specific interactions between components.41
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In recent years, the field of DSC has seen new advancements especially when fast
heating or cooling rates are performed. Fast DSC, hyper DSC or flash DSC is helpful for
cases where heating or cooling rate faster than the time scale of the event in interest is
required.42 Thus, fast cooling rates and fast heating rates can be useful for in situ
amorphization of rapidly crystallizing drugs and thermally unstable materials,
respectively. Moreover, hyper DSC measurements permit better assessment of
miscibility in ASDs, as fast heating rates do not affect the miscibility of the drug and
polymer in the sample.

Figure 1.6. A typical mDSC plot showing the three signals corresponding to total heat
flow (top), non reversible heat flow (middle), and reversible heat flow (bottom). The
glass transition (Tg) is apparent in the reversible heat flow, whereas the crystallization
exotherm is apparent both in reversible and non reversible heat flow. Melting is apparent
in all three signals.
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Table 1.2. Commonly used characterization techniques for ASDs.
Properties

DSC

TGA

FTIR/Raman

PXRD

SSNMR

Glass Transition (Tg)
temperature











Crystallinity











Mobility











Drug-polymer interactions











Moisture/ Residual content











Number of phases











Hydration/ Dehydration











Sample destructiveness











Abbreviations
DSC

Differential scanning calorimetry

TGA

Thermogravimetric analysis

PXRD

Powder X-ray diffraction

FTIR/Raman

Fourier transform infrared spectroscopy and Raman
spectroscopy

SSNMR

Solid state nuclear magnetic resonance spectroscopy

1.3.3.2 Thermogravimetric Analysis
In TGA analysis, the change in sample weight is measured as a function of time
and temperature. It is useful for studying the thermal stability of a material, total volatile
content, kinetics of drying or desolvation, as well as dehydration.43 As with DSC, this
method is sensitive to sample condition and experimental variables like heating rate. A
typical TGA plot is illustrated in Figure 1.7. For spray dried ASDs, TGA is used
15

routinely to evaluate the residual solvent content in the samples.27 Another useful
application is found for stability dispersions samples, where the moisture uptake can be
measured easily following equilibration of the sample at a particular condition.

Figure 1.7. A typical TGA plot showing weight % as a function of temperature for a
spray dried dispersion sample.
1.3.3.3 Powder X-ray Diffraction
PXRD is the most common technique for detecting crystallinity in ASDs and
confirms the amorphous nature of dispersion samples, since it is relatively simple to
operate, non-destructive and can provide both qualitative and quantitative information.23
Its principle is based on Bragg’s law, which can be described by the equation:
𝑛𝜆 = 2𝑑 𝑠𝑖𝑛𝜃
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(1.3)

where n, λ, d and θ are an integer, the incident x-ray wavelength, the spacing between a
set of lattice planes and the angle between the diffraction planes respectively. The
common laboratory X-ray instruments use a monochromatic X-ray source (Cu or Mo)
and measures a diffraction pattern by continuously increasing θ till the entire coverage of
d satisfying Bragg’s condition for each plane. Furthermore, the measurements are
conducted in either reflection mode (Bragg-Brentano geometry) or transmission mode
(Debye-Scherrer geometry). In a typical powder diffractogram, diffraction intensity is
plotted against 2θ. For crystalline powder samples, Bragg peaks related to particular
space groups are observed and this pattern of peaks would typically correspond to a
unique signature of the material. In contrast, analysis of amorphous powder samples
gives broad, diffuse scattering signals without distinct Bragg peaks (Figure 1.8).
Amorphous materials are characterized by lack of long-range order and exhibit shortrange periodicity (translational, orientational and/or conformational).44 Thus, amorphous
samples including ASDs portray a continuous “halo” pattern, which is the mean response
of the average local order of an ensemble of short-range orders. In characterizing ASDs
samples, PXRD analysis is useful for determining the residual crystallinity in samples
after manufacturing or during stability studies. It should be noted here that typical
detection limit for crystalline content is 5-10 % (w/w).23 In addition, in recent years
PXRD has been explored to characterize miscibility and phase structure in ASD using
atomic pair distribution function (PDF).45 Another recent advancement permit
measurements to be performed under non ambient conditions with the introduction of
variable temperature (VT) or humidity control set up to assess structural changes
associated with recrystallization under stressed conditions.46
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Figure 1.8. PXRD patterns for crystalline (as-received) and amorphous celecoxib (CEL).
Amorphous celecoxib is devoid of characteristic Bragg peaks as seen in as received
celecoxib.
1.3.3.4 Vibrational Spectroscopy
FTIR and Raman spectroscopy are two well-established techniques for probing
molecular

vibrations

in

pharmaceutical

samples.

These

two

techniques

are

complementary and have been used extensively for evaluating intermolecular
interactions, phase transitions, polymorph identification, crystallinity and phase
separation. The signal is seen as a result of change in polarizability of molecules in
Raman spectrum, whereas in IR spectrum it originates from the change in the dipole
moment of the molecules.23 The IR spectrum consists of three regions: the near-IR (NIR)
region between 0.78-2.5 μm, the mid-IR region between 2.5-50 μm and the far-IR region
between 50-1000 μm. With the arrival of attenuated total reflectance (ATR) sampling
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mode, it is possible to study bulk samples for routine analysis.47 The mid-IR region has
been employed to probe drug-polymer specific interactions via variations in peak shape
and or position that are involved in molecular interactions especially through the analysis
of O-H, N-H and C=O stretching frequencies. For instance, the presence of hydrogen
bonding between the donor and acceptor groups can be inferred from the shift to lower
wavenumbers and or peak broadening.48 A number of publications highlight the
applications of FTIR spectroscopy in the area of ASDs.49,50 Apart from the mid-IR
region, NIR region has been found to be applicable especially for evaluating powder
samples without saturation.51 In addition, NIR spectroscopy has been routinely used as a
process analytical tool (PAT) for real time monitoring as well as for quantification of
crystalline or amorphous content in a multi component system.52
Raman spectroscopy is a powerful light scattering technique, which sometimes
offers advantages in sampling and specificity when compared to IR spectroscopy.51 With
shorter wavelengths of light being used it can be combined with microscopy. Confocal
Raman microscopy has enabled detailed spatial analysis of pharmaceutical materials.53,54
For this thesis work, focus is given to FTIR spectroscopy for its more convenient
experimental setup and data collection.
1.3.4

Physical Stability of Amorphous Solid Dispersions
For a robust ASD formulation, it is desired that the dosage form remains stable

during the manufacturing and the shelf life. Moreover, stability is preferred in solution
phase as well when the formulation dissolves upon expose to the biological fluids. In
solution phase, ASDs provide a “spring + parachute” effect, thereby sustaining the
supersaturation achieved for longer times to elicit its action (Figure 1.9).55 If the “spring
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+ parachute” effect fails, it is clear that the solubility advantage from ASDs will not be
realized. Hence, it is of utmost importance to understand the factors affecting the
physical stability of these enabling dosage forms. Before we list the factors affecting the
physical stability, it is equally important to review the crystallization theory.

Figure 1.9. Illustration of “spring and parachute” mechanism. Adapted from reference.30

1.3.4.1 Theory of Crystallization
Crystallization is a two-stage process: (1) nucleation and (2) crystal growth.
During the nucleation stage, small number of molecules come together to form a nucleus.
At the start of the nucleation process, the growth of the assembly is unfavorable.
However, once the critical size is reached the process continues irreversibly.56 As per the
classical nucleation theory, the Gibbs free energy of nucleation consists of two terms
given by the equation:
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∆𝐺(𝑟) = ∆𝐺𝑣 + ∆𝐺𝑠

(1.4)

where ΔGv is the bulk free energy difference between the crystalline and amorphous
phase and ΔGs is the energy required to make a new interface. Here, ΔGv is negative
(favorable to nucleation) and ΔGs is positive (unfavorable to nucleation).56,57 For a
spherical nucleus, equation 1.4 can be written as:
4
∆𝐺(𝑟) = − 𝜋𝑟 3 ∆𝐺𝑣 + 4𝜋𝑟 2 𝛾
3

(1.5)

where r is the radius of nucleus and γ is the interfacial tension between the nucleus and
the supercooled liquid. It is clear from equation 1.5 that ΔGv and ΔGs are proportional to
r3 and r2 respectively. The relationship of ΔG versus r is illustrated in Figure 1.10. The
maximum of ΔG(r) corresponds to the critical nucleus size r*, and defines the energy
barrier for nucleation ΔG*.
∆𝐺 ∗ =

𝑟∗ =

16𝜋𝛾 3
3∆𝐺𝑣2

(1.6)

2𝛾
∆𝐺𝑣

(1.7)

It is apparent from the above discussion that once the size of assembly reaches the
critical radius the process becomes thermodynamically favorable and continues. In
addition, ΔGv can be estimated from enthalpy of fusion (ΔHfus) and the melting
temperature of the crystal (Tm).58
∆𝐺𝑣 =

∆𝐻𝑓𝑢𝑠 (𝑇𝑚 − 𝑇)𝑇
𝑇𝑚2
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(1.8)

𝐼 = 𝐼0 exp[−

∆𝐺 ∗
]
𝑘𝐵 𝑇

(1.9)

It can be inferred from equation 1.9 that several variables influence the nucleation rate.
Most importantly, the degree of undercooling (Tm-T) should increase the nucleation rate
indefinitely. However, experimentally it is seen that the rate of nucleation increases with
the degree of undercooling, reaches a maximum and then decreases (Figure 1.11). This
behavior can be explained by the increase in the viscosity as the temperature decreases
and thereby decreasing the molecular mobility.60 To account for this behavior, an
additional kinetic term (ΔGa) is included in the equation 1.9, which defines the molecular
mobility of crystallizing species.
𝐼 = 𝐼0 exp[−

∆𝐺 ∗ + ∆𝐺𝑎
]
𝑘𝐵 𝑇

(1.10)

In practice, homogenous nucleation is seldom encountered and therefore presence of
foreign bodies, impurities and surfaces may also influence the observed nucleation.60
The second stage is the crystal growth, where the critical size nucleus increases in
size resulting in the development of the crystalline phase. There are several ways
molecules can join to the growing crystal surface. In the case of smooth crystal
interfaces, models like screw-dislocation and two dimensional or surface nucleation
growth have been employed. For pharmaceutical systems, the crystal growth rate U is
given by61:
𝑈=

6𝑎𝐷
∆𝑆
∆𝐺𝑐
𝑓𝑒𝑥𝑝(− )[1 − exp
]
2
𝜆
𝑘
𝑘𝐵 𝑇
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(1.11)

where a is the molecular diameter, D is the diffusion coefficient, λ is the diffusion jump
distance, f is the fraction of interface sites that are active growth sites, ΔS is the entropy
difference between the two phases, k is the Boltzmann’s constant, ΔGc is the
thermodynamic driving force for crystal growth and T is the absolute temperature. The
observed nucleation rate and crystal growth rate is dependent on factors such
thermodynamic, kinetic and intermolecular. Additionally, the external conditions like
humidity, method of preparation, stress may also impact the overall crystallization
tendency of amorphous dosage forms.60

Figure 1.10. Schematic representation of free energy ΔG as a function of nucleus radius
r. Adapted from the reference.60
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Figure 1.11. Schematic representation of nucleation rate and crystal growth rate as a
function of temperature for undercooled melts. Adapted from reference.60

1.3.4.2 Role of Polymers in Physical Stabilization
There are wide varieties of polymers that are employed in formulation of ASDs.
Chemically, polymers consist of structural units known as “monomers” which are
combined together to form a chain-like structural backbone. They can be classified on
the basis of their charge into: (a) nonionic or non pH dependent and (b) ionic or pH
dependent. Additionally, nonionic polymers can further be categorized into
polyvinyllactam polymers and cellulosic ethers. The ionic polymers are further
subdivided into two sub groups: anionic and cationic polymers.62 A summary of common
polymers with their important properties is listed in Table 1.3. Polymers can impact
physical stability to a large extent and control factors like overall Tg of the system,
mobility etc. Moreover, intermolecular interactions between the dug and polymer also
play a crucial role in physical stabilization of ASDs.63,64 Thus, important performance
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factors of polymers like Tg, thermal stability, solubility in solvents, drug-polymer
miscibility should be considered in the polymer selection process. The list of
commercially available solid dispersion products along with the polymer used is given in
Table 1.4.
1.3.4.3 Glass Transition Temperature
ASDs are often characterized by their Tg, which is an important parameter
dictating their physical stability.36 In general, high Tg for the system is desired as it
guarantees better stability at room temperature and under typical storage conditions. For
drug-polymer mixtures, it is possible to predict the Tg of the blend through many models,
which have been widely studied for ASDs. One popular quantitative model for the
prediction of Tg of a multicomponent system is the Gordon-Taylor relationship. It uses
the Tg values of the individual components and predicts the Tg of the dispersion
intermediate in value of Tg’s of each component. It is based on the assumption that the
free volumes of both components are additive and that the system lacks any specific
interactions.65 Based on these assumptions, the resultant Tg of the mix can be calculated
by:
𝑇𝑔𝑚𝑖𝑥 =

𝑤1 𝑇𝑔1 + 𝑘𝑤2 𝑇𝑔2
𝑤1 + 𝑘𝑤2

(1.12)

where w1, w2 are weight fractions of each component, Tg1 and Tg2 are their glass
transition temperatures. The constant k is related to density and expansion coefficient and
may be approximated using Simha-Boyer rule.66
𝑘=

𝜌1 ∆𝛼1 𝜌1 𝑇𝑔1
≈
𝜌2 ∆𝛼2 𝜌2 𝑇𝑔2
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(1.13)

The Gordon-Taylor equation can be modified with a different value of k to define
Couchman-Karaz relationship with the value k being defined by heat capacity change at
Tg.67
𝑘=

1
𝑇𝑔𝑚𝑖𝑥

=

∆𝐶𝑝1
∆𝐶𝑝2

(1.14)

𝑤1 𝑤2
+
𝑇𝑔1 𝑇𝑔2

(1.15)

The component with the lower Tg is called a plasticizer whereas the component
with the higher Tg is called an antiplasticizer. Polymers generally have higher Tg values
than the drug and therefore act as antiplasticizers and increase the overall Tg of the
system. The presence of moisture in the system can reduce the Tg to a significant extent.
Water is a great plasticizer (Tg ~ -140 °C) and can lead to physical and chemical
instability of product.69
In practice, deviations from ideality have been reported.13,36 This signifies that
mixing of components is non ideal and are classified as: positive and negative deviations
(Figure 1.12). In the case of positive deviations where experimental Tg values are greater
than the predicted Tg values result from lower net excess free volume upon mixing or the
drug-polymer interactions (D-P) are stronger than the drug-drug (D-D) and the polymerpolymer (P-P) interactions. The negative deviations result from higher net excess free
volume upon mixing or the drug-polymer interactions (D-P) are weaker than the drugdrug (D-D) and the polymer-polymer (P-P) interactions, which leads to experimental Tg
values being lower than the predicted Tg values.
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Table 1.3. Physicochemical properties of the polymers commonly used in ASDs.

Solubility

Molecular
weight
(g/mol)

Hygroscopicity

Tg
Polymers

Classification
(°C)

Cellulosic Derivatives
Hypromellose
(HPMC)

Nonionic

170180

Water
Soluble

85,000150,000

High

Hypromellose
acetate
succinate
(HPMCAS)

Anionic

~125

> pH 5.0

~50,000

Low

Hypromellose
phthalate
(HPMCP)

Anionic

133137

> pH 5.0

80,000130,000

Medium

Cellulose
acetate
phthalate
(CAP)

Anionic

~160170

> pH 6.0

~2534

Medium

Polyvinyl lactam (co)polymers
Polyvinyl
pyrrolidone
(PVP)

Nonionic

150180

Water
Soluble

30,000100,000

High

Copovidone
(Kollidon®
VA64)

Nonionic

105110

Water
Soluble

45,00070,000

High

Soluplus®

Nonionic

~70

Water
Soluble

118,000

Medium

Methacrylate (co)polymers
Eudragit® EPO

Cationic

~48

< pH 5.0

~47,000

Low

Eudragit®
L100

Anionic

> 150

> pH 6.0

~125,000

Low

Eudragit®
L100-55

Anionic

~110

> pH 5.5

~320,000

Low

Eudragit®
S100

Anionic

> 130

> pH 7.0

~123,000

Low
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Comments
Soluplus®

Polyvinyl caprolactam-polyvinyl acetate-polyethylene copolymer

Eudragit® EPO

Poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-comethyl methacrylate) 1:2:1

Eudragit®
L100-55

Poly(methacrylic acid-co-ethylacrylate) 1:1

Hypromellose

Hydroxypropyl methyl cellulose

Copovidone

Poly(vinyl pyrrolidone-co-vinyl acetate)

Furthermore, Tg is an important parameter for molecular mobility under typical
storage conditions (15-30 °C). As a rule to predict the stability of ASDs under long term
conditions, it has been suggested to store at 50 °C below Tg (Tg-50 rule).13 This rule
suggests that a Tg of at least 75-80 °C is preferred for storing ASD products at ambient
storage conditions.
1.3.4.4 Specific Interactions
Intermolecular drug-polymer interactions play a significant role in making the
matrix stable. Additionally, drug-polymer interactions prevent drug precipitation upon in
vivo dissolution by maintaining supersaturation. The drug-polymer interactions can exist
as ionic interactions, hydrogen bonding, dipole-dipole interactions and van der Waals
interactions. These interactions differ in their relative strength with ionic and van der
Waal interactions being the strongest and weakest respectively (Table 1.5).70 Many
pharmaceutically grade polymers have hydrogen bond donors or acceptors in their
structures, whereas many APIs also have chemical groups to form a hydrogen bond.
Therefore, hydrogen bonding is one of the most common drug-polymer interactions
observed in pharmaceutical systems.71-73 For instance, Matsumoto and Zografi
28

demonstrated the role of polymers like PVP in disruption of indomethacin dimers for
enhanced stability.74 In a different study by Song et al., the role of polystyrene sulfonic
acid was highlighted to stabilize two APIs, lapatinib and gefitinib, through ionic
interactions.75 The stronger drug-polymer interactions will result in better miscibility and
favor a single phase ASD. Moreover, it has been reported that specific interactions like
hydrogen bonding can inhibit nucleation process, thereby rendering the system more
stable.76
Moisture uptake by hydrophilic polymers can interfere with physical stability by
promoting demixing of the drug and polymer by weakening the existing interactions. In a
study published by Rumondor et al., it was postulated that the physical stability of
dispersions is based on the interplay of two factors, the strength of drug-polymer
interactions and hygroscopicity.77 Additionally, water also reduces the Tg of the system
and increase the mobility, which can further pose stability challenges.69

Figure 1.12. Deviations from the Gordon-Taylor equation; D represents drug and P
represents polymer. Adapted from reference.13
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1.3.4.5 Drug-Polymer Miscibility
The drug-polymer miscibility is one of the key factors that may impact the
physical stability and performance of ASDs.36 Amorphous miscibility can be defined in
terms of the level of mixing which results in a single-phase system. It must be kept in
mind that even a miscible single-phase system can undergo crystallization, as the system
is still metastable relative to its crystalline form. Consequently, it is important to review
some key aspects related to miscibility. Here, we shall address some thermodynamics
principles for binary amorphous systems. The Gibbs free energy of mixing, ΔGmix, at
temperature T is given by:
∆𝐺𝑚𝑖𝑥 = ∆𝐻𝑚𝑖𝑥 − 𝑇∆𝑆𝑚𝑖𝑥

(1.16)

where ΔHmix and ΔSmix are the enthalpy and entropy of mixing respectively. In general,
mixing increases the disorder of the system, which makes the entropic term positive.
Hence, the sign of ΔHmix will dictate whether the mixing is favorable or unfavorable.
Stronger drug-polymer interactions will result in loss of enthalpy, while stronger drugdrug and polymer-polymer interactions will lead to an increase in enthalpy. Therefore,
exothermic mixing is attained when adhesive interactions are stronger and/or more
numerous than cohesive interactions. Athermal mixing results when adhesive
interactions are similar and/or extent to the cohesive interactions.78 Thus, it is important
to determine the nature of intermolecular interactions between the drug and polymer.
Furthermore, it is desirable to predict the drug polymer miscibility based on predictive
models such as the Flory-Huggins theory, which is a lattice based solution model
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originally developed for polymers.79 Based on this model, the free energy of mixing,
ΔGmix, can be described as:
∆𝐺𝑚𝑖𝑥
= 𝑛𝑑 𝑙𝑛𝜙𝑑 + 𝑛𝑝 𝑙𝑛𝜙𝑝 + 𝜒𝑑𝑝 𝑛𝑑 𝜙𝑝
𝑅𝑇

(1.17)

where R is the gas constant, T is the absolute temperature, nd,p are the number of moles
the drug and the polymer respectively, ϕd,p are the volume fractions of the drug and the
polymer, and χdp is the Flory-Huggins interaction parameter. The first two terms on the
right side describe the entropic contribution (combinatorial entropy) and the last term
signifies the enthalpic contribution to the total fee energy of mixing of the binary
system.80 The enthalpic contribution will dictate the sign of the ΔGmix and thus, the sign
of χdp is the determining factor. It is therefore considered an indicator for drug-polymer
miscibility. The smaller or more negative the Flory-Huggins interaction parameter, the
stronger the intermolecular interaction between the drug and polymer. The value of χdp
can be determined by the melting point depression approach and the solubility parameter
approach.81 The details on how to obtain the value of χdp are discussed in Chapter 4. The
drawbacks of the Flory-Huggins theory are that it does not account for the specific
interactions and the energy for breaking the crystal lattice so that makes it only
applicable for amorphous polymers.
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Table 1.4. List of pharmaceutical solid dispersions available in the market.
Product

API

Preparation
Method

Company

Year of
Approval

Carrier

Cesamet®

Nabilone

Solvent
Evaporation

Meda
Pharmaceuticals

1985

PVP

Sporanox®

Itraconazole

Fluid Bed
Bead
Layering

Janssen
Pharmaceuticals

1992

HPMC

Prograf®

Tacrolimus

Spray
Drying

Astellas Pharma

1994

HPMC

Kaletra®

Lopinavir,
Ritonavir

Melt
Extrusion

AbbVie Inc.

2007

PVP/VA

Intelence®

Etravirine

Spray
Drying

Janssen
Pharmaceuticals

2008

HPMC

Zortress®

Everolimus

Spray
Drying

Novartis
Pharmaceuticals

2010

HPMC

Norvir®

Ritonavir

Melt
Extrusion

AbbVie

2010

PVP/VA

Onmel®

Itraconazole

Melt
Extrusion

Merz Pharma

2010

HPMC

Incivek®

Telaprevir

Spray
Drying

Vertex
Pharmaceuticals

2011

HPMCAS

Zelboraf®

Vemurafenib

Coprecipitation

Roche

2011

HPMCAS

Kalydeco®

Ivacaftor

Spray
Drying

Vertex
Pharmaceuticals

2012

HPMCAS

Orkambi®

Lumacaftor,
Ivacaftor

Spray
Drying

Vertex
Pharmaceuticals

2015

HPMCAS
/SLS
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Table 1.5. Relative strength of drug-polymer interactions. Adapted from reference.70
Bond Energy (kJ/mol)

Approximate Relative
Strength

850-1700

1000

50-170

100

Dipole-dipole
Interactions

2-8

10

van der Waals
Interactions

~1

1

Type of Interaction
Ionic Interactions
Hydrogen Bonding

1.4

Thesis Overview
Chapter 1 deals with the introduction to the amorphous state, the importance of

ASDs in drug development, the preparation methods, a brief outline of common
analytical tools used for characterization of amorphous solids, and the factors affecting
physical stability of ASDs. The central objective of my thesis research is to gain
fundamental insights into the role of drug-polymer phase homogeneity and the factors
impacting (specifically drug-polymer interactions) phase homogeneity and the physical
stability of ASDs.
1.4.1

Chapter 2
In Chapter 2, the fundamentals and key features of SSNMR are introduced. It

highlights the underlying principles of SSNMR, its advantages and limitations, and the
applications pertaining to the field of ASDs. In addition, special focus has been given to
the proton relaxation measurements and their importance in evaluating phase
homogeneity in ASDs.
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1.4.2

Chapter 3
Chapter 3 presents a case study involving felodipine (FEL) as a model drug with

three polymers, poly(vinylpyrrolidone), or PVP, poly(vinylpyrrolidone-co-vinylacetate),
or PVP/VA, and polyvinylacetate or PVAc. In this investigation, the role of drugpolymer hydrogen bonding and its impact on phase homogeneity is studied in-depth. A
detailed comparative evaluation using DSC and SSNMR is presented on the model
systems to investigate the phase homogeneity and hydrogen bonding interactions.
1.4.3

Chapter 4
Previously in Chapter 3, we studied the role of hydrogen bonding on phase

homogeneity using felodipine as a model drug. Chapter 4 focuses on two structurally
similar APIs nifedipine and felodipine, and their miscibility with Soluplus. In this
chapter, both the aspects of miscibility: thermodynamic and kinetic are dealt with.
Furthermore, differences in the hydrogen bonding patterns of two APIs will be
discussed.
1.4.4

Chapter 5
So far through Chapters 3-4, we focused on the investigation of binary ASDs. In

Chapter 5, we provide an in-depth comparative assessment of binary and ternary ASDs
involving

ketoconazole

and

two

polymers,

polyacrylic

acid

(PAA)

and

hydroxypropylmethyl cellulose (HPMC). The underlying molecular interactions are
revealed in both the systems, which involved the identification and quantification of
various species present. In addition, long-term physical stability is assessed for the
samples at two different conditions.
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1.4.5

Chapter 6
Chapter 6 describes the impact of different grades of hydroxypropylmethyl

cellulose acetate succinate (HPMCAS) on the phase behavior of itraconazole dispersions.
The dispersions are prepared using two approaches and the role of preparation method is
evaluated at various drug loadings. The samples are subjected to accelerated physical
stability to investigate the influence of temperature and moisture on the dispersions.
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CHAPTER 2. SOLID-STATE NMR OF PHARMACEUTICALS: AN OVERVIEW
2.1

Introduction
Nuclear magnetic resonance (NMR) spectroscopy has

been used in

pharmaceutical analysis typically for (a) structure elucidation1, (b) chirality analysis of
drug substances2, (c) protein studies3, and (d) determination of cellular metabolism4. In
most of these applications, solution NMR spectroscopy has been employed. However,
since approximately 80-90% of pharmaceutical products on the market exist in the solid
form,2 solid-state NMR spectroscopy has the potential to play a large role in the
characterization of pharmaceutical solids, and recent developments in the field of
SSNMR spectroscopy have made it amenable for a routine analysis for Pharm. Res. and
development.
In the area of solid-state characterization of pharmaceuticals, several techniques
apart from SSNMR spectroscopy are utilized, such as PXRD, FTIR spectroscopy,
Raman spectroscopy, DSC, optical and electron microscopies, and TGA. Usually, a
combined application of many of these techniques is required, depending on the aim and
the nature of the system under study. However, in this chapter, the focus is on SSNMR,
where we want to highlight the advantages and limitations of this technique and its
application in characterization of ASDs.
It is important to mention that SSNMR is a non-destructive, non-invasive,
flexible, quantitative, multinuclear technique that allows a variety of experiments to
performed to examine the physical and chemical states of both API and the excipients.5
Moreover, with the development of NMR crystallography, crystal structures may be
solved through the combined use of X-ray diffraction and SSNMR.6 Furthermore,
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SSNMR has the capability to selectively investigate individual component of ASDs and
does not usually require any previous treatment of the sample.7 For all these aspects,
SSNMR analysis can provide crucial and relevant information on pharmaceutical solids.
Unfortunately, there are a few limitations associated with this technique, which
arise from its complexity, long experimental times and high operation costs.8 However,
with recent advancements in SSNMR hardware and software these disadvantages may be
overcome. There are many excellent reviews on the pharmaceutical applications of
SSNMR available in the literature.2,9-11

2.2
2.2.1

NMR-General Introduction
NMR Theory
The NMR phenomenon is based on the Zeeman interaction between the magnetic

moment of the nucleus (μ) and the external magnetic field (B0). The nuclear magnetic
moment is described by the following equation:
𝜇=

𝛾𝐼ℎ
2𝜋

(2.1)

where I is nuclear spin quantum number, γ is the magnetogyric ratio and h is Planck’s
constant. The Zeeman interaction takes place with nuclei having a non zero spin
quantum number (I). When nuclei having a magnetic moment are placed into a static
magnetic field, they start to precess around their z-axis. The frequency of this movement
is termed Larmor frequency ω0 and is proportional to the strength of B0 and the
magnitude of γ. For instance, 1H in the magnetic field of 7.05 T will possess a Larmor
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precession frequency of ~300 MHz, while 13C in the same static magnetic field will have
a Larmor frequency of ~75 MHz.
In the absence of external magnetic field, the nuclear magnetic moment is
quantized into 2 I + 1 possible orientations or energy levels. Here, the discussion is
limited to nuclei having spin I = 1/2 such as 1H and 13C. In this case, the nuclei can line
up either parallel or antiparallel to B0. The low energy state is labeled α (+1/2) with
magnetic moment aligned with the magnetic field, whereas the high energy state is
labeled β (-1/2) with magnetic moment aligned opposite to the magnetic field (Figure
2.1). The transition between these states give rise to observable NMR signal and the
population difference between these states is governed by the Boltzmann distribution:
𝑁𝛽
= 𝑒 −∆𝐸/𝑘𝑇
𝑁𝛼

(2.2)

where N is the number of nuclei present in each spin state, ΔE = γhB0/2π, k is the
Boltzmann constant, and T is the absolute temperature. It can be seen from this relation
that higher magnetic field spectrometers lead to a larger population difference and hence
a stronger signal, and signal-to-noise ratio (S/N).
The respective energy is provided by applying a radio frequency pulse (rf), B1,
with a frequency of about ω0 along a direction perpendicular to B0. This causes the net
magnetization to precess in the x-y plane of the laboratory frame at an angle governed by
the intensity and duration of the rf pulse. This nuclear precession generates an alternating
current in a coil surrounding the sample, whose evolution with time represents the NMR
signal. The signal or free induction decay (FID) is collected in the time domain and then
subjected to Fourier transformation to give rise to the NMR spectrum.
38

2.2.2

The Chemical Shift
The nucleus is surrounded by electrons that generate a small local field and shield

the local magnetic field experienced (Bloc) by the nucleus (Figure 2.2). The strength of
the Bloc depends on the specific electron density and this shielding give rise to the
phenomenon of chemical shift. Therefore, chemically non-equivalent nuclei experience
different magnetic fields causing them to precess at different frequencies and in the
NMR spectrum they are revealed as well separated peaks. In the NMR spectrum, the xaxis is commonly expressed in terms of chemical shift (δ) having the units in parts per
million (ppm). This scale is considered useful because it is independent of the strength of
B0 and the location on the scale is relative to the location of a reference substance whose
δ is conventionally taken to be zero. In the case of 13C and 1H, tetramethylsilane (TMS)
is used as a reference.12
Generally, Bloc is the product of B0 and (1- σ), where σ is the element of the
shielding tensor. In a molecule, electrons are distributed anisotropically and that makes
the value of σ dependent upon the molecular orientation with respect to B0. For
molecules in liquid state, where fast and isotropic Brownian molecular tumbling exists,
the anisotropy averages to zero. However, in solids where molecular tumbling is absent
and consequently the resonance frequency for each nucleus is slightly different. This
implies that for a “powder” sample, where all possible molecular orientations occur, the
different δ values result in a very broad resonance lines and subsequent loss of
resolution.
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Figure 2.1. Schematic depicting the response of nuclear spins in the presence of the
external magnetic field. The splitting of nuclear spin states is also shown.

Figure 2.2. Illustration of the magnetic shielding of a nucleus by surrounding electrons
and the effective magnetic field experienced by the nucleus.
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2.3

SSNMR Principles and Techniques
In the early 1950s, NMR spectroscopy was essentially used as a solution based

technique, where unlike solids a high-resolution spectra could be acquired. Through the
1950s and 1960s, researchers were devoted to advancing the field of SSNMR. As
discussed in the previous section, the spectrum obtained for a solid sample showed line
broadening, and that limited the application of SSNMR. It was not until the late 1970s
that Schaefer et al. were able to demonstrate the utility of 13C SSNMR for solid polymer
samples with the help of cross polarization (CP) and magic angle spinning (MAS).13,14 In
this section, we will review the basic principles involving a SSNMR experiment and
some other useful techniques, especially those used in ASDs research.
2.3.1

Dipolar Coupling and High-Power Proton Decoupling
On a molecular level, the magnetic dipoles of neighboring nuclei perturb the

magnetic field experienced by surrounding nuclei. This result in the direct magnetic
coupling of two nuclei directly thorough space and can occur on a heteronuclear and
homonuclear base. It is important to note that the extent of this depends upon the
magnetic moments of nuclei, the distance r between them, and their orientation with
respect to B0. Thus, this interaction is significant for spin ½ nuclei with large magnetic
moments such as 1H and
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F. In the pharmaceutical domain, samples are abundant in

carbon and proton nuclei, and that makes heteronuclear

13

C-1H coupling a significant

contributor to line broadening (based on their natural abundance, Table 2.1). In fact,
heteronuclear 13C-1H and homonuclear 1H-1H coupling in the solid state are generally in
the order of 50 kHz and 100 kHz, respectively. The heteronuclear 13C-1H coupling can be
suppressed by applying high decoupling fields at the 1H Larmor frequency, which cause
41

1

H spins to flip between the α (+1/2) and β (-1/2) spin states so that the dipolar

interactions are averaged to zero.9 Even after eliminating heteronuclear dipolar
interactions

13

C-1H, the broad lines are still seen in SSNMR spectrum primarily due to

chemical shift anisotropy (CSA).
2.3.2

Chemical Shift Anisotropy and Magic Angle Spinning
As mentioned previously, the molecules in the solid state exist at fixed

orientations relative to B0 and which results in distribution of chemical shifts termed as
chmeical shift anisotropy (CSA). The concept of magic angle spinning (MAS) was
originally proposed by Andrew et al. in 1958 to remove line broadening for solid
samples.15 The idea can be understood by taking into account the nature of shielding
tensor, σ, which can be divided into two components- an isotropic component and an
isotropic component as described by the following equation:
𝜎𝑜𝑏𝑠 = 𝜎𝑖𝑠𝑜 + (3 cos 2 𝜃 − 1) 𝜎𝑎𝑛𝑖𝑠𝑜

(2.3)

where θ is the angle made between the internuclear vector and B0. By spinning the
sample at “magic angle” of 54.74 ° or 54°44` causes the anisotropic term to reduce to
zero and only the isotropic chemical shift is retained. Thus, spinning the sample at an
angle equal to the magic angle at sufficient high speed (sample rotation greater than the
magnitude of CSA) will average the orientation dependent interactions (Figure 2.3).
If the sample spinning rate is less than the width of CSA, spinning side bands
(SSB) are generally observed at intervals equal to the spinning speed. These SSB contain
intensity from the parent peak and can potentially overlap with the other signals, which
complicate the spectral interpretation. Generally, they are easily identified by changing
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the spinning rate and observing which signals change in frequency. Moreover, specific
pulse sequences like total suppression of spinning sideband (TOSS) can be incorporated
to minimize their occurrence.16
Table 2.1. NMR frequency listing for a few common nuclei found in the pharmaceutical
samples.

Nucleotide
1

H

Spin

Natural Abundance

NMR frequency (MHz) at a
field (T) of
5.87

11.74

1/2

99.98

250.00

500.00

13

C

1/2

1.10

38.38

76.75

15

N

1/2

0.37

25.33

50.66

F

1/2

100

235.19

470.39

31

P

1/2

100

101.20

202.40

14

N

1

99.63

18.06

36.12

17

O

5/2

3.7*10-2

33.89

67.78

19

Figure 2.3. A schematic of magic-angle spinning.
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2.3.3

Cross Polarization
In general, SSNMR experiments lack sensitivity because of a nearly equal

population distribution of the two spin states for spin 1/2 nuclei. Moreover, for solid
samples, the sensitivity is decreased further due to the low natural abundance of the 13C
nuclei (~1%), which constitute the majority of the sample chemically. In a SSNMR
experiment, owing to the long T1 time of rare spin nuclei (13C or

15

N), very long

acquisition times may be needed for a reasonable S/N ratio. In order to overcome this
issue, the technique of cross polarization (CP) was first implemented by Pines et al.17,18
The basic idea of this technique is that bulk magnetization is transferred from the
abundant spin system having short T1 (1H) to the rare spin system (13C or 15N) with long
T1.
As per the principles of quantum mechanics, any polarization transfer between
the two spin systems can take place only when ΔE between the energy levels of the two
participating spin systems be of equal magnitude. This is the case when the HartmannHahn condition is satisfied.
Δ𝐸𝐻 = 𝛾𝐻 𝐵1𝐻 = 𝛾𝑋 𝐵1𝑋 = Δ𝐸𝑋

(2.4)

where, γH is the gyromagnetic ratio of 1H and B1H is the 1H-rf-field while B1X and γX are
the respective parameters for X-spin system. The CP pulse sequence consists of
simultaneous irradiation of the 1H and X spin systems by variable magnetic fields
through a locked rf-pulse during contact time, tc (Figure 2.4). The magnitude of the spin
locking fields B1H and B1X is chosen correctly to satisfy the Hartmann-Hahn condition.
Once this condition is fulfilled, the dilute X spin system takes the magnetization from the
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abundant 1H spins. As a last step in the sequence, the NMR signal of the X spins is then
measured during the acquisition time under 1H high-power decoupling.
The advantage from the CP pulse sequence is two fold: first, signal enhancement
of X spins, which is determined by the gyromagnetic ratios of participating spin systems
(~ 4x in

13

C experiments); and second, reduction of the delay time between pulse

sequences, since only the 1H spin-lattice relaxation remains relevant, which corresponds
to a greater number of scans translating to higher S/N.9

Figure 2.4. A scheme of cross polarization pulses sequence. The rectangles represent rf
pulses, while the oscillating curve represents the FID.

2.3.4

Relaxation
After the termination of rf pulse the net magnetization of the ensemble of spins

begins to relax back to their equilibrium values. The process of returning to equilibrium
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is termed as relaxation.10 Broadly speaking, there are three important relaxation
processes briefly described below:
1. Spin-lattice relaxation (also known as longitudinal relaxation) – This is defined as
the amount of time taken to regain equilibrium of the z component of M following
a perturbation. The term “lattice” denotes the surroundings, which receive the
energy in the process to re-establish the equilibrium. The process is generally
described by an exponential relationship with a relaxation time constant, T1, given
by the following equation:
𝑀𝑧 (𝑡) − 𝑀0 = [𝑀𝑧 (0) − 𝑀0 ]exp(−

𝑡
)
𝑇1

(2.5)

where Mz(0) is the magnetization in the z direction after the perturbation. The time
T1 is the inverse of a first-order rate constant for the relaxation process. For
multipulse experiments, the optimum recycle delay of 5 x T1 is suggested in order
to observe the fully relaxed signal after each pulse.19
2. Spin-spin relaxation (also known as transverse relaxation) – This is related to the
xy component of M and describes its decay to zero. It is given by the time
constant, T2 and in general for solids T1 >> T2, but although in liquids they are
often of the same order of magnitude. For example, for protons T2 is typically in
the range of 10-100 μs whereas T1 is typically in the range 0.1-100 s.10
3. Spin-lattice relaxation in the rotating frame – This is described as the return to
equilibrium of transverse magnetization kept aligned to a given direction by a
“spin-lock” pulse. It is denoted by T1ρ.
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2.4

Applications - Amorphous solid dispersions
In the previous sections, we discussed the fundamentals of SSNMR and other key

concepts related to the experiments. This section is devoted to the applications of
SSNMR in the field of ASDs. In this regard, SSNMR stands out among currently
available techniques in probing the structural and dynamic behavior of individual
components, as well as the intermolecular interactions and the phase mixing on a
molecular level.5 With the advancements in the area, it is possible to investigate various
subtle but important features pertaining to ASDs in terms of the state of the amorphous
API, quantification of hydrogen bonding, distance of hydrogen bonds, and homogeneity
on the nanometric scale.12,20-22 In the following sections, we will discuss and highlight
various SSNMR methodologies utilized in exploring drug-polymer homogeneity and
molecular interactions for complex systems like ASDs.
2.4.1

Proton Relaxation Times and Spin Diffusion
SSNMR provides very useful tools for measuring the degree of mixing among

each component in systems like ASDs via proton relaxation times. The proton relaxation
times: spin-lattice relaxation time (1H T1) and spin-lattice relaxation time in the rotating
frame (1H T1ρ) are commonly used to provide valuable information about the
heterogeneity of the sample. These relaxation times are affected by the process of spin
diffusion.19 Basically, spin diffusion is an outcome of dipolar coupling and in a network
of dipolar-coupled spins, the spatial diffusion of nuclear magnetization occurs from a
locally excited site to distant sites. In case of two components close together spatially,
proton magnetization within them is averaged by spin diffusion. Thus, for a
homogeneous sample the proton relaxation times tend to average to a common value,
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whereas a non-uniform relaxation behavior is detected for each component for a
heterogeneous sample. The proton relaxation times are usually measured using a highresolution CP method and are conveniently detected via

13

C nucleus to achieve spectral

resolution of various components. The pulse sequences used to record 1H T1 and 1H T1ρ
are listed in Table 2.2. For methods employed to obtain 1H T1 times, the saturation
recovery sequence was employed for the experiments described in this thesis work. In a
typical saturation recovery experiment, the recovery of nuclear magnetization to the
equilibrium after perturbation via a train of π/2 pulses is observed. In order to follow the
build up of magnetization in the direction of external magnetic field B0, Mz is determined
after various delay times t by applying π/2 pulses to flip the instantaneous magnetization
Mz(t) in the xy plane and observe the subsequent signal. The signal recovery is fitted to
the following function:
𝑀𝑧 (𝑡) = 𝑀0 (1 − 𝑒

𝑡
−
𝑇1 )

(2.6)

where, M0 is the equilibrium magnetization and T1 is the spin-lattice relaxation time
constant. In the case of 1H T1ρ pulse sequence, spectra are recorded as function of the
spin-lock time and the signal decay is fitted to the following function:
𝑀𝑧 (𝑡) = 𝑀0 𝑒

𝑡
−
𝑇1𝜌

(2.7)

where, M0 is the equilibrium magnetization and T1ρ is the spin-lattice relaxation in
rotating frame time constant. The pulse sequences for measuring 1H T1 and 1H T1ρ are
shown in Figure 2.5 and 2.6.
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Table 2.2. List of pulse sequences used for measuring relaxation times.
Pulse Sequence

Relaxation Time

Nucleus

Inversion recovery

T1

H or X

Saturation recovery

T1

H or X

Inversion recovery with CP

T1

H

“Torchia” method

T1

X

Variable spin-lock

T1ρ

H or X

Delayed contact

T1ρ

H

Variable spin-lock with CP

T1ρ

X

Figure 2.5. A scheme of pulse sequence for 1H T1 using saturation recovery.
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Figure 2.6. A scheme for pulse sequence for measuring 1H T1ρ.
A useful semiquantitative estimation of domain sizes can be obtained from the
average diffusive path length L:
𝐿 = (6𝐷𝑇)1/2

(2.8)

where, D is the spin diffusion coefficient and T is the time 1H T1 or 1H T1ρ. In this
relationship, D is dependent upon the average proton-proton distance and the strength of
the dipolar interaction. In the current work, the value of D was taken to be 10-12 cm2/s.23
If the diffusive path length is smaller than the domains in the sample, protons for each
component will decay independently of one another and different values of relaxation
time are measured for each component. Conversely, if the diffusive path length is larger
than the size of domains in the sample, a single relaxation is obtained for each
component. The main difference between 1H T1 and 1H T1ρ is that they probe molecular
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motion of different timescales. In general, 1H T1 relaxation time is sensitive to motions
occurring on MHz scale, whereas 1H T1ρ is sensitive to motions occurring on kHz
scale.10 Thus, 1H T1ρ << 1H T1 so spin diffusion has an influence over smaller distances
than it does for 1H T1.
Since 1H T1 is typically of the order of 5 s and 1H T1ρ of the order of 50 ms, the
maximum diffusive path lengths are about 50 nm and 5 nm respectively.24 Based on
these typical values and assuming that component relaxation times are sufficiently
different, there exist three possibilities for phase homogeneity in ASDs:
(1) An ASD is classified as “homogenous” when common values for 1H T1 and 1H
T1ρ are observed and any domains must be smaller than 5 nm.
(2) An ASD is classified as “partially homogenous” when a common 1H T1 but
multiple 1H T1ρ values are obtained and for such a system the average domain size
is between 5 and 50 nm.
(3) An ASD is classified as “non-homogenous” when multiple 1H T1 and 1H T1ρ
values are measured for each component and the average domain size is larger
than 50 nm.
The main advantages of using SSNMR to characterize phase homogeneity in ASDs are
listed below:
(1) The domain size accessible to SSNMR can go below 30 nm25, which is below
DSC limit of detection. Hence, it is well-suited for investigating nano-phase
separation in ASDs beyond the limits of thermal analysis.
(2) The information obtained is usually very detailed and an accurate estimation of
domains can be easily made.
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(3) Using CP, it is easier to distinguish the relaxation behaviour of each component
and can be resolved without decomposing the proton relaxation curves.
2.4.2

Molecular Interactions
In the study of ASDs, another important area for applications of SSNMR is

molecular interactions. Very often, molecular interactions play a significant role in
physical stabilization of ASDs and hence their detailed characterization is usually
required. For complex systems like ASDs, SSNMR analysis can reveal the presence of
interactions either directly through the changes in the high-resolution

13

C spectra or

indirectly via detecting the changes in parameters sensitive to the dynamics of the
system. Usually changes in

13

C CP/MAS spectra can reveal the presence of specific

interactions such as hydrogen bonding between the groups when compared with neat
drug and polymer or physical mixtures. In systems where hydrogen bonding exists,
deshielding is observed in 1D 13C spectra as a result of change in local environment with
isotropic chemical shift moving toward higher values.26 In pharmaceutical systems,
typical hydrogen bonding involve groups such as –OH, -NH and –SH, where the labile
protons attached to the heteroatoms act as donors. For such cases, X CP/MAS
experiments can serve as a special probe to study drug-polymer H-bonding. The nucleus
like

19

F offers several advantages like 100% natural abundance, short accusation times,

high sensitivity and no interference from excipients.27 This makes 19F MAS experiments
highly desirable for fluorinated APIs. In this thesis work, we acquired

15

N CPMAS

spectra for ketoconazole dispersions, where changes in the local environment of nitrogen
were monitored in the presence of polyacrylic acid. The drawbacks that come with

15

N

SSNMR experiments are long acquisition times and low sensitivity.28 This issue may be
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solved by isotopic enrichment. The other potential option is to utilize quadrupolar nuclei
like 14N to circumvent the need of isotopic labelling.29 Recently, quadrupolar nuclei (spin
> 1/2) such as

14

N,

35

Cl,

17

O have been used to study the change in hydrogen bond

geometry in ASDs.30,31 In a study done by Vogt et al., a computational method involving
the comparison of isotropic 1H chemical shift of a single molecule with that of its crystal
structure was used to assess the relative strength of hydrogen bonding interactions in
ASD of diflunisal.31
The advancements in high resolution two-dimensional SSNMR involving 2D
correlation experiments allow excellent opportunities to investigate spatial proximities
between chemically distinguished nuclei. In these experiments, homonuclear and
heteronuclear dipolar decoupling pulse sequences are used in order to obtain a muchimproved resolution in comparison to standard one-dimensional experiments.
Homonuclear decoupling sequences such as frequency switched Lee-Goldburg (FSLG)
or phase- modulated Lee-Goldburg (PMLG) are incorporated with MAS in CRAMPS
(combined rotation and multiple pulse sequence) to obtain high resolution two
dimensional spectra. Pham et al. demonstrated the applicability of HETCOR experiments
in conjunction with TOSS for exploring miscibility and molecular interactions for
multiple model systems involving binary and ternary ASDs.12
2.4.3

Detection and Quantitation of Amorphous Phases
One criterion to confirm the presence of amorphous phase is through broader

resonances as shown in the Figure 2.7. In amorphous samples, molecules can exist in
multiple conformations resulting in broad distribution of isotropic chemical shift values
for each chemically inequivalent nuclear site. In addition, comparing line widths with the
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crystalline phase may be useful evidence of amorphization. For the cases where
crystalline and amorphous phase coexist within the same sample, the detection of
amorphous phase may be difficult due to likely overlap with crystalline peaks and the
weak intensity of the amorphous phase peaks. In such a situation, one potential strategy
is to decrease the recycle day between two consecutive transients in a regular CP/MAS
experiment. Decreasing the recycle delay results in a partial suppression of crystalline
signals, and subsequently favoring the amorphous signals.

Figure 2.7. A comparison of

13

C CP/MAS spectra of crystalline and amorphous

itraconazole (ITZ).
Once the presence of the amorphous phase is confirmed, it is important to
quantify it as well from a pharmaceutical standpoint. There are several case studies
published in the literature where SSNMR has been used for the quantification of
amorphous systems.32-34 The NMR signal is proportional to the number of nuclei,
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provided that the spectrum is suitably recorded. Generally, it is assumed that CP/MAS
spectra are not quantitative, as the transfer of magnetization does not occur uniformly for
each carbon during the CP step.32 In order to obtain quantitative information from

13

C

CP/MAS spectra, it is important to carefully select the contact time for the CP pulse
sequence. The intensity of the signal strongly depends on the contact time, which is
usually specific to each chemically inequivalent nucleus, and can also change depending
on the phase. Offerdahl et al. successfully quantified different forms of the artificial
sweetener neotame.32 In the Figure 2.8, the experimental CP dynamics of the crystalline
and the amorphous form of neotame is shown.

Figure 2.8.

13

C cross polarization dynamic curves for various forms of neotame, taken

from reference.32
In general, CP dynamics depend on the two rate constants, TCH and T1ρH as shown
in the equation. This equation can be applied when T1ρC >> TCH.
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𝑀(𝑡) =

𝑀0 [exp (− 𝑇

𝑡

1𝜌𝐻

𝑡
) − exp (− 𝑇 )]

(2.9)

𝐶𝐻

𝑇
1 − ( 𝐶𝐻 )
𝑇1𝜌𝐻

where M(t) is the magnetization and t is the contact time. T1ρH is the spin-lattice
relaxation times in the rotating frame for proton. TCH is the cross polarization time
constant, which depends on the strength of the dipolar coupling between 13C and 1H. TCH
time determines the rate of increase of 13C magnetization, whereas T1ρH dictates the decay
of magnetization. By fitting the CP dynamics curve to the equation, it is possible to
obtain the information on parameters T1ρH, TCH and M0 is the thermal equilibrium value
of 13C magnetization.

2.5

Conclusions
In this chapter, a comprehensive overview of the basics of SSNMR was

presented. The main focus of this chapter was to introduce some key concepts and
experimental features pertaining to the use of SSNMR for pharmaceutical samples. In
addition, some important applications of SSNMR with respect to the amorphous systems
were highlighted. Special emphasis was given to the applications of proton relaxation
time measurements for evaluating phase homogeneity in ASDs.
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CHAPTER 3. PHASE BEHAVIOR OF AMORPHOUS SOLID DISPERSIONS OF FELODIPINE:
HOMOGENEITY AND DRUG-POLYMER INTERACTIONS
3.1

Introduction
Over the past few decades, amorphous solid dispersions (ASDs) have been of

great interest to pharmaceutical scientists to address the oral bioavailability issues
associated with poorly water-soluble drugs.1-4 ASDs consist of an active pharmaceutical
ingredient (API) that is typically dispersed in an inert polymeric matrix.5,

6

Despite

promising advantages, a major concern that has resulted in limited marketed formulations
is the physical instability of these complex formulations.7 Physical instability is often
manifested as the API crystallizing in the formulation, which is often predicated on phase
separation, where the drug and carrier migrate and generate distinct phases. Thus, phase
separation can be a prelude to recrystallization.8 It is therefore important to understand
phase homogeneity in ASDs to enable rational formulation design.
One important factor that dictates the physical stability of ASDs is the spatial
distribution of the API in the polymeric matrix.9 Three possibilities exist: (1) a
homogenous system with a single phase where API is uniformly distributed throughout
the polymeric matric, (2) a non-homogeneous system where API and polymer are totally
phase separated, and (3) a partially homogeneous system with drug rich and polymer rich
phases. From a pharmaceutical viewpoint, an intimately mixed ASD is usually preferred,
as it is likely to have better physical stability and product efficacy.10 In addition to phase
homogeneity, other factors to potentially impact physical stability include storage
conditions, hygroscopicity of the polymer, solubility of the drug in polymer, and the glass
transition temperature (Tg) of the system.11-13 Regardless of the mechanism, it is generally
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agreed that intimate mixing of the drug and the polymer is desired to achieve maximum
stabilization14. Therefore, understanding the factors controlling phase behavior and nanodomain structure of ASDs is crucial to rational formulation design.
There are many analytical tools that have been used for determining drugpolymer miscibility in ASDs. Differential scanning calorimetry (DSC) is one of the
standard techniques for characterizing phase homogeneity in ASDs if the minimum size
of phase separated domains is 30 nm or higher.15, 16 A single Tg, intermediate to those of
an API and polymer is considered as a sign of a homogenous system. In contrast,
multiple Tg values indicate a phase separated system but this criterion is not reliable. In
several instances, it has been demonstrated that it is possible to observe a single Tg for a
phase separated system, and vice versa.17,

18

Furthermore, detection of sub 30 nm

domains may be challenging to characterize via DSC. Other analytical tools include
Raman mapping, which has shown to be able to detect phase separation in systems where
Tg is undetected by DSC.19 Conventional high-resolution imaging techniques such as
scanning electron microscopy (SEM), transmission electron microscopy (TEM), and
atomic force microscopy (AFM) have also been employed to study miscibility. 20-22
However, these traditional characterization methods often have low spatial resolution
with respect to the distribution of the components of ASD, and are unable to identify the
chemical compositions of different microstructures. The lack of analytical methodology
that can detect phase heterogeneity on the order of a few nanometers often leads to the
difficulties in elucidation of phase behavior of ASDs at that level of resolution.
Solid-state nuclear magnetic resonance (SSNMR) spectroscopy has recently
emerged as a technique to investigate phase behavior of ASDs with atomic level
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specificity and selectivity.23 SSNMR can provide valuable information on the
heterogeneity of the sample at the nanometer level.24-28 It is especially useful for ASDs
where nano heterogeneities can exist beyond the resolution limits of thermal analyses.
Specifically, proton spin-lattice relaxation times (1H T1 and T1ρ) are measured to
determine and understand phase homogeneity.29, 30 An intimately-mixed ASD is reflected
in identical values of 1H T1 and T1ρ for the API and the polymer components. On the
contrary, a detectable difference between the relaxation times for the API and the
polymer provides the evidence for a heterogeneous or phase separated system.31,

32

In

recent years, SSNMR has attracted increased attention in the field of ASDs to study
phase homogeneity.24, 33-35 Policianova et al., probed homogeneity of acetylsalicylic acid
dispersions on the scale of ca. 10-500 nm.36 In a study by Yuan et al., compositional
dependent homogeneity was studied for nifedipine-PVP ASDs prepared by different
methods. 1H T1ρ measurements indicated that 95:5 and 90:10 nifedipine-PVP ASDs
prepared by melt-quenching were non-homogeneous on the molecular level.27 Most
recently, Yang et al. demonstrated that at extrusion temperature higher than 160 ˚C better
miscibility was achieved for the drug and polymer with length scale of mixing of 20-80
nm for nifedipine-copovidone dispersions prepared via hot melt extrusion.33 In spite of
these previous studies, little SSNMR work has been reported on the systematic study of
the factors affecting the compositional homogeneity in ASDs.
The domains are affected by the composition of the drug-polymer mixture and the
underlying molecular interactions. The level of mixing between API and the polymer is
maximized when the individual components are involved in intermolecular interactions
such as hydrogen bonding (H-bonding).37-39 There are several examples in the literature
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where pharmaceutical polymers containing H-bond donor/acceptors have shown to form
H-bond with drug molecules containing acceptor/donor groups. The formation drugpolymer interactions can lead to better physical stability and dissolution properties.40, 41
Routinely, H-bonding interactions between the drug and polymer are studied by fourier
transform infrared (FT-IR) spectroscopy. There are numerous examples in literature
where presence of H-bonding has been shown by FT-IR measurements.42-47 Even though
widespread, FT-IR technique has its drawbacks. It is possible to achieve unreliable results
due to broad and overlapping absorption bands. SSNMR can offer better resolution
between the components of ASDs and reveal the nature of interactions between H-bond
donors and acceptors quantitatively. Yuan et al., demonstrated the use of high resolution
13

C SSNMR measurements to monitor H-bonding interactions in amorphous

indomethacin and its ASDs.35
For the current study, we hypothesize that the systems with stronger and more
extensive drug-polymer H-bonding interactions will exhibit better compositional
homogeneity than the systems with weaker and less extensive drug-polymer interactions.
We used a BCS class II API felodipine (FEL) as our model drug and three different
polymers poly(vinylpyrrolidone) (PVP), poly(vinylpyrrolidone)/vinyl acetate (PVP/VA),
and poly(vinylacetate) (PVAc). FEL is a dihydropyridine derivative with one H-bond
donor and several acceptors in its structure. The polymers have only H-bond acceptors in
their backbone thereby offering different possibilities for H-bonding interactions with
FEL, thus helping us establish our hypothesis. In H-bonded systems, the phase behavior
of resulting dispersions is determined by the extent and strength of H-bonds between the
donor and acceptor groups. We are aware of no previous SSNMR studies regarding the
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role of H-bonding on compositional homogeneity. The chemical structure of all the
compounds along with the physicochemical properties is shown in Table 3.1. The first
part of this article is devoted to investigate the phase behavior of FEL dispersions using
DSC. In the second part of this article, SSNMR is used to elucidate the extent of Hbonding and correlate that to phase homogeneity. We show that SSNMR methods can be
used to study comprehensively the phase behavior and speciation in ASDs, which cannot
be achieved using conventional analytical tools.

3.2
3.2.1

Experimental Section
Materials
Felodipine (FEL; purum 99%) was purchased from BOC Sciences (Shirley, NY).

PVP K25 (Kollidon 25, Mw = 28-34 kg/mol) and PVP/VA (Kollidon VA 64, Mw = 45-70
kg/mol) were kindly donated by BASF Corp. (Edison, NJ). PVP and PVP/VA were dried
at 70 ˚C under vacuum to remove residual moisture before use. PVAc (average Mw = 100
kg/mol) was purchased from Sigma-Aldrich (St. Louis, MO). Polymer samples were
stored over Drierite at all the times.
3.2.2

Preparation of Amorphous Materials
Preparation of Amorphous Felodipine. Amorphous felodipine was prepared by

in situ melt quenching inside the spinning NMR rotor. Sample was packed into 7.5 mm
zirconia rotors with Teflon or Kel-F end caps (Revolution NMR, LLC., Fort Collins,
CO). The rotor was heated in the NMR probe equipped with a variable-temperature
accessory stack (Varian, Palo Alto, CA) at 155 ˚C for approximately 10 min while
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spinning at 4 kHz. The rotor was then rapidly cooled to room temperature to generate
glassy felodipine.
Preparation of Felodipine Amorphous Solid Dispersions. Amorphous solid
dispersions of felodipine with PVP, PVP/VA, and PVAc were prepared by melt
quenching in the lab setting. To prepare dispersions via this approach, one gram samples
at various drug:polymer weight ratios ranging from 50:50 to 90:10 (on weight basis)
were cryomilled at 10 Hz (SPEX SamplePrep 6770 Freezer/Mill, SPEX SamplePrep
LLC., Metuchen, NJ) for five cycles, each comprising 2 min of milling and 2 min of
cooling. Liquid nitrogen was employed as a coolant. The cryomilling procedure was
used to ensure optimally mixed drug-polymer mixtures before melting. The cryo-milled
mixtures were then transferred into a Teflon beaker and heated in an oil bath at 160 ˚C
for 10 min or until completely melted. The melted mixtures were then quenched-cooled
using liquid nitrogen to generate dispersions. The resulting dispersions were vacuumdried at room temperature overnight to remove any residual moisture. All dispersions
samples were confirmed amorphous by powder X-ray (Figure 3.5). All amorphous
samples were stored in glass vials over Drierite in the freezer when not analyzed.
3.2.3

Differential Scanning Calorimetry (DSC)
DSC analyses were performed using a Q2000 (TA Instruments, New Castle, DE)

equipped with a RCS90 refrigerated cooling system (TA Instruments; New Castle, DE).
The instrument was calibrated for temperature and heat flow using indium as a standard.
Approximately 5-7 mg of sample was hermetically sealed in an aluminum pan with one
pinhole in the lid. All the dispersion samples were analyzed via heat-cool-heat cycle
under nitrogen purge (50 mL/min). A typical thermal cycle consisted of following stages:
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1) heating from 20 ˚C to 165 ˚C (first heating); 2) isothermal for 10 min followed by
cooling to -10 ˚C (cooling stage); 3) reheating to 165 ˚C (second heating). For the heating
cycles, an underlying heating rate of 2 ˚C/min was used with modulation amplitude of
±0.21 ˚C applied every 40 s. For each sample, measurements were conducted in
duplicate. The data were analyzed by Universal Analysis software (Version 4.7, TA
Instruments, New Castle, DE). The value of Tg reported was the half height of the
transition in the reversing heat flow signal.
3.2.4

Solid-State NMR Spectroscopy
13

C SSNMR spectra were acquired using a Tecmag Redstone spectrometer

(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz for
13

C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-F

end-caps (Revolution NMR LLC., Fort Collins, CO). One dimensional

13

C spectra were

acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total
sideband suppression (TOSS)48 and SPINAL6449 decoupling. The 1H 90˚ pulse width was
set to 4.0 μs and the contact time of 1.5 ms was used in all the measurements. The

13

C

chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which
was set to 18.84 ppm.50
The proton relaxation times were detected via

13

C nucleus to resolve the

resonances for respective components. The chemical shift regions unique to FEL and the
polymers were integrated to obtain the proton relaxation times (details in Results and
Discussion). Proton spin-lattice relaxation time in the laboratory frame (1H T1) was
measured using a

13

C-detected saturation recovery pulse sequence with TOSS. 1H T1

obtained by fitting intensity-recovery time data by the following equation:
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𝑀(𝑡) = 𝑀0 (1 − 𝑒

−

𝑡
𝑇1 )

(3.1)

where M(t) is the integrated signal intensity at delay time t, M0 is an amplitude parameter
from the fit, and T1 is the obtained spin-lattice relaxation time. Proton relaxation time in
the rotating frame (1H T1ρ) was measured by varying the spin lock duration time after a
90˚ pulse. The T1ρ decay times were obtained by analyzing the integrated carbon signal
intensity according to the following equation:
𝑀(𝑡) = 𝑀0 𝑒

−

𝑡
𝑇1𝜌

(3.2)

where M(t) is the integrated peak intensity and t is the spin-lock duration time. M0 is an
amplitude parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the
rotating frame. All data fitting was done using GraphPad Prism (GraphPad Saoftware,
Inc., La Jolla, CA).
The NMR spectra of amorphous FEL and the dispersions samples were
deconvoluted using MNOVA software (MestreLab Research, Version 10.0, Santiago de
Compostela, Spain) in the carbonyl region. For the dispersion samples, the spectra were
fitted with three or four peaks depending on the system. The parameters like the peak
width and the Gaussian/Lorentzian ratio were kept fixed across samples in the same
system. The area percentages for the various species were calculated from the total area
of the deconvoluted peaks and the area for FEL peaks were then normalized to the total
area of its carbonyl peaks.
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Table 3.1. Chemical Structures showing H-bond donors (in blue) and acceptors (in red)
of model compounds along with their physicochemical properties.
Tm (⁰C)

Tg (⁰C)

H-Bond
Donors/Acceptors

Felodipine

144.4

46.2

Donor and
Acceptors

PVP K25

--

170.0

Acceptor

PVP/VA

--

109.0

Acceptors

PVAc

--

44.4

Acceptor

Compound

3.2.5

Structure

Theoretical Calculations
Gas-phase calculations were completed with the Gaussian09 software package,51

utilizing the B3PW9152 density functional and the 6-311G(2d2p)53 basis set for structural
optimizations. This particular theory was chosen based upon its performance as reported
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by Chen et. al.,54 and its performance on the systems studied herein. All gas-phase
calculations used molecular structures extracted from the single crystal X-ray data
retrieved from the CCDC as starting points. All geometry optimizations allowed the
molecules to fully relax with no symmetry restrictions, while the single-point energy
calculations held the molecules in rigid conformations. The default total energy
convergence criteria for was used (ΔE < 10-6 hartree) for geometry optimizations. The
DFT grid was set to program option “ultrafine” for all simulations. The NMR chemical
shifts were predicted using HF/6-31G(d)55, 56 level of theory and the GIAO command in
Gaussian09.

3.3

Results and Discussion
The most common approach to analyze homogeneity at the molecular level is

DSC. The presence of a Tg in a dispersion of drug and polymer has been suggested to
indicate that the sample is homogeneous at a molecular domain size of ≥ 30 nm. When
studying homogeneity at smaller domain sizes, more advanced techniques such as
SSNMR are needed that can probe down the 2-5 nm range. For this reason, the samples
were initially analyzed using DSC to probe whether any differences in homogeneity
could be observed based upon multiple Tg values or deviations from the predicted values.
3.3.1

DSC Results

3.3.1.1 DSC Heating Cycles
As noted in the above paragraph, thermal analysis is one of the most convenient
approaches to assess the homogeneity and thermal behavior of dispersions.57
Inhomogeneity is often marked by two Tg values, corresponding to the Tg values of the
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individual components.58 The DSC analysis of the neat polymers showed a Tg of 170 ⁰C
for PVP, 109 ⁰C for PVP/VA and 44.4 ⁰C for PVAc (Table 3.1). Amorphous FEL
showed a Tg of 46.2 ⁰C, accompanied by an exothermic crystallization, and followed by
melting with an endothermic peak at 144 ⁰C, which is consistent with previouslyreported results.43 It is worth noting that PVAc has slightly lower Tg than the amorphous
FEL.
The DSC thermograms from the first heating cycle for FEL:Polymer dispersions
with various compositions are shown in Figure 3.1. For each set of ASDs, a single
composition-dependent Tg was observed in the reversing heat flow traces, which implies
that the FEL and polymers were homogeneous over the composition range. Melting
endotherms were observed for certain compositions (samples containing less than or
equal 20% PVP, 20% PVP/VA and 40% PVAc) in each system. The presence of a
melting endotherm can be attributed to either the presence of residual crystallinity in the
sample, or to crystallization taking place at temperatures above Tg. Because a
crystallization exotherm was observed in the non-reversing heat flow (vide infra), the
latter explanation is more likely. This suggests that there is some degree of nano
heterogeneity and the amorphous drug-rich domains can rearrange into crystalline phases
due to increased mobility of the system above Tg. This phenomenon of crystallization
above Tg is polymer dependent and the details will be discussed in the later section. In
order to further investigate this phenomenon, a second DSC scan was performed on these
samples to see if the crystallization exotherm/melting endotherm was observed for
samples when the thermal history was removed as a variable.
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The characteristics seen in first heating cycle represent the state of the samples as
they were prepared, which was by melt quenching. After the first heating scan, both the
thermal history of the samples and any residual moisture content are removed from the
samples, and this can result in the samples being more homogenous for accurate
measurement of Tg of a homogeneous system. The DSC thermograms of the second
heating scans were slightly different than the first heating scan, with sharper Tg step
changes and the absence of any melting endotherms. The absence of melting endotherms
signifies that quench cooling in the DSC pan after the first heating scan was sufficient to
eliminate the crystal formation during the cooling cycle. As it can be seen from Figure
3.2, only one Tg was detected in each set of dispersions for the composition range
studied, with the Tg value being a function of the drug to polymer ratio. In order to
understand the impact of this crystallization appearing in the first heating scan but not the
second, the data was analyzed first to see if there was any drug-polymer interactions that
might be observed in the DSC data, specifically in the form of a change in the T g values.
A change in the Tg from the first to second scan could indicate a change in the
homogeneity of the samples, where the second scan may result in a more homogeneous
sample, and therefore less susceptible to crystallization.
The DSC thermograms (first and second) had similar mean Tg values from both
the cycles. Even though these dispersions appear to be homogeneous, since they
exhibited a single Tg for both the heating runs that was very close in value, this does not
necessarily ensure that they are homogenous below the 30 nm scale as noted above for
DSC homogeneity measurements.
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Figure 3.1. DSC thermograms from first heating scan for FEL:Polymer dispersions A)
FEL:PVP B) FEL:PVP/VA and C) FEL:PVAc. The values reported here are the mean
glass transition temperatures.
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Figure 3.2. DSC thermograms from second heating scan for FEL:Polymer dispersions A)
FEL:PVP B) FEL:PVP/VA and C) FEL:PVAc. The values reported here are the mean
glass transition temperatures.
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3.3.1.2 Fitting DSC Data to Gordon-Taylor Equation
DSC data can be plotted as a function of composition to determine if there are
potential interactions between the drug and the polymer, where deviations from linearity
suggest that there may be drug/polymer interactions. A number of empirical models have
been proposed to study the Tg composition dependence of dispersions. Among the
equations proposed, the Gordon-Taylor equation is widely used.59 It is described as
follows:
𝑇𝑔 =

[(𝑤1 𝑇𝑔1 ) + (𝑘𝑇𝑔2 )]
[𝑤1 + (𝑘𝑤2 )]

(3.3)

where Tg is the glass transition of the dispersion, Tg1 and Tg2 are those of pure
components, w1 and w2 are the weight fractions of each component, and the constant k is
an adjustable fitting constant. The mean Tg values from the second heating scans were
used for the Gordon-Taylor equation. For fitting the data it is convenient to linearize and
rewrite the original Gordon-Taylor equation as:
𝑤2
𝑇𝑔 − 𝑇𝑔1 = k ∗ (Tg2 − 𝑇𝑔 ) ∗ ( )
w1

(3.4)

A plot of Tg-Tg1 versus (Tg2-Tg)*(w2/w1) will yield k via linear regression. Using this
approach, we get k values of 0.81, 1.18, 0.91 for FEL:PVP, FEL:PVP/VA, and
FEL:PVAc dispersions respectively.
Figure 3.3 shows the plot of Tg values obtained after the second heating scan vs.
the weight fraction of polymer for the three polymer systems. The broken lines in Figure
3.3 were obtained by inserting the resulting values of k into equation (3) and plotting the
corresponding Tg values. A slight negative deviation is seen for FEL:PVP and
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FEL:PVP/VA dispersions, which likely reflects the presence of weak specific
interactions. Compared to FEL:PVP and FEL:PV/VA dispersions, FEL:PVAc system
had no deviations from the predicted Gordon-Taylor curve. This ideal behavior could be
due to negligible presence of any specific intermolecular interactions, or that the
intermolecular FEL-FEL interactions were replaced with the similar strength of
intermolecular FEL:PVAc interactions. It is worth mentioning that the Tg of amorphous
FEL and PVAc were almost similar, which caused Tg values of resulting dispersions to
change very slightly for the composition range studied.
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FEL:PVP/VA, and FEL:PVAc). The respective Gordon-Taylor curves are shown in
colored broken lines.

3.3.1.3 Drug Crystallization-First Heating Scan
Figure 3.1 showed that for samples containing less than or equal to 20 % polymer
for FEL:PVP and FEL:PVP/VA ASDs, FEL crystallized upon heating. For FEL:PVAc
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ASDs, samples containing less than 50% polymer showed signs of FEL crystallizing
upon heating. To support the idea that the crystallinity was produced during heating and
was not present prior to analysis via DSC, PXRD (Figure 3.5) and 13CP/MAS (vide infra)
clearly pointed to the absence of any crystallinity present within their detection limit.
The reversible heat flow data shown in Figure 3.1 is useful for determining the Tg
values, but the non-reversible heat flow events can provide insight into events such as
crystallization occurring in the samples. Figure 3.4 shows DSC thermograms for the nonreversing heat flow for the 90:10 (Plot 3.4 A) and 80:20 (Plot 3.4 B) compositions.
Amorphous FEL exhibited a crystallization exotherm at 80.9 ⁰C. The crystallization
temperature of amorphous FEL increased with polymer loading for all three polymers. In
addition, it can be seen that the crystallization temperature was the highest with PVP for
both of the polymer loadings. Overall, the stabilization potential of a polymer is rank
ordered as PVP>PVP/VA>PVAc. In fact, the rank ordering correlates well with the
results reported by Bhugra et.al.60 The authors showed that crystallization temperature
could be an indicator of the strength of drug-polymer interaction. For their case study
with nifedipine, a similar trend was seen and the authors concluded that PVP had the
most potential to retard crystallization in comparison with other polymers studied. This is
also consistent with the study performed by Yuan et.al, where the authors showed that
PVP systems had a stronger interaction with indomethacin as compared to systems with
PVP/VA35.
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Figure 3.4. DSC thermograms showing non reversing heat flow versus temperature as a
function of polymer loading: A) 10% polymer B) 20% polymer.

3.3.1.4 Summary – DSC Results
The DSC data in the previous sections highlighted several trends. First, there
were differences between the first and second heating cycles in the DSC thermograms,
suggesting that the samples as initially prepared were different than the samples that
were heated above the melting point of the drug, cooled, and then reheated. The most
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likely explanation we have pointed out is that there was some degree of phase
heterogeneity present when the samples were initially prepared. However, the most
definitive evidence for that could be the observation of two glass transition temperatures
in the DSC thermograms, or even a change in the Tg of the samples from the first and
second heating curves, which was not observed. There was no direct evidence for phase
heterogeneity from the DSC results. Second, the strength of drug-polymer interactions
was consistent with PVP having the strongest H-bonding interaction with FEL, followed
by PVP/VA and PVAc in that order. However, the relative strength of this interaction
was not quantified, except by the change in the crystallization temperature.
To answer these questions, SSNMR was used to study the homogeneity of the
samples as a function of polymer composition, and for a select sample, the equivalent of
a second heating scan was done in situ in the SSNMR rotor. In addition, SSNMR was
employed to investigate the structural changes in the drug as a function of polymer
loading to better understand the strength and extent of the drug-polymer H-bonding
interactions.
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Figure 3.5. X-ray powder diffraction patterns of FEL:Polymer dispersions for A)
FEL:PVP, B) FEL:PVP/VA and C) FEL:PVAc.

3.3.2

13C

CP/MAS Solid-State NMR Results – Miscibility

3.3.2.1 SSNMR Spectra and Interpretation
The

13

C CP/MAS spectra of as-received FEL and amorphous FEL are shown in

Figure 3.6. The assignments of resonances as given in Table 3.1 for various carbons of
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as-received FEL were done based on previous literature reports.61 In the recorded

13

C

CP/MAS spectrum, the crystalline material could be easily be identified and
distinguished from the amorphous state based on its narrow and well resolved resonances
in contrast to broad NMR signals seen for the amorphous FEL. The 13C CP/MAS spectra
for the polymers are displayed in Figure 3.6. All the three polymers depicted amorphous
characteristics as exhibited by their broad resonances. For pure PVP, four distinct peaks
were observed although it has six carbons in its structure. This is owing to the overlaps
observed in the carbon resonances. The resonance at 175 ppm corresponded to the
carbonyl group (C=O) of PVP pyrrolidone backbone. Similarly for neat PVP/VA, only
eight resonances could be resolved in the spectrum. The carbonyl region of the spectrum
of PVP/VA consisted of resonances at 175 ppm and 170.9 ppm, which arose from two
carbonyl carbons one from the pyrrolidone moiety and other from the acetate
functionality. In the PVAc spectrum, four resonances were seen with no overlap in the
resonances. Peaks at 40 ppm and 66 ppm corresponded to the polymer backbone.
Meanwhile, the other resonance at 170.2 ppm came from the carbonyl group.
The 13C CP/MAS spectra of FEL dispersions with various polymers are shown in
Figure 3.7 (Plots A, B and C). The spectra confirmed the amorphous nature of the
dispersions formulated via melt quenching. For the spectra of dispersions, it was noted
that there were some non-overlapping resonances for the drug and polymers. The carbon
signals around 146 ppm, 128 ppm and 104 ppm were selective for FEL (red dashed
boxes in Figure 3.7). Meanwhile, the carbon signals around 175 ppm served as nonoverlapping peak for PVP and the carbon resonance around 68 ppm was selective for
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both PVP/VA and PVAc (blue dashed boxes in Figure 3.7). These specific peaks act as a
unique probe to follow the relaxation behavior of FEL and polymers in the dispersions.

Figure 3.6. Stacked plot of

13

C CP/MAS spectra for (A) Felodipine (as received) (B)

amorphous felodipine (C) PVP (D) PVP/VA and (E) PVAc. The 13C resonances relate to
the numbering scheme presented in Table 3.1.
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Figure 3.7. 13C CP/MAS spectra of (A) FEL:PVP dispersions (B) FEL:PVP/VA and (C)
FEL:PVAc. In each stacked plot the spectra from top to bottom include amorphous FEL,
FEL:Polymer dispersions with 50-90% drug load and neat polymer. The central aromatic
peaks at 146 ppm, 128 ppm and 104 ppm (indicated by the red box; plot A-C) were
attributed to FEL specific resonances while the peaks at 175 ppm (indicated by blue box;
plot A), 68 ppm (indicated by blue box; plots B and C) were identified as nonoverlapping regions for PVP, PVP/VA and PVAc respectively.
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3.3.2.2 SSNMR Relaxation Times - Investigation of Phase Behavior
In order to obtain more detailed information on the compositional homogeneity
and phase behavior of dispersions, the proton relaxation experiments were performed,
which consisted of measuring the spin-lattice relaxation time in the laboratory frame (1H
T1), and in the rotating frame (1H T1ρ) for both the drug and polymer peaks. The
measurements are usually performed via

13

C resonances to be able to determine the

relaxation time values for the drug separately from the polymer. As depicted in Table
3.2, the neat samples of FEL (as-received and amorphous) and polymers were
characterized by different 1H T1 and T1ρ times. An examination of experimental 1H T1
and T1ρ data for FEL showed that amorphous state has shorter relaxation times than the
crystalline FEL, which is characteristic of disordered materials. From Table 3.2, a single
proton relaxation value was observed for pure polymers, indicating a single-phase
amorphous system. The experimental 1H T1 and T1ρ values are rank ordered as
PVAc>PVP/VA>PVP.
For a system containing multiple components, such as a drug and a polymer, the
scale of compositional homogeneity can be estimated from the relaxation behavior of the
individual components. Three possibilities exist for the phase behavior classification of
dispersions, namely a homogeneous, a partially homogeneous, and a non-homogeneous
system, corresponding to a uniformly mixed system, a partially-mixed system, and a
phase separated system. In case of a homogeneous system on the molecular scale, the
protons of different components spin diffuse and relax at an identical rate. For a phaseseparated system, the drug and polymer have different relaxation behavior is observed
owing to domain sizes of the drug and polymer being so large that there is incomplete
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spin diffusion between the drug and polymer at the largest domain size measured. It
should be noted that when a difference in relaxation times is observed, it simply indicates
that the entire sample is not fully homogeneous over that domain size, and there could
easily be domains that are homogeneous, along with some domains that are only partially
or completely phase separated. Since any degree of phase heterogeneity can potentially
indicate that there is a propensity for the sample to crystallize, the observation of a lack
of homogeneity is more important than determining if the sample is completely phase
separated. In most cases, solid-state NMR spectroscopy will indicate a lack of full
homogeneity of the sample, rather than total phase separation.
Table 3.2. 1H T1 and T1ρ values along with the standard errors associated with the fit for
FEL (as-received and amorphous) and Polymers measured via 13C resonances.
Felodipine
Proton
Relaxation
Time
T1 (s)
T1ρ (ms)

Polymers

As received

Amorphous

PVP

PVP/VA

PVAc

61.34±1.56

4.82±0.13

1.73±0.02

2.15±0.04

3.73±0.03

305.00±6.44 140.70±5.95 23.68±0.13 25.56±0.16 39.86±0.24

The characteristic 13C resonances for FEL and polymers were identified from the
13

C CP/MAS spectra (Figure 3.7). It should be noted that the absolute values for 1H T1

and T1ρ relaxation times depend on the many factors like water content, particle size,
etc.62,
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The absolute relaxation times for the dispersions were intermediate in values

when compared to those for the neat components (data not shown). For the current
investigation, the differences in the relaxation times between FEL and polymer were
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compared for samples in each system. The plots of 1H T1 differential between FEL and a
given polymer are shown in Figure 3.8. As displayed in Figure 3.8, no apparent trend
could be seen in the plot of 1H T1 differentials for all the systems. The FEL:PVP system
had the same values for 1H T1 for FEL and polymer across all the compositions within the
error of the measurement. The FEL:PVP/VA also had similar values across all
compositions, although the higher drug concentrations (80% and 90%) were slightly
different, still within the 95% confidence intervals. Thus, these systems are essentially
homogenous on the length scale measured by 1H T1, except potentially the higher drug
loading samples. In the case of FEL:PVAc dispersions, no significant differences in 1H
T1 were observed between FEL and PVAc at PVAc > 10% w/w, confirming phase
uniformity at 1H T1 length scale of mixing for those compositions.
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Figure 3.8. 1HT1 differential between FEL and polymer in dispersions for A) FEL:PVP,
B) FEL:PVP/VA and C) FEL:PVAc as a function of weight fraction of polymer. The
error bar signifies 95% confidence interval associated with the fit. The dashed line
represents the zero.
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The relaxation time constant 1H T1, which is usually a few seconds for ASDs and
is usually about two orders of magnitude longer than 1H T1ρ, is averaged out over a large
distance (tens of nanometer) while 1H T1ρ is typically a few tens of milliseconds and is
averaged out to over few nanometers.64,
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This makes 1H T1ρ a way to determine

homogeneity over a much smaller domain size compared to 1H T1 values. The
differential 1H T1ρ plots between FEL and a given polymer are presented in Figure 3.9.
For all polymers, there was a change in the 1H T1ρ values, where the differential values
increased with decreasing polymer concentration. It was observed that the FEL:PVP had
the lowest differentials, followed by the FEL:PVP/VA and finally the FEL:PVAc. This
trend is consistent with the crystallization trends observed in the DSC data. The samples
with less than or equal to 10% PVP, 20% PVP/VA and 30% PVAc exhibited non
identical 1H T1ρ times within the error of measurement. This clearly indicates nano-phase
separation existing for these compositions on the length scale of 1HT1ρ.
We also investigated whether the molecular weight of the PVP had an impact on
phase miscibility as studied by 1H T1ρ. The differential 1H T1ρ plots between FEL and
different grades of PVP polymer for 90% drug loading sample are shown in Figure 3.10.
It is apparent from Figure 3.10 that the 1H T1ρ were different for FEL and PVP grades,
suggesting the presence of drug rich nano domains. The extent of phase heterogeneity
can be confirmed by the magnitude of the differential. The differential is larger for the
higher molecular weight polymers, which is consistent with poorer mixing and less
homogeneity due to the lower mobility of polymers for higher molecular weight grades.
All of these samples showed a single glass transition, crystallization in the first heating
cycle, and no endotherm in the second DSC scan (data not shown).
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3.3.2.3 SSNMR Relaxation Times - Determination of Domain Sizes
If the diffusion path length is smaller than the dimensions of the domains in the
dispersions, two different relaxation times will be observed, one for the drug and the
other for the polymer, or also different relative compositions of drug and polymer, or
some combination of these. However, if the diffusion path length is larger than the
dimensions of domains in the dispersions, effective spin diffusion causes single average
relaxation time for both the components or various domains.65 The upper limit of the
length scale of mixing can be approximated by the one dimensional Fickian diffusion
equation, which is given as:
< 𝐿2 ≥ (6𝐷𝑇𝑖 )

(3.5)

where D is the spin diffusion coefficient, which depends on the average proton to proton
distance as well as a dipolar interaction. Although the coefficient can vary somewhat, a
typical value of 10-12 cm2/s is often used for rigid organic solids with a moderate proton
spin density.32, 66 Ti is the relaxation time, T1 or T1ρ. Using this approach, a reasonable
estimation of spatial heterogeneities can be made, which is order of magnitude different
than DSC, where it is hard to confirm existence of phase homogeneity based on a single
Tg. In addition, the length scale of DSC measurements is usually 10-30 nm,15 and any
heterogeneity which may be present on a smaller scale will go undetected by thermal
analysis. From this SSNMR study and the previous DSC study on the dispersions, the
scales of domain sizes for the samples are summarized in Table 3.3. It can be clearly seen
that FEL:PVP and FEL:PVP/VA dispersions were all homogeneous on a scale below 7
nm for the samples with drug loading less than 90% and 80% respectively. Additionally,
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the samples with higher drug loading(s) (90% for FEL:PVP and 80% and 90 % for
FEL:PVP/VA) were characterized by larger domains. From the results observed for
FEL:PVAc dispersions, we see variation in the homogeneity profile across the
compositions studied. The dispersions at PVAc > 30% were found to be intimately mixed
on the scale of less than 5 nm. For the compositions with PVAc at 30% and 20%, we
observed that domain sizes between 5-40 nm. These findings suggest that these
compositions are only partially homogeneous. As to the composition with PVAc at 10%,
exhibited non-homogeneous behavior with domains larger than 40 nm.
The data shown here is consistent with the presence of nano-domains being
present in the samples prior to the first heating scan, and then being removed by melting
in the DSC pan and reheating a second time. Unfortunately, the traditional method of
determining phase homogeneity using DSC, i.e. the presence of multiple Tg events, is not
useful for these samples, as all showed only a single Tg that was consistent between the
first and second heating scans. However, the NMR data so far does not indicate whether
the sample becomes homogeneous upon the equivalent of a second heating scan. Figure
3.11 shows the differential 1H T1ρ plots between a FEL:PVP sample at 90% drug loading
before and after heating in the NMR rotor, which is essentially equivalent to a first and
second DSC scan. The sample prior to heating had a significant difference in 1H T1ρ
values, whereas the sample after second heating had almost identical 1H T1ρ values,
indicating that the sample was now more homogeneous. This observation is consistent
with the first and second heating scans DSC data and supports the presence of nano
heterogeneities in as prepared samples.
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Figure 3.9. 1HT1ρ differential between FEL and polymer in dispersions for A) FEL-PVP,
B) FEL:PVP/VA and C) FEL:PVAc as a function of weight fraction of polymer. The
error bar signifies 95% confidence interval associated with the fit. The dashed line
represents the zero.
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Figure 3.10. 1HT1ρ differential for 90:10 FEL:PVP ratio as the function of PVP grade.
The error bar signifies 95% confidence interval associated with the fit. The dashed line
represents the zero.

Figure 3.11. 1HT1ρ differential for 90:10 FEL:PVP before and after heating in situ in
NMR rotor. The error bar signifies 95% confidence interval associated with the fit. The
dashed line represents the zero.
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3.3.3

13C

CP/MAS Solid-State NMR Results – Molecular Interactions

In the SSNMR spectra shown in Figure 3.7, the peak intensities for the carbonyl
carbons of both FEL and the various polymers change depending upon drug to polymer
ratios. In addition, the chemical shifts of the carbonyl carbon (C=O) of PVP and
PVP/VA change monotonically with composition (Table 3.4). In general, variation in
chemical shifts is seen when the groups are in involved H-bonding.67 This is based on the
fact that the specific interactions influences the electronic density around a given carbon
comprising interacting functionalities, which can induce changes in magnetic shielding
due to increase or decrease in its electron density and hence the variation in the chemical
shift. For FEL:PVP and FEL:PVP/VA dispersions, the formation of H-bond between the
carbonyl group in polymers and an amine group in FEL resulted in a downfield shift in
the resonance of the C=O carbon atom of the polymer as the amount of FEL increased in
the dispersions. A downfield shift of 1 ppm relative to that of pure PVP was seen for the
carbonyl carbon in the 90:10 FEL:PVP dispersion. For the 90:10 FEL:PVP/VA
dispersion, a downfield shift of 0.6 ppm relative to that of pure PVP/VA was observed.
In the case of FEL:PVAc dispersions, however, no detectable differences in the chemical
shift was seen. This result reflects that the acetate group appears to interact very weakly
with FEL. Based on the variation in the chemical shift of the carbonyl carbon of
polymers, the strength of the H-bonding interactions can be rank ordered as
PVP>PVP/VA>PVAc.
In order to study the extent of FEL-polymer interactions, the 13C CP/MAS spectra
were subjected to deconvolution procedure based on Gaussian-Lorenzian function to
decompose the multiple overlapping peaks emerging from the composition dependent
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FEL:Polymer interactions. In the current investigation, we employed the relative areas of
the individual species present in the carbonyl region to estimate the percentage of each
component. The deconvoluted spectrum of amorphous FEL in the carbonyl region is
illustrated in Figure 3.12. The spectrum revealed a main peak at 167 ppm and a shoulder
at 169 ppm. The main peak was attributed to the H-bonded carbonyl group
(dimer/bonded) while the shoulder was assigned to the non H-bonded carbonyl group
(free/non-bonded) of FEL. These assignments agree well the results from the simulation
studies (discussed in later section).

Table 3.3. Domain Sizes in amorphous solid dispersions for FEL:Polymer systems as
estimated by SSNMR and DSC. Composition represents felodipine to polymer ratio.
System

FEL:PVP

FEL:PVP/VA

FEL:PVAc

Composition

Domain Size (nm)
SSNMR
DSC

Classification
Type

50:50

< 4-5

< 30

Homogeneous

60:40

< 4-5

< 30

Homogeneous

70:30

< 4-5

< 30

Homogeneous

80:20

< 4-5

< 30

90:10

5-30

< 30

50:50

< 4-7

< 30

Homogeneous
Partially
Homogeneous
Homogeneous

60:40

< 4-7

< 30

Homogeneous

70:30

< 4-7

< 30

80:20

4-40

< 30

90:10

6-45

<30

50:50

< 4-5

< 30

Homogeneous
Partially
Homogeneous
Partially
Homogeneous
Homogeneous

60:40

< 4-5

< 30

70:30

5-40

< 30

80:20

5-40

< 30

90:10

>40

< 30

90

Homogeneous
Partially
Homogeneous
Partially
Homogeneous
Non
homogeneous

Table 3.4.

13

C chemical shifts (ppm) of carbonyl carbon of polymer in FEL:Polymer

dispersions.
Resonance C=O group of polymer
Composition (Drug:Polymer)

System
0:100

50:50

60:40

70:30

80:20

90:10

FEL:PVP

174.9

175.3

175.4

175.5

175.7

175.9

FEL:PVP/VA

175.2

175.3

175.4

175.5

175.7

175.8

FEL:PVAc

170.2

170.1

170.1

170.2

170.2

170.3

167.2 ppm Non-bonded
carboxyl (Free) (60.9%)

169.7ppm Bonded carboxyl
(Dimer) (39.1%)

Figure 3.12. Deconvolution of carbonyl region of amorphous FEL. The experimental
spectrum is shown in brown; the simulated spectrum is shown in magenta while the
residual spectrum is depicted in red. The blue lines represent the fitted individual species
used in deconvolution.
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Amorphous FEL can exist as dimer by forming self-association via H-bond
between the NH group of one molecule with the carbonyl group of the other molecule.68
The free C=O fraction comprised 61% while the dimer C=O fraction constituted 39% of
the total area. Our experimental results are in good agreement with what Xiang et al.
found using molecular dynamic simulations.68 Additionally, the carbonyl region of
FEL:Polymer dispersion was deconvoluted to explore the molecular interactions of FEL
with the polymers for quantitative purpose (Figure 3.13). In this study, the

13

C carbonyl

carbon region was resolved into three (PVP, PVAc) or four (PVP/VA) peaks depending
on the polymer type for the systems under study. The intensity of H-bonded (dimer)
carbonyl peak of FEL decreased with the increase in the polymer content in the
dispersion. It was expected that a large portion of these dimer carbonyl groups of FEL
were consumed by formation of the intermolecular H-bonds between FEL and the
polymer. This phenomenon revealed that a new distribution of H-bonds was taking place
resulting from the competition between dimer and FEL:Polymer H-bonded fractions. By
calculating the total area from the contributing components corresponding to the dimer
and free carbonyl of FEL, their respective fractions could be obtained. The fraction of
dimer and free carbonyl carbon of FEL obtained from peak fitting exercise with the
polymers is compared in Figure 3.14. Several observations can be made from the data
presented in Figure 3.14. Across this composition range, the dimer fraction of FEL
decreased, together with the simultaneous increase in the free fraction. This trend was
same for all the three polymers. However, there is a difference in the extent of H-bonding
interactions with the three polymers. In the dispersion with 50% polymer load, the dimer
fraction was smallest for PVP when compared with PVP/VA and PVAc, suggesting that
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the highest number of FEL molecules were bonded with PVP at the same polymer weight
percentage. The extent of H-bonding interactions were in decreasing order of
PVP>PVP/VA>PVAc. PVP/VA is a copolymer of 60% water-soluble vinyl pyrrolidone
and 40% water-insoluble vinyl acetate by weight. Therefore, PVP/VA presents lesser
interactions sites for FEL in comparison to PVP for a given weight percent of polymer.
PVAc is least effective in breaking the self-association between FEL molecules owing to
the fact that the vinyl acetate moiety interacts via relatively weak H-bonding.
FEL has a weak NH donor group.69 Using our deconvolution studies, we were
able to quantify the extent of H-bonding in weakly bonded systems. Usually,

15

N

SSNMR experiments would have been more apt to study the local environment of NH
donor group. Song at al. investigated H-bonding interaction in 30% FEL spray dried
dispersion with PVP/VA using

15

N solid-state NMR.70 For the dispersion sample, the

authors found slight change (~ 3 ppm) in

15

N chemical shift with respect to pure drug,

which was attributed to the presence of intermolecular H-bonding between FEL and
PVP/VA in dispersion. However, the authors mentioned that 15N chemical shifts were not
conclusive because of broad nature of peaks. Furthermore, the authors confirmed Hbonding via 1H DUMBO NMR experiments.
15

15

N SSNMR study has its own challenges.

N is very low natural abundance with low magnetogyric ratio, and overall low

sensitivity. In order to avoid use of

15

N SSNMR experiments, which might not prove to

be useful with a compound like FEL, we quantified the extent of H-bonding by
monitoring the changes in the 13C spectra in the carbonyl region. The polymers were rank
ordered as PVP>PVP/VA>PVAc for their strength and extent of H bonding with FEL.
The rank ordering presented here is in agreement with the results obtained by FTIR
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spectroscopy for FEL dispersions.71 This trend could also be understood by taking into
consideration basicity of proton acceptor. Wegiel et al. studied the potential of chemically
diverse polymers as crystallization inhibitors for resveratrol based on the basicity of
proton acceptor as one of the factors. Through their results, it is apparent that PVP
carbonyl has the strongest acceptor group (the pKBHX value of 1-methyl-2-prrolidone as
an acceptor is 2.38) while PVAc has the weakest acceptor group in the polymers studied
(the pKBHX value of ethyl acetate as an acceptor is 1.07).72 Our SSNMR stimulation
results also corroborated these findings (vide infra). Through this case study, it is evident
that knowledge of phase behavior on a nanometric is needed to explain the presence of
heterogeneities in ASDs.
Another interesting aspect to consider here is to understand that the disruption of
the dimers is due to the formation of H-bonding interactions between the drug and
polymer. In order to test this, we formulated a dispersion of FEL with inert polymer
polystyrene with 50% drug loading. Polystyrene (PS) can help us understand this
because it lacks any H-bond acceptors in its structure. Therefore, it has almost no
capability to interact with FEL via H-bonding. From the data obtained it can be seen,
there is very less change seen in the dimer and free fractions when compared to
amorphous FEL for the sample with polystyrene whereas a drastic reduction in dimer
fraction was observed in the case of polymers PVP, PVP/VA, and PVAc in that order
(Figure 3.15). This clearly explains that in the three systems studied, disappearance of
dimers is not due to dilution effect rather it can be accounted through H-bond formation.
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Figure 3.13. 13C SSNMR sub spectra of FEL:Polymer dispersions in the carbonyl region
for A) FEL:PVP, B) FEL:PVP/VA and C) FEL:PVAc. The experimental spectrum is
shown in brown; the simulated spectrum is shown magenta while the residual spectrum is
depicted in red. The blue lines represent the fitted individual species used in
deconvolution.
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Figure 3.14. The fraction of dimer and free FEL carbonyl carbon for FEL:Polymer
dispersions with A) PVP, B) PVP/VA and C) PVAc as a function of polymer weight
fraction.
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Figure 3.15. The comparison of dimer and free fractions for 50:50 FEL:Polymer
samples.

3.3.4

NMR Chemical Shift Calculations for Proposed Species
Several species have been proposed in this paper, including free FEL and dimers

of FEL. For this reason, DFT calculations of the proposed species were carried out to
ensure that the calculated chemical shifts agreed at least qualitatively with those observed
experimentally. Pure FEL was simulated as a single molecule and as dimers, with
interactions between the amine and methyl-ester, and the amine and ethyl-ester as
separate starting structures. The DFT-calculated chemical shifts were 170 ppm for the Hbonded ester group and 166 ppm for the non H-bonded ester, while the experimental
chemical shifts were 169 ppm and 167 ppm, respectively. The results from these
simulations helped to confirm the experimental
97

13

C SSNMR spectral assignment of the

pure drug, while also indicating the difference in carbonyl peak location in the
presence/absence of H-bonding interactions. While the absolute values obtained from the
simulation were not the same as the experimental chemical shifts, the relative positions
are the same. Since the calculations of the pure FEL were consistent with the
experimentally observed values, an investigation of the FEL-polymer interactions was
explored.
In this study, all polymers were created as shortened versions (3-5 monomers)
with 3 FEL molecules placed around in favorable positions to allow for completion of
the calculations in a timely manner. The calculations illustrated the strength of Hbonding between the FEL and polymer similar to those seen in the experimental data
with the theoretical rankings by chemical shift changes being the same:
PVP>PVP/VA>PVAc. Although the relative ordering is the same, the absolute values for
the chemical shifts are not. The theory tended to over predict the chemical shift change,
suggesting stronger hydrogen bond interactions than the experimental data illustrated.
This behavior can be explained by the number of H-bonded polymer monomers in the
theory vs the experiment. In the calculations, all H-bond acceptor sites in the polymers
were forced to H-bond, whereas in the experiment the steric hindrances from having
some drug molecules so closely packed would overcome the tendency to H-bond. The
ability for the short-chain polymer to bend freely allowed the three monomers to get as
far apart, spatially, as they could. In a real-world polymer, the monomers would not all
be even spaced out, with parts of the polymer being squeezed or bent based on the solidstate shape.
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Another indicator of H-bond strength is the H-bond length (shorter H-bonds
usually correlates with stronger H-bonds73), and can be obtained from the optimization
output files. The H-bond length (N-O bond) for the FEL-PVP, FEL-PVP/VA, and FELPVAc dispersions was 2.980  0.007, 3.009  0.023, and 3.077  0.039, respectively.
Using these values and the standard deviations from three H-bond donor-acceptor pairs
per calculation, the rank ordering of the polymers by H-bond strength follows the same
rank order as found by chemical shift change (PVP>PVP/VA>PVA). According to
Jeffrey, the length of H-bond in these three dispersion indicates medium strength, mostly
electrostatic interactions (4-14 kcal/mol).73 The distances show similarity between the
PVP and PVP/VA dispersion interactions, suggesting the inclusion of vinyl acetate does
not inhibit the propensity to H-bond in the PVP/VA even though the number of acceptor
sites has decreased. The PVAc does not have as strong of interactions with the FEL as
the PVP monomer and the larger standard deviation suggests the location of the
monomer on the polymer chain affects the interactions more in the PVAc than the PVP
and PVP/VA.

3.4

Conclusions
With a wide variety of analytical tools available to characterize ASDs, a major

challenge lies in detecting phase heterogeneity and speciation. From this case study, it
was shown how characterization via DSC alone might not be sufficient in order to
understand phase heterogeneity on a nanometer level in ASDs. The results from SSNMR
were able to explain the existence of nano domains with the matrix more efficiently.
However, overall these two approaches agreed in their general trends. Additionally, we
demonstrated how SSNMR can be used to quantify drug-polymer H-bonding. We
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observed that the strength and extent of FEL:Polymer H-bonding could be ranked order
as PVP>PVP/VA>PVAc. Our findings suggest that the phase behavior of ASDs is
governed by the nature of H-bonding interactions between the drug and polymer.
Moreover, our results from the current exercise have practical value in both
understanding and formulating stable ASDs.
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CHAPTER 4. UNDERSTANDING DRUG-POLYMER MISCIBILITY IN TWO
STRUCTURALLY SIMILAR MOLECULES
4.1

Introduction
Over the last decade, amorphous forms of active pharmaceutical ingredients

(APIs) have been used successfully as a platform technology to enhance the oral
bioavailability of poorly water soluble drug candidates.1-4 However, the amorphous state
is inherently unstable and possesses the risk of converting to the more stable crystalline
form during storage, manufacturing, and/or dissolution. To overcome this physical
instability, a polymer is usually used as a carrier matrix to disperse the API to form an
amorphous solid dispersion (ASD).5 The physical stabilization achieved through the use
of polymers have been attributed to a combination of restricted mobility, increased glass
transition temperature (Tg), and intermolecular interactions such as hydrogen bonding,
van der Waals forces, and electrostatic interactions.6, 7 In order to develop a robust ASD,
a homogenous solid dispersion is desired where the drug and polymer are mixed
intimately. Since even partial phase separation can be a prelude to recrystallization, a
partially mixed or completely phase separated system can potentially negate the
advantages obtained from ASDs. Hence, in recent years drug-polymer miscibility has
been an area of extensive research.8-10 There are two aspects to consider when it comes to
drug-polymer miscibility: thermodynamic miscibility and kinetic miscibility. Both are
equally important while ensuring the robust development of complex systems like ASDs.
From thermodynamics standpoint, a system is considered miscible when the free
energy of mixing (ΔGmix) of the two components is negative, where ΔGmix is given by:
Δ𝐺𝑚𝑖𝑥 = Δ𝐻𝑚𝑖𝑥 − 𝑇Δ𝑆𝑚𝑖𝑥
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(4.1)

where ΔHmix is the enthalpy of mixing, ΔSmix is the entropy of mixing and T is the
absolute temperature. In contrast, a positive value of ΔGmix signifies unfavorable mixing
and potential phase separation. The Flory-Huggins theory, which based on lattice-based
solution models, has been used extensively to assess miscibility in drug-polymer
blends.11, 12 According to this classical approach, ΔGmix can be described as:
𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
𝑙𝑛𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
𝑚
+ 𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝜙𝑑𝑟𝑢𝑔 𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟 )

ΔGmix = 𝑅𝑇(𝜙𝑑𝑟𝑢𝑔 𝑙𝑛𝜙𝑑𝑟𝑢𝑔 +

(4.2)

where R is the gas constant, T is the absolute temperature, ϕdrug and ϕpolymer are the
volume fraction of drug and polymer respectively, m is the ratio of the volume of a
polymer chain to drug molecular volume and χdrug-polymer is the Flory-Huggins interaction
parameter between the drug and polymer. The first two terms on the right hand side
defines the entropic contribution, and the last term defines the enthalpic part of the
equation to the total free energy of mixing. Given that the entropic contribution is always
favorable, the enthalpic contribution will therefore determine the sign of ΔGmix and that
makes χdrug-polymer an important factor. A negative value of χdrug-polymer favors mixing by
making the overall value of ΔGmix negative. The Flory-Huggins interaction parameter can
be estimated through several methods.13 The most-studied approach is based on melting
point depression, which was first used by Marsac et al. for pharmaceutical systems and
has been used for several drug-polymer systems.14-17 In this approach, the depression in
melting point of the drug in the presence of polymer is used to predict the interaction
parameter using the following relationship:
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1
𝑇𝑚𝑖𝑥

−

1
𝑇𝑝𝑢𝑟𝑒

𝑅
1
[ln𝜙𝑑𝑟𝑢𝑔 + (1 − ) 𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
ΔHfus
𝑚
+ 𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝜙 2 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 ]

=−

(4.3)

where Tmix and Tpure are the melting points of the drug in the binary drug polymer
mixture and the pure drug respectively, ΔHfus is the heat of fusion of the pure drug, R is
the gas constant, ϕdrug and ϕpolymer are the volume fractions of drug and polymer
respectively, m is the ratio of the volume of polymer chain to drug molecular volume and
χdrug-polymer is the Flory-Huggins interaction parameter between the drug and polymer.
While using this approach for calculating χdrug-polymer, several points are to be considered.
Firstly, this method requires the drug and polymer to be stable over the temperature
range of interest and that they form a miscibile system for the melting point depression to
be observed. Secondly, this approach works the best for systems where the polymer Tg is
significantly lower than the melting point of the pure drug. In addition, it should be noted
that this approach does not provides a universal value of χdrug-polymer but an estimation
close to the melting point of the drug. Although this approach has its own limitations, it
has shown to give a reasonable and reliable estimate of χdrug-polymer in comparison to
theoretical approach based on solubility parameters.
The thermodynamic drug-polymer miscibility relates to the phase behavior in the
equilibrium state. However, in many real situations the drug molecules in the polymeric
matric may never achieve thermodynamic equilibrium but remain kinetically stable.
Hence, it is imperative to assess the kinetic miscibility as well. The kinetic miscibility
can be assessed using calorimetric approaches or spectroscopic methods. DSC has been
used traditionally to evaluate kinetic miscibility based on the number of Tg events. A
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single Tg denotes a miscible system whereas multiple Tg denotes an immiscible system.18
It has been shown that the rule of a single Tg does not necessarily imply phase
homogeneity.19 Moreover, since the resolution scale for a DSC measurement is generally
taken to be > 30 nm, any heterogeneity, which may be present on a smaller scale, may go
undetected by DSC analysis. In recent years, spectroscopic techniques like SSNMR has
been used to study phase homogeneity on a molecular level based on the proton
relaxation time measurements (1H T1 and 1H T1ρ).20-22 Through these measurements, it is
possible to study phase homogeneity on two length scales of mixing. In theory, they can
be used to give semi quantitative information on domain sizes and can study phase
mixing at domain sizes < 5 nm. In addition, SSNMR can also provide additional
information on molecular interactions and mobility.23 We have earlier shown how in
depth analysis can be performed through SSNMR with respect to phase homogeneity and
molecular interactions in Chapter 3.
Considering the growing interest in understanding drug-polymer miscibility and
how important is to the overall stability of the system, it is useful to evaluate both the
aspects miscibility. From this perspective, it would be interesting to use this dual
approach to perform a comparative study of two common model BCS class II drugs:
nifedipne (NIF) and felodipine (FEL) when formulated as an ASD with Soluplus®. Both
drugs have similar structural features and properties like Tg24 and it therefore important
to understand the differences if any between them in terms of drug polymer miscibility
and interactions. We have previously studied FEL with polymers like PVP, PVP/VA,
PVAc and NIF has also been studied in the Munson group before. Thus, we have prior
baseline knowledge of these APIs. Recently, Soluplus® has been used as a polymeric
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matrix and solubilizer for ASDs.15,

25

Its low Tg and good thermal stability makes it

especially amenable for hot melt extrusion processes and spray drying.26 Chemically,
Soluplus® is a polyvinyl caprolactam–polyvinylacetate–polyethylene glycol graft
copolymer, which was first launched by BASF in 2009.
In this chapter, the melting point depression approach was used to estimate χ
value for NIF/FEL-Soluplus systems. Also, Gibb’s free energy of mixing was calculated
using χ at respective temperatures and phase diagrams were predicted from data obtained
from thermal analysis. Moreover, SSNMR was employed to evaluate kinetic miscibility
for both systems at different compositions and a comparison of intermolecular
interactions was achieved by analyzing 13C SSNMR spectra.

4.2
4.2.1

Experimental
Materials
Nifedipine and felodipine were purchased from TCI America (Portland, OR) and

BOC Sciences (Shirley, NY) respectively. Soluplus was a generous gift from BASF
(Edison, NJ). Soluplus was stored over Drierite at all times and vacuum dried at 40 °C
overnight every time before use. NIF is photo labile and hence was protected from light
whenever possible. The chemical structures of raw materials and their physiochemical
properties are listed in Table 4.1.
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Table 4.1. Physicochemical properties of raw materials.

Compound

Chemical Structure

Tg
( °C)

Molecular
Density
Weight
(g/cm3)
(g/mol)

Felodipine

47.1

384.26

1.28

Nifedipine

46.7

346.34

1.2

Soluplus

77.7

118000

1.2

4.2.2

Solubility Parameter Calculation
The solubility parameters were calculated using the Hoftzer-Van Krevelen group

contribution method27, which is expressed as:
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𝛿 2 = 𝛿𝑑2 + 𝛿𝑝2 + 𝛿ℎ2

(4.4)

where δd, δp and δh are contribution from dispersive forces, polar forces and hydrogen
bonding respectively. These may be individually defined as:
𝛿𝑑 =

𝛿𝑝 =

Σ𝐹𝑑𝑖
𝑉

2
√ΣF𝑝𝑖

(4.5)
(4.6)

𝑉

ΣEhi
𝛿ℎ = √
𝑉

(4.7)

Fdi is the molar attraction constant due to dispersion component, Fpi is the molar
attraction constant due to polar component, Eh is the group contribution to hydrogen
bonding energy and V is the molar volume.
4.2.3

Preparation of Amorphous Materials
Amorphous FEL and NIF were prepared by melting crystalline as received

materials (5 °C above their respective melting points) in a Teflon beaker over an hot oil
bath. Once melted, the molten mass was quenched cooled using liquid N2 to generate the
glassy form and was lightly ground in a mortar and pestle. The pure amorphous samples
were analyzed immediately to prevent crystallization. The dispersions samples were
prepared at various drug loadings from 50% to 90% w/w via melt quenching. To ensure
optimum mixing between the drug and polymer, the physical mixtures were first
cryomilled (SPEX SamplePrep 6770 Freezer Mill, SPEX SamplePrep, Metuchen, NJ) at
10 Hz for five cycles, each comprising 2 min of milling and 2 min of cooling in a liquid
N2 environment. The cryomilled mixtures were then further treated for melt quenching
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with the same procedure as used for the neat amorphous drugs. The dispersion samples
thus generated were then vacuum dried at room temperature and stored at -20 °C in
desiccators containing Drierite until further analyzed.
4.2.4

Thermal Analysis
DSC experiments were performed using a Q2000 (TA Instruments, New Castle,

DEI equipped with a refrigerated cooling accessory (RCS90). Nitrogen gas at a flow rate
of 50 mL/min used to maintain the inert atmosphere. The instrument was calibrated
using indium and sapphire.
Melting Point Depression Measurement. Mixtures of NIF/FEL with Soluplus
were prepared with via cryo milling at 10 Hz for three cycles, each comprising 2 min of
milling and 2 min of cooling in a liquid N2 environment at various weight ratios. These
mixtures were then packed in Tzero aluminum pans (5-7 mg) and heated at 1 °C/min from
20 to 200 °C. All samples were analyzed in duplicate and the mean values of melting
peak was used.
Measurement of Tg. The samples were subjected to modulated DSC experiments
with modulation of 0.5 °C every 60 s. To record the Tg values of pure drugs, the
amorphous form was generated in situ DSC by heating the samples at 10 °C/min from 20
to 180 °C, cooled at a rate of 30 °C/min to -10 °C, and then reheated at 2 °C/min to just
above their melting points. For the dispersion samples prepared via melt quenching, the
samples (5-7 mg) were packed in Tzero aluminum pans and treated with heat-cool-heat
cycle. The samples were first heated at the rate of 5 °C/min to 185 °C followed by
cooling to -10 °C at a cooling rate of -30 °C/min and reheated at the rate of 5 °C/min to
185 °C. The Tg values were recorded from the second heating cycle and determined by
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half height at mid point using the Universal Analysis software (TA Instruments,
Newcastle, DE). All samples were run in duplicate and the mean Tg values were
reported.
Theoretical prediction of Tg. The Tg values of solid dispersions were predicted
using the Gordon Taylor equation28, which is expressed as:
𝑇𝑔 =

[(𝑤1 𝑇𝑔1 ) + (𝑘𝑇𝑔2 )]
[𝑤1 + (𝑘𝑤2 )]

(4.8)

𝑇𝑔1 ∗ 𝜌1
𝑇𝑔2 ∗ 𝜌2

(4.9)

𝑘=

where Tg is the glass transition of the dispersions, Tg1 and Tg2 are those of pure
components, w1 and w2 are the weight fractions of each component, and ρ1,2 are the true
densities of each component. The corresponding ρ values were obtained from literature.
4.2.5

13C

Solid-state NMR Spectroscopy

13

C SSNMR spectra were acquired using a Tecmag Redstone spectrometer

(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or KelF end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total
sideband suppression (TOSS)29 and SPINAL6430 decoupling. The 1H 90˚ pulse width
was set to 4.0 μs and contact time of 1.5 ms was used in all the measurements. The 13C
chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which
was set to 18.84 ppm.31
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The NMR spectra of pure amorphous drugs and the dispersion samples were
subsequently deconvoluted using MNOVA software (Mestrelab Research, Version 10.0)
in the carbonyl region. The parameters for peak width and Gaussian/Lorentzian ratio
were kept same while the constraint for peak position was kept at ± 5%. The area
percentages for the various species were calculated from the total area of the peaks
deconvoluted and the drug peaks were then normalized to their respective carbonyl
peaks.
The proton relaxation times were detected via

13

C nucleus to facilitate the

identification of regions for respective components. The chemical shift regions specific
to FEL/NIF and Soluplus were integrated to obtain the relaxation times. Proton spinlattice relaxation times in the laboratory frame (1H T1) were measured using a

13

C-

detected saturation recovery pulse sequence with TOSS. 1H T1 was obtained by fitting
integral-recovery time data by the following equation:
𝑀(𝑡) = 𝑀0 (1 − 𝑒

−

𝑡
𝑇1 )

(4.10)

where M(t) is the integrated signal intensity at delay time t, M0 is an amplitude parameter
from the fit, and T1 is the spin-lattice relaxation time in the laboratory frame. Proton
relaxation times in the rotating frame (1H T1ρ) were measured by varying the spin lock
duration time after a 90˚ pulse. The T1ρ decay time was obtained by analyzing the
integrated carbon signal intensity according to the following equation:
𝑀(𝑡) = 𝑀0 𝑒
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−

𝑡
𝑇1𝜌

(4.11)

where M(t) is the integrated peak intensity and t is the spin-lock duration time. M0 is an
amplitude parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the
rotating frame. Data was fitted using GraphPad Prism software (GraphPad Software,
Inc., La Jolla, CA).

4.3
4.3.1

Results and Discussion
Baseline Characterization
The melt quenched amorphous drugs were observed to be X-ray amorphous (data

not shown). The Tg values of model drugs were obtained by generating the amorphous
form in situ in the DSC pan. The as-prepared dispersion samples were also observed to
be X-ray amorphous (data not shown) and the same observation was confirmed by

13

C

SSNMR spectra (vide infra).
4.3.2

Solubility Parameters
In order to understand and predict miscibility between FEL/NIF and Soluplus,

theoretical solubility parameters (δ) were calculated via Hoftyzer-Van Krevelen group
contribution approach. Solubility parameter values for the materials used in the current
study are listed in Table 4.2. The difference of the solubility parameter (Δδ) of two
materials is suggestive of miscibility or immiscibility. For systems having Δδ < 7.0
MPa1/2 are likely to be miscible whereas Δδ > 10.0 MPa1/2 are likely to be immiscible.32
In the present case, the solubility parameters for FEL and NIF were calculated to be
20.53 and 19.43 respectively. Meanwhile, the solubility parameter for Soluplus was
reported to be 21.79.33 The Δδ values for FEL:SOL and NIF:SOL were less than 7.0
MPa1/2.
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Table 4.2. Calculation showing solubility parameters of felodipine and nifedipine based
on the Hoftyzer-Van Krevelen group contribution method.
Group

Frequency

Fdi (J1/2 cm3/2 mol-1)

F2pi (J cm3 mol-2)

Ehi (J/mol)

Felodipine
CH3

4

1680

0

0

CH2

1

270

0

0

NH

1

160

44100

3100

Cl

2

900

605000

800

COO

2

780

480200

14000

Phenylene

1

1270

12100

0

C=

4

280

0

0

ring (6)

1

190

0

0

CH

1

80

0

0

Sum

-

5610

1141400

17900

δ = 22.74

-

20.86

3.97

8.16

Nifedipine
CH3

4

1680

0

0

CH2

0

0

0

0

NH

1

160

44100

3100

NO2

1

500

1144900

1500

COO

2

780

480200

14000

Phenylene

1

1270

12100

0

C=

4

280

0

0

ring (6)

1

190

0

0

CH

1

80

0

0

Sum

-

4940

1681300

18600

δ = 19.43

-

17.12

4.49

8.03
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Thus, it can be predicted that both the drugs should exhibit miscibility with
Soluplus. This approach has been widely used in literature but comes with several
limitations.14,

18

For instance, in the case of drug-polymer mixtures expected to form

hydrogen bonding or ionic bonding, this method can result in erroneous outcomes.
Nonetheless, this approach could be useful as a means for initial miscibility assessment
and needs further confirmation from other experimental based methods.
4.3.3

Differential Scanning Calorimetry

4.3.3.1 Estimation of Drug-Polymer Miscibility
The melting point depression approach was used to estimate the Flory-Huggins
interaction parameter between FEL/NIF and Soluplus. The depression in melting point of
the drug is usually observed in the case of a miscible drug-polymer system and has been
used as an indicator of drug-polymer miscibility. This phenomenon results from the
negative free energy of mixing linked with the spontaneous mixing of the polymer with
the drug and the chemical potential of the drug in the mixture is lowered than the pure
drug melt.14 The extent of melting point depression observed for FEL and NIF systems is
used here to distinguish their propensities to mix with Soluplus. From the analysis of the
melting point depression data (Figure 4.1) it is shown that melting point of both FEL and
NIF decreased with increase in Soluplus content, which is indicative of both the drugs
being miscible with Soluplus. However, larger depression in melting point was observed
in NIF-SOL system in comparison to FEL-SOL system especially at higher Soluplus
concentrations, which potentially resulted from higher miscibility of NIF with Soluplus
than FEL. The interaction parameter was estimated from the slopes of (1/Tmix-1/Tpure) *
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(ΔHfus/-R)-ln(ϕdrug)-(1-1/m)ϕpolymer plots against the second power of the polymer volume
fraction (ϕ2polymer) by rearranging the Flory-Huggins equation (Figure 4.2). The linear
regression analysis was done for the data points with low Soluplus weight fractions, as at
higher concentrations the linearity was lost. Marsac et al. have earlier reported the
phenomenon of nonlinear relationship at higher polymer weight fractions.14 For NIF-SOL
and FEL-SOL systems, interaction parameters with a value of -1.413 (r2 = 0.991) and 0.743 (r2 = 0.998) were obtained respectively. The negative value of the interaction
parameter for both the systems is suggestive of miscibility and an endothermic heat of
mixing. It should be noted that the value obtained with NIF is more negative than FEL,
which is reflective of more favorable mixing of Soluplus with the former. In addition, it
is also important to mention that the Flory-Huggins interaction parameter is not constant
but a function of temperature34, which can be empirically described by:
𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 = 𝐴 +

𝐵
𝑇

(4.12)

where A and B are constants. In order to further understand miscibility between the two
components, the melting point depression data was then used to construct a plot χdrugpolymer

versus 1/Tm for each system. The plots were used to obtain the values of the

entropic (A) and enthapic (B) contributions to χdrug-polymer for both the systems. The
values of constants “A” and “B” are listed in Table 4.3. Through this analysis, a series of
χdrug-polymer values could be calculated at different temperatures. In addition, this also
enabled construction of Gibb’s free energy diagrams as a function of both temperature
and composition for each system by combining eqs 4.2 and 4.3 with eq 4.12. The Gibb’s
free energy of mixing diagrams for FEL-SOL and NIF-SOL as a function of temperature
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and composition are shown in Figure 4.3. It has been pointed out that a negative ΔGmix
value is reflective of a miscible system, whereas a positive value signifies a likely partial
miscible or immiscible system.11 As shown in Figure 4.3 A, it is apparent that at
temperatures ≥ 120 °C the value of ΔGmix/RT was negative at all compositions for FELSOL system. It is interesting to note that at temperatures ≤ 100 °C all compositions were
found to have a positive value of ΔGmix/RT and especially at 25 °C larger positive values
were obtained. Accordingly, at 25 °C the calculated solubility (% wt) of FEL in Soluplus
was found to be extremely low (~ 8.29*10-9). It is clear from Figure 4.3 B that at
temperatures ≥ 100 °C resulted in a negative value of ΔGmix/RT, suggesting miscibility at
all compositions in the case of NIF-SOL system. Furthermore, at 25 °C a positive value
of ΔGmix/RT was observed at all compositions. Consequently, the calculated solubility
(% wt) of NIF in Soluplus at 25 °C was estimated to be 8.54*10-3. Overall, it can be
predicted that NIF has better miscibility and solubility than FEL in Soluplus. This
exercise is useful in selection of the components during ASD formulation development
and also help in optimizing process parameters for processes like hot melt extrusion.
Table 4.3. F-H interaction constants A and B as obtained from melting point depression
data.
Constant

NIF:SOL

FEL:SOL

A

-11.23

-56.49

B

22499

4270.1
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Figure 4.1. Melting temperatures (Tm) of NIF (black circles) and FEL (red diamonds) as
a function of drug weight percent. The data points represent the average of two separate
runs and errors bars represent the standard deviation.

Figure 4.2. Plot used to calculate the Flory-Huggins interaction parameter for NIF:SOL
(green circles) and FEL:SOL (blue circles). The slope would represent the value of the
Flory-Huggins interaction parameter. The respective values of slope were obtained using
linear regression.
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Figure 4.3. A plot of ΔGmix/RT as a function of volume fraction of drug (ϕdrug) for (A)
FEL:SOL and (B) NIF-SOL.
Another important piece of information that can be further generated here is the
temperature-composition phase diagram. In theory, phase diagrams can allow estimation
of regions of stability, instability and metastability. Typically, temperature phase
diagrams consists of two curves: binodal and spinodal. The binodal curve represents the
phase boundary between the stable and metastable region, whereas the spinodal curve
represents the phase boundary between the unstable and metastable region. To the right
side of spinodal curve, phase separation is expected to occur spontaneously. On the other
hand in the metastable region, the system will start to phase separate only after large
fluctuation in drug density.35 Moreover, the spinodal phase separation curve can be
calculated by equating the second derivative of the free energy to zero as described by:
𝑇𝑠 =

2𝐵
1

1

(4.13)

(
)+(
) − 2𝐴
𝜙𝑑𝑟𝑢𝑔
𝑚𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟

The phase diagrams for each system are shown in Figure 4.4. It is evident from
Figure 4.4 that both the systems showed temperature dependent solubility and miscibility
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but relative to FEL-SOL system, the phase diagram of NIF-SOL shifted towards the
higher composition range. Moreover, with NIF-SOL system larger gap was observed
between the solubility and miscibility curves. This suggests that NIF has higher
solubility and miscibility in Soluplus than FEL. The construction of phase diagrams is a
useful exercise since detailed information could be extracted with regards to potential
processing conditions, identification of metastable regions, achievable drug loadings and
storage temperature.12, 35
4.3.3.2 Glass Transition Temperature (Tg)
The dispersions samples prepared from melt quenching process were subjected to
heat cool heat cycle in MDSC experiments. The glass transition temperature event (Tg)
from the first cycle was hard to detect due to the nature of very broad and
undistinguished signal, a characteristic trait of Soluplus dispersions (data not shown).
Hence, the Tg values were recorded from the thermograms of the second heating cycle
for each set of dispersions. A single Tg event was observed in the second heating cycle
across the composition range studied for both the systems, possibly signifying phase
miscibility based on a single Tg rule. As the Tg values of neat amorphous NIF and FEL
were close to each other, the experimental Tg values for the dispersions samples from
both the systems were found to be similar. The experimental Tg values were compared to
the predicted Tg values calculated from the Gordon-Taylor equation in order to
understand the nature of deviations as shown in Figure 4.5. The predicted Gordon-Taylor
curves were near identical to each other. It is apparent from the Figure 4.5 that both the
systems exhibited negative deviation with regard to the predicted curves. In each system,
almost identical magnitude of negative deviation was observed except for 10% Soluplus
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sample with NIF. The deviation from the ideal behavior is generally considered as
indicative of differences in the strength of homointeractions and heterointeractions
between the components.18 A negative deviation could result from the stronger
homointeractions leading to an increase in free volume upon mixing and hence a lower
Tg value than predicted. A number of other systems have shown a similar behavior.36, 37
These empirical models have been used extensively but have their own limitations.
Therefore, the results should be interpreted with caution, especially for systems
exhibiting deviations. Nonetheless, in the present study Gordon-Taylor equation
predicted the presence of specific intermolecular interactions between the components
and would be further studied in subsequent sections.

Figure 4.4. Binary phase diagram for (A) FEL:SOL and (B) NIF:SOL.

119

Figure 4.5. A plot showing experimental and predicted Tg as a function of Soluplus
weight fraction. The red and green circles represent mean experimental Tg values from
DSC second heating cycle for NIF:SOL and FEL:SOL respectively. The error bars
denote the standard deviation. The broken lines represent the predicted Tg values from the
Gordon-Taylor equation.
To summarize the results discussed in this section, melting point depression data
analysis

yielded the Flory-Huggins interaction parameter and predicted the

thermodynamic miscibility and solubility for both systems. Our results indicated that the
interaction potential with Soluplus was higher with NIF and same for the solubility and
miscibility. Despite several limitations associated with the melting point depression
approach, a reasonable comparison could be drawn for both the systems. We ensured
sufficient mixing between the drug and polymer via cryo-ground mixtures, giving each
component a better chance for optimum interaction. In addition, the melting point
temperature of both the drugs was higher than the Tg of Soluplus, allowing Soluplus to
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exist in the supercooled liquid state and thereby ensuring better mixing and interaction.
The thermodynamic miscibility between FEL/NIF and Soluplus is an important
parameter to study but an equally important aspect to consider here is the kinetic mixing
between them. The state of mixing between FEL/NIF and Soluplus will be investigated
in the later section from SSNMR. The predictions derived from Gordon-Taylor equation
were consistent in both the systems and possibly pointed to the presence of specific
intermolecular interactions.
4.3.4

FTIR Spectroscopy
In order to understand the nature of underlying interactions between the drug and

polymer, FTIR spectra were recorded for ASDs and compared with the pure
components. Both FEL and NIF have hydrogen bond donor and acceptor groups in their
structures. It has been shown in the literature that the amine group in the structure of FEL
and NIF can participate in hydrogen bonding. Soluplus has potential sites in its structure
to interact through hydrogen bonding as well. Hence, any changes in the peak position
and shape in the FTIR spectrum relative to the pure components would provide evidence
for any specific interactions such as hydrogen bonding. FTIR spectra of FEL:SOL and
NIF:SOL system are presented in Figure 4.6. For amorphous FEL (Plot A), two peaks
marked the NH stretching region: a main peak at 3331 cm-1 and a shoulder peak at 3415
cm-1. These were assigned to a NH group bonded to the carbonyl group of adjacent
molecule of FEL, and to a non-hydrogen bonded NH group, respectively. The FITR
spectrum of amorphous NIF in the NH stretching region was characterized by similar
peak positions (Plot B).38 With increasing SOL content, the hydrogen bonded NH peak
became broader and a shoulder started to develop around 3290 cm-1 in the case of
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FEL:SOL system. The shoulder peak increased in intensity with increase in SOL
concentration and can be attributed to FEL-SOL hydrogen bonding interaction, wherein
the amine group of FEL acts as a donor. In the case of NIF:SOL, similar trend was
observed with increasing SOL weight %. In the carbonyl region (Plots C and D), the
spectrum of pure Soluplus displayed two peaks assigned to ester carbonyl (1732 cm-1)
and tertiary amide carbonyl (1632 cm-1).25 For hydrogen bonding to take place between
FEL/NIF and Soluplus, either or both of these carbonyl groups can act as a proton
acceptor leading to change in the peak positions in the carbonyl region. However, no
direct evidence of any change for these peaks could be obtained because of heavy
overlap from FEL and NIF absorbance peaks (Plots C and D). From FTIR analysis, it is
clear that both FEL and NIF interacted in a similar fashion with Soluplus and formed
possibly drug-polymer hydrogen bonds interactions.
4.3.5

Solid-state NMR Spectroscopy
In recent years, SSNMR has been used to analyze molecular interactions,

homogeneity and phase behavior in ASDs on a molecular level.23 We utilized SSNMR to
further elucidate the intermolecular interactions between FEL/NIF and Soluplus. The 13C
CP/MAS spectra of the as received materials are displayed in Figure 4.7. The
assignments of the resonances for crystalline FEL were reported previously in chapter 4,
whereas for crystalline NIF the peaks were assigned based on previous literature
reports.21 The spectrum of Soluplus consisted of resonances at 175.7 ppm from the
carbonyl group of vinylcaprolactam ring, at 170.6 ppm due to carbonyl group of acetate
and in the range of 22 to 72 ppm ascribed to aliphatic carbons. The comparison of

13

C

spectra of dispersions with the pure amorphous components is shown in Figure 4.8. It is
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clear from the spectra of dispersions that melt quenching rendered samples amorphous as
evident by broad resonances in contrast to sharp resonances seen for crystalline drugs. In
the spectra of dispersion samples for both FEL:SOL and NIF:SOL, the intensity of
Soluplus peaks decreased with decrease in Soluplus concentration and vice versa. In
addition, the same trend was observed for drug peaks as its concentration varied. In
general, the spectra of dispersion samples were superposition of the spectra of the pure
amorphous components except in the carbonyl region, where some differences were
observed. In the carbonyl region (160-180 ppm), some apparent differences in chemical
shifts were seen. The carbonyl peak of Soluplus at 175.7 ppm showed a downward shift
in the dispersion samples for both systems with decrease in Soluplus content. At 10%
Soluplus loading, the peak resonated further downfield around 177.2 ppm for both the
systems. This variation in chemical shift may indicate formation of hydrogen bonding
between FEL/NIF and Soluplus. The carbonyl peak of 170.6 ppm from acetate functional
group did not seem to shift to this extent and no apparent movement could be detected
for this peak. In this case, the carbonyl group from vinylcaprolactam is a stronger proton
acceptor than acetate group and hence participates in hydrogen bond formation. The
strength of this interaction seems to be similar in both the systems as evident by near
identical downfield shift behavior. The results seen here are in agreement with previous
study conducted in Chapter 3, wherein acetate group interacted to a lesser extent in
comparison to the pyrrolidone group. In addition, it is interesting to note here that a
larger downfield shift was seen with Soluplus than PVP, which may signify that the
acceptor strength of the carbonyl group of vinylcaprolactam moiety is stronger than the
carbonyl group of pyrrolidone ring.
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Figure 4.6. FTIR spectra for FEL:SOL (plots A, C) and NIF:SOL (plots B, D) samples.
The NH stretching region (3150-3450 cm-1) and the carbonyl stretching region (15501800 cm-1) are shown in plots (A, B) and (C, D) respectively.

124

Figure 4.7. Stacked plot for

13

C CP/MAS Spectra of as received felodipine (top), as

received nifedipine (middle) and Soluplus (bottom). Resonance assignments are done in
reference to the numbering scheme used in Table 4.1.

Figure 4.8. Stacked

13

C CP/MAS spectra for dispersions samples (A) FEL-SOL system

and (B) NIF-SOL system.
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We have earlier seen in Chapter 3 that it was possible to quantify the hydrogen
bonding interactions in the case of felodipine with polymers such as PVP, PVP/VP and
PVAc. The same approach was adopted here with the goal of understanding how FEL
and NIF interacted with Soluplus. From our previous study, it was shown that in
amorphous FEL approximately 40% of molecules existed in hydrogen bonded (dimer)
state and remaining 60% were non-hydrogen bonded (free). Similar analysis of the
carbonyl region of amorphous NIF was performed in order to quantify the different
states. Upon deconvolution, amorphous NIF carbonyl region was found to exhibit two
populations: (i) hydrogen bonded (dimer) at 169.9 ppm and (ii) non-hydrogen bonded
(free) at 167.5 ppm, constituting 29% and 71% respectively. Thus, a lesser degree of
self-association was seen in amorphous NIF in comparison to amorphous FEL. The
deconvolution exercise was also performed on dispersion samples to elucidate the
changes in these two fractions. In the presence of Soluplus, drug-polymer hydrogen
bonding is expected and that could change the ratio of “dimer” and “free” fractions in
both systems. The carbonyl region was deconvoluted to obtain the underlying peaks
areas. In the present study, we focused on the two peaks attributed to FEL/NIF, which
represented the two states in which FEL/NIF carbonyl region existed. Hence, the
percentage for the two populations were reported based on total FEL/NIF carbonyl peak
areas. The results from this exercise are summarized in Figure 4.9 and a few common
trends could be seen. With increase in Soluplus concentration, the percentage of “dimer”
population decreases with concurrent increase in the percentage of “free” population for
both the systems. This clearly suggest that FEL/NIF self-association gets disrupted in the
presence of Soluplus and more free FEL/NIF becomes available to form drug-polymer
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hydrogen bond. For both the systems, the “dimer” fraction declined gradually with
increase in Soluplus concentration. The trends seen here suggested a similar interaction
pattern existed in both the systems with some slight differences. Very interestingly, at
any given Soluplus weight percent “free” NIF fraction was higher than the corresponding
FEL fraction. One potential explanation is that NIF has a lower molecular weight than
FEL, resulting in NIF hydrogen bonding with Soluplus to a greater extent than FEL.
Thus, NIF presents higher ratio of donor to acceptor group relative to FEL on the molar
basis. Furthermore, it was shown in Chapter 3 that the extent of hydrogen bonding in
felodipine-polymer dispersions could be rank ordered as PVP>PVP/VA>PVAc.
However, in the present study with Soluplus somewhat different behavior was seen
where Soluplus was found to be less effective in terms of the extent of hydrogen bonding
in comparison with those three polymers. For instance, at 50% PVP weight percent
dimer fraction disappeared almost completely whereas in the case of Soluplus there was
still a reasonable percentage detected. From the structure of Soluplus, it can be seen that
it contains fewer R-C(O)-N-R2 (6.6 mmol/g) groups than PVP (9 mmol/g). In addition,
steric considerations may also affect the availability of Soluplus donor groups to
hydrogen bond with FEL. Considering these factors, Soluplus does not hydrogen bond
with drugs like FEL or NIF as efficiently.
The length scale of mixing in ASDs could also be studied using proton relaxation
measurements detected through the

13

C nucleus. By determining the proton relaxation

times of individual components in an ASD in comparison to the proton relaxation times
of neat components, it may be used to establish an upper limit of length scale of mixing.
These experiments are based on spin diffusion phenomenon, which tend to average the
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proton relaxation times to a single value in an intimately mixed system. In contrast in a
non homogenous system, spin diffusion process is not as efficient, and therefore different
protons relax independently of one another, giving rise to different relaxation profiles.
Furthermore, the domains sizes ranging from a few angstroms to a few tens of
nanometers can be estimated through these experiments, depending on the use of
relaxation times of either 1H T1 or 1H T1ρ. The main difference between 1H T1 and 1H T1ρ
is that they are sensitive to motions on different time scales (MHz vs kHz).39 Therefore,
1

H T1 with a longer time scale provides information about domains over larger length

scales than 1H T1ρ. Using this analysis, it is possible to study and characterize nanoheterogenous structures on two domain sizes, which is very useful for systems like
ASDs. Moreover, it is very important to use complementary techniques like DSC, which
has been a tool to assess homogeneity in ASDs based on a single Tg rule, to help detect
phase heterogeneity on a smaller scale. The detection of nanophases in ASDs is crucial
for understanding the propensity to crystallize, and techniques like SSNMR can permit
analysis of nano heterogeneities beyond the resolution limits of traditional techniques.
The plots of 1H T1 and 1H T1ρ for FEL:SOL system as a function Soluplus weight
% are shown in Figure 4.10. For compositions ≥ 30% Soluplus loading, common 1H T1
values for each component were obtained that were within the experimental error (Plot
A). This implies that domain sizes for these compositions are smaller than the diffusion
path length within the time 1H T1. For the compositions < 30% Soluplus loading,
different

1

H T1 values were recorded for each component within the error of

measurement, which indicates an non-homogeneous system on the scale of the spin
diffusion path length within the 1H T1 measurement size for these compositions. It is
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evident from Figure 4.10 (Plot B) that different relaxation behavior was observed for both
components for the 1H T1ρ measurements for all compositions, which strongly suggest at
least some degree of non-homogeneity on 1H T1ρ length scale of mixing, although at
higher Soluplus loadings, these heterogeneities get very small. Thus, heterogeneity was
detected for these compositions on a smaller scale based on 1H T1ρ measurements. It is
interesting to note that same trends are seen for NIF:SOL system, as evident from the
plots in Figure 4.11. An examination of the experimental 1H T1 data showed similar
relaxation behavior for compositions ≥ 30% Soluplus, whereas clear differences existed
for samples with < 30% Soluplus loading (Plot A). As to the 1H T1ρ data in Figure 4.11
(Plot B), non-identical 1HT1ρ relaxation times within experimental error were measured
for both components across the composition range. This clearly indicates nanoheterogeneities existing for these compositions on the length scale of the 1H T1ρ
measurement.

Figure 4.9. Bar graphs depicting the differences in “free” and “dimer” fractions for
NIF:SOL system (green bars) and FEL:SOL system (pink bars).
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Figure 4.10. 1HT1 (black squares) and 1HT1ρ (red circles) plots for FEL:SOL system as a
function of Soluplus weight percent.

Figure 4.11. 1HT1 (black squares) and 1HT1ρ (red circles) plots for NIF:SOL system as a
function of Soluplus weight percent.
The phase behavior of both the systems on a nanometric scale revealed some
similarities as discussed in the paragraph above. Nonetheless, some small differences
could be seen especially in the 1H T1ρ data. The degree of phase heterogeneity for both
systems was more or less same based on the 1H T1 data, but larger degree of phase
heterogeneity was estimated in the case of FEL:SOL system especially for the
composition with 10% Soluplus loading. In our opinion, this can result from the
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differences seen earlier for the extent of hydrogen bonding. We have shown in previous
sections that NIF:SOL system was more extensively hydrogen bonded to Soluplus in
comparison to FEL:SOL system, and this could influence the nature of nanoheterogeneous domains with the matrix to some extent especially on a smaller scale. In
addition, a useful approximate estimation of the upper limit of the domain size can be
calculated based on the following equation:
1

< 𝐿 >≅ (6𝐷1 𝐻𝑇𝑖 )2

(4.14)

where <L> is the average diffusive path length for the effective spin diffusion, D is the
spin diffusion coefficient and 1H Ti is the characteristic time over which spin diffusion
takes place. Typically, value of D is assumed to be 10-12 cm2/s. Equating 1H Ti with
either 1H T1 or 1H T1ρ provides a reasonable estimation of domain sizes of nano
heterogeneities. The results for domain sizes for ASDs of both the systems are listed in
Table 4.4. The results from the Table 4.4 indicate that the domain sizes in both the
systems were near identical for the compositions studied. It should be noted here that the
calculation of domain sizes is based on the relaxation times of individual components.
Hence, the extent of phase heterogeneity, which is based on the difference in the
relaxation times of drug and polymer, does not always reflect in domain sizes.
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Table 4.4. Domain sizes (nm) as calculated from SSNMR analysis.
Composition (Drug:Polymer)

NIF:SOL

FEL:SOL

50:50

2-35

2-35

60:40

2-39

2-37

70:30

2-40

2-37

80:20

>40

>37

90:10

>40

>37

4.4

Conclusions
In this chapter, the miscibility of two structurally similar molecules, felodipine

and nifedipine, with Soluplus was studied in depth. The melting point depression
approach was employed to study the thermodynamic miscibility for both the systems.
The results from the melting point depression study indicated better miscibility of NIF
with Soluplus in comparison to FEL. In addition, phase diagrams of temperaturecomposition were successfully constructed for both the systems. The experimental Tg
values for the compositions studied were compared to those predicted from the GordonTaylor equation. It was found that both the system showed a similar pattern in terms of
the deviations observed. The hydrogen bonding patterns were studied via FTIR and
SSNMR analyses. It was revealed that both the drugs interacted with Soluplus via
hydrogen bonding, and the preferred interaction site was the vinylcaprolactam moiety in
Soluplus backbone. Furthermore, it was shown that NIF hydrogen bonded more
extensively with Soluplus in comparison to FEL. The proton relaxation time
measurements revealed the presence of heterogeneous domains in both the systems and
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the upper limit of the domain sizes were also estimated. The analysis of the proton
relaxation measurements indicated that higher extent of phase heterogeneity in FEL:SOL
system. Overall, this study is important to understand the drug-polymer miscibility to
rationally design ASDs formulations.
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CHAPTER 5. MOLECULAR INTERACTIONS AND PHASE BEHAVIOR OF BINARY AND
TERNARY AMORPHOUS SOLID DISPERSIONS OF KETOCONAZOLE
5.1

Introduction
In recent years amorphous solid dispersions (ASDs) have gained widespread

attention to address the issue of poor bioavailability for poorly-water soluble drugs.1 This
formulation strategy is a viable approach for BCS Class II and IV compounds but the
inherent propensity of amorphous form to convert to the crystalline form poses a serious
challenge to the bioavailability advantage that comes with it.2-4 Consequently, the role of
polymers in overall stabilization of the system has been studied in great depth.5-7 It is now
well recognized that polymers stabilize via two mechanisms: (a) increasing glass
transition temperature (Tg) of the system, and (b) forming intermolecular drug-polymer
interactions.8 Typically, ASDs have been formulated using one polymer in the matrix. In
recent years, a new class of ternary ASDs has emerged, which can contain a mixture of
two polymers.9-14
In order to better understand the physicochemical properties of ternary ASDs, it is
important to elucidate the phase behavior and molecular interactions present within the
system. In contrast to a simple system like binary ASDs, presence of two polymers in
ternary ASDs may strongly influence the overall phase mixing of the different
components, and with it the physical stability of the system. Moreover, characterizing
these intermolecular interactions is equally important because the interplay of various
intermolecular species can impact phase homogeneity and hence the resultant stability of
ternary ASDs. However, in depth details of intermolecular interactions and phase
behavior are still not clear in ternary ASDs due to the limited amount of research done on
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them. Based on the preceding discussion, it is apparent that there is a need to fully
understand these complex systems on a molecular level.
In the present study, we evaluated the physical stability of ketoconazole (KET), a
BCS class II antifungal compound, in presence of different polymers for spray dried
binary and ternary ASDs. Hydroxypropyl methylcellulose (HPMC) and polyacrylic acid
(PAA) were chosen as polymeric carriers for this study. HPMC and PAA present
different possibilities for drug-polymer interactions individually based on their chemical
structures. Both the polymers have been previously studied as carriers for ASDs
formulations.15,16 Mistry et al. studied the role of drug-polymer interactions on the
molecular mobility of KET ASDs with polymers like PAA, poly (2-hydroxyethyl
methacrylate) (PHEMA) and PVP. The authors demonstrated reduced mobility and a
decrease extent of crystallization for ASDs containing PAA, which was attributed to the
fact PAA interacted strongly with KET.17 Chen et al. correlated drug polymer-interaction
and phase mixing with initial drug dissolution for KET ASDs with PVP, PVP/VA,
HPMC or HPMCAS.18 Although both PAA and HPMC have used individually for KET
ASDs, the combined use of these polymers has not been studied so far. This work
presents a detailed solid-state characterization for KET ternary ASDs in comparison to
individual binary ASDs. The specific goal of the current research is to investigate the
impact of addition of a second polymer on the phase mixing and solid-state interaction
patterns for KET in ternary ASDs at a molecular level. A detailed solid-state
characterization approach was employed using several analytical techniques such as
DSC, FT-IR spectroscopy and solid-state NMR spectroscopy. Finally, the physical
stability of binary and ternary ASDs was evaluated by PXRD at two different conditions.

135

The findings of this comprehensive study can provide useful mechanistic insights into
these systems and serve as a precedent for understanding the role of a second polymer on
phase mixing and drug-polymer interactions, which is critical for the rational design of
novel ternary ASDs.

5.2
5.2.1

Experimental
Materials
Ketoconazole (KET; 99%) was purchased from BOC Sciences (Shirley, NY).

HPMC (Pharmacoat 606) was a kind gift from Shin-Etsu Chemical Co., Ltd. (Tokyo,
Japan). PAA (Mw ~ 1800) was purchased from Aldrich (St. Louis, USA). Polymer
samples were stored in a vacuum desiccator over Drierite at room temperature.
5.2.2

Preparation of Amorphous Materials
Preparation of Amorphous Ketoconazole. Amorphous ketoconazole was

prepared by melt quenching. The as-received sample was transferred to a Teflon beaker
and heated in an oil bath at 160 ˚C until completely melted. The sample was then
quench-cooled using liquid nitrogen, and the resulting glass was powdered using a
mortar and pestle. Amorphous state was confirmed by PXRD, and all other
characterizations were performed immediately.
Preparation of KET:PAA Amorphous Solid Dispersions. ASDs of KET with
PAA were prepared via spray drying with ProCept 4M8-Trix spray dryer (ProCept,
Zelzate, Belgium) with N2 closed loop recirculation unit. A solution of drug and polymer
were dissolved in 95:05 (v/v) mixture of methanol and water (5% w/v solids). Spray
dryer conditions were as follows: N2 gas, medium cyclone, atomization pressure 0.35
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bar, liquid flow rate 85 rpm, 0.8 mm bifluid nozzle, process gas flow 7.4 L/min, inlet
temperature 85 ˚C. The resulting dispersions were dried in a vacuum desiccator over
Drierite at room temperature overnight to remove any residual moisture. All dispersions
samples confirmed amorphous by PXRD, and were stored in 20 mL glass scintillation
vials in the freezer until analysed.
Preparation of KET:HPMC and KET:PAA:HPMC Amorphous Solid
Dispersions. Binary dispersions of KET with HPMC and ternay dispersions of KET,
HPMC and PAA were prepared via spray drying with ProCept 4M8-Trix spray dryer
(ProCept, Zelzate, Belgium) with N2 closed loop recirculation unit. A solution of drug
and polymer were dissolved in a 75:25 mixture of ethanol and water (5% w/v solids).
Spray dryer conditions were as follows: N2 gas, medium cyclone, atomization pressure
0.35 bar, liquid flow rate 85 rpm, 0.8 mm bifluid nozzle, process gas flow 7.4 L/min,
inlet temperature 105 ˚C. The resulting dispersions were dried in a vacuum desiccator
over Drierite at room temperature overnight to remove any residual moisture. All
dispersions samples confirmed amorphous by PXRD and were stored in 20 mL glass
scintillation vials in the freezer until analysed.
5.2.3

Differential Scanning Calorimetry
DSC analyses were performed using a Q2000 (TA Instruments, New Castle, DE)

equipped with a RCS90 refrigerated cooling system (TA Instruments; New Castle, DE).
The instrument was calibrated for temperature and heat flow with an indium standard. 57 mg of sample was loaded into an aluminum DSC pan with a hermetically sealed lid
with one pinhole. All the dispersion samples were analyzed via heat-cool-heat cycle
under nitrogen purge (50 mL/min). A typical thermal cycle consisted of following stages:
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1) heating from 20 ˚C to 180 ˚C at 5 ˚C/min (primary heating); 2) isothermal for 5 min
followed by cooling to -10 ˚C at 30 ˚C/min (cooling stage); 3) heating to 200 ˚C at 5
˚C/min (secondary heating). For the heating cycles, a modulation amplitude of ± 0.5 ˚C
was applied every 60 s to discern reversible thermal events. The first heating cycle was
used to erase any thermal history of the sample and to get rid of any residual solvent. For
each sample, measurements were done in duplicate. The data was analyzed by TA
Universal Analysis software (version 4.7, TA Instruments, New Castle, DE). The value
of Tg reported was the half height of the transition in the reversing heat flow signal.
Theoretical Tg of the mixture was calculated using the Gordon-Taylor equation
(eq. 5.1) in conjunction with the Simha-Boyer rule (eq. 5.2).
𝑇𝑔 =

𝑤1 𝑇𝑔1 + 𝑘𝑤2 𝑇𝑔2
𝑤1 + 𝑘𝑤2

(5.1)

where w1 and w2 are the weight fractions and Tg1 and Tg2 are the glass transition
temperatures (˚C) of each component. k is found by using eq. 5.2.
𝑘=

𝜌1 𝑇𝑔1
𝜌2 𝑇𝑔2

(5.2)

where ρ1 and ρ2 are the densities of each component.
5.2.4

Fourier Transform Infrared Spectroscopy
A Thermo Fisher Scientific Nicolet iS50 FT-IR (Thermo Fisher Scientific,

Waltham, MA) with an attenuated total reflectance (ATR) attachment was used to collect
FTIR spectra from 400 cm-1 to 4000 cm-1. Data were collected in 64 scans with a
resolution of 4 cm-1 and a data spacing of 0.482 cm-1. Spectra were normalized and base
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line corrected using Omnic software (Version 9.5, Thermo Fisher Scientific, Waltham,
MA).
5.2.5

Solid-state Nuclear Magnetic Resonance Spectroscopy
13

C SSNMR spectra were acquired using a Tecmag Redstone spectrometer

(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or KelF end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total
sideband suppression (TOSS)19 and SPINAL6420. The 1H 90˚ pulse width was set to 4.5
μs and contact time of 1.5 ms was used in all the measurements. The pulse delay for 1D
experiments was 4 s and a total of 4096 scans were collected. The

13

C chemical shift

scale was referenced with the methyl peak of 3-methylglutaric acid, which was set to
18.84 ppm.21 The relaxation times were detected via

13

C nucleus, which facilitates

identification of regions for respective components. Proton spin-lattice relaxation time in
the laboratory frame (1H T1) were measured using a

13

C-detected saturation recovery

pulse sequence with TOSS. 1H T1 were obtained by fitting integral-recovery time data by
the following equation:
𝑀(𝑡) = 𝑀0 (1 − 𝑒

−

𝑡
𝑇1 )

(5.3)

where M(t) is the peak intensity at delay time t, M0 is an amplitude parameter from the fit,
and T1 is the obtained spin-lattice relaxation time in the laboratory frame. Proton
relaxation times in the rotating frame (1H T1ρ) were measured by varying the spin lock
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duration time after a 90˚ pulse. 1H T1ρ decay times were obtained by analyzing the
integrated carbon signal exponentially according to the following equation:
𝑀(𝑡) = 𝑀0 𝑒

−

𝑡
𝑇1𝜌

(5.4)

where M(t) is the peak intensity and t is the spin-lock duration time. M0 is an amplitude
parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the rotating
frame. All data fitting was done using GraphPad Prism (GraphPad Software, Inc., La
Jolla, CA). The regions selective for drug and polymers were used to get the integrals.
The region from 111-159 ppm was selective for KET, the regions 177-190 and 27-33
ppm were non-overlapping for PAA, and the regions 57-65 and 99-105 ppm were unique
for HPMC. These resolved areas are shown in highlighted boxes in Figure 5.7 (vide
infra).
5.2.6

Powder X-ray Diffraction
PXRD patterns were collected on the Rigaku Miniflex 600 benchtop

diffractometer (Rigaku Corporation, Tokyo, Japan), with Cu Kα radiation (40 kV x 15
mA). The experiments were conducted at room temperature, between 2° to 50° 2θ at a
scan speed of 2.0°/min and a step size of 0.02° 2θ under continuous mode.
5.2.7

Physical Stability
The physical stability of the binary and ternary dispersions was studied for 70%

drug loading at two different stress conditions: 40 °C/75% RH and RT/94% RH. This
drug loading was chosen to observe crystallization in samples in real time. The samples
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were analyzed by PXRD at different time points (time 0, 1 week, 2 weeks, 1 month, 2
months, 3 months, and 6 months).

5.3
5.3.1

Results and Discussion
Chemical Structures
The chemical structures of compounds are shown in Figure 5.1. The model

lipophilic drug, KET, belongs to the class of antifungal compounds. It is a weak base
with two pKa values; the imidazole ring (pKa = 6.51) and the piperazine ring (pKa =
2.94).22 Its structure presents potential sites for intermolecular interactions such as acidbase or hydrogen bonding interactions. PAA is a strong donor and medium acceptor, and
has a carboxylic acid as its monomer with pKa of 4.75.23 HPMC is a neutral cellulosic
polymer, which has been extensively used as a polymeric matrix for ASDs.24 HPMC has
many hydroxyl groups in its structure with capability of acting both as donor and
acceptor. HPMC is devoid of any carbonyl groups and hence will act an excellent system
with no interference in the carbonyl regions both for FTIR and SSNMR analyses.
5.3.2

DSC Results
For an accurate measurement of the Tg, amorphous KET was generated in situ

inside DSC pan by heating the crystalline drug above its melting point, followed by
quench cooling. Amorphous KET had a Tg of 47.0 °C, which is consistent with the
previous reports.25 The polymers were amorphous in nature and displayed an average T g
of 99.9 °C and 145.5 °C for PAA and HPMC respectively. It is clear from the Tg values
of neat materials that they are different from each other. This wider gap is desired when
DSC is used to study phase homogeneity in ASDs. It is generally recommended that Tg
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of individual components must be at least 10 °C apart in order to determine phase
homogeneity via DSC.26
Tg is an important index for assessing the physical stability and mobility of
ASDs.27 We also evaluated the Tg values of binary and ternary ASDs as a function of
composition by mDSC exposing the samples to a heat cool heat protocol. The results
from the first heating cycle are shown in Figure 5.2. The binary systems of KET:PAA
and KET:HPMC displayed a single Tg between the Tgs of individual components for all
compositions, implying phase homogeneity. Similar trend was seen in the ternary
samples. The Tg values obtained for KET:PAA were higher than for the KET:HPMC
system. Thus, the rank ordering of the polymers based on effectiveness of the polymers
to increase the Tg of KET is PAA>HPMC. Furthermore, 90:10 sample in all the systems
displayed a melting endotherm, which possibly signifies the existence of drug-rich
amorphous domains within the matrix. In the DSC analysis, it has been shown that the
presence of a single Tg does not always indicate phase homogeneity.28 Therefore, solidstate NMR was used to confirm phase homogeneity for these samples (vide infra).

Figure 5.1. Chemical structures of (A) ketoconazole (KET) (B) PAA and (C) HPMC.
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Figure 5.2. DSC thermograms from first heating cycle for (A) KET:PAA binary system
(B) KET:HPMC binary system and (C) KET:PAA:HPMC ternary system. The
composition of the samples is indicated by drug:polymer ratio on a weight basis: black
for KET, gold for PAA and blue for HPMC.
The thermal history of the sample generally affects the Tg of the system. In order
to erase the thermal history of the sample, it is generally agreed to expose the sample to
heat cool heat cycle in DSC. The Tg values from the second heating cycle yield more
accurate values with sharper step change (shorter Tg widths). This is clearly depicted in
the thermograms obtained from the second heating cycle in Figure 5.3. The Tg values
thus obtained were slightly higher than the first heating cycle. This trend was most
pronounced in KET:HPMC binary system. The change in the Tg values from the second
heating cycle reflects the behavior of spray-dried samples in the DSC, where the samples
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lose residual solvent following heating, and thus showing higher Tg values without any
melting endotherms, in part due to better mixing.
A number of equations are reported in the literature for predicting theoretical Tg
values for drug-polymer mixtures.27 In the Figure 5.4, the Gordon-Taylor equation was
used to generate the theoretical Tg curve lines, and the experimental values were drawn
from the mean Tg values from the second heating cycle. Typically, the deviation positive
or negative is suggestive of non-ideal mixing behavior between the drug and polymer,
and has often been used to indicate the presence of specific intermolecular interactions.
In addition, the direction and magnitude of deviation in these plots have been used to
determine if homo or hetero interactions are dominating.29 The experimental Tg values
for the samples with less than 50% drug loading could only be generated for binary
KET:PAA system by preparing in situ dispersions inside the DSC pan from the
respective physical mixtures. For systems containing HPMC, both binary and ternary,
this approach could not be adopted, and therefore the experimental curves do not cover
the entire composition range.
In the binary KET:PAA system, a pronounced positive deviation was observed
for the composition range from 10-90% drug loading. It is interesting to observe that the
highest Tg value was noted for the composition 30:70 (105.5 °C), and the largest
deviation between the experimental and theoretical Tg values was seen for the
composition 50:50 (ΔTg = 32.7 °C). Similar positive deviations of experimental Tg
values have been reported for the other drug-polymer systems like indomethacineugragit and loperamide-PAA.30,31 This strong positive deviation shows that the drugpolymer

heterointeractions

are

stronger
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than

drug-drug

or

polymer-polymer

homointeractions. Based on the basic nature of KET and the acidic nature of PAA, there
is a possibility of ionic interaction. For salt formation to take place between acids and
bases, it is generally accepted that the ΔpKa > 2.32 If we compare the ΔpKa between KET
(imidazole ring) and PAA, we get a value of 1.76. This value of ΔpKa does not satisfy
the rule of thumb completely, but the strong positive deviation between the experimental
and theoretical Tg values does point to partial proton transfer taking place in this
scenario. Another potential interaction site is the carbonyl group of KET, which can take
part in hydrogen bonding. It has been reported in literature that a specific interaction like
strong hydrogen bonding can also result in positive deviation for systems like IMCPVA.33 In this case, it is difficult to ascertain using Tg data which interaction is
responsible for this behavior, if we also take hydrogen bonding in account as a
contributing interaction.
In contrast to the KET-PAA binary system, the KET-HPMC binary system
showed a negative deviation between the experimental and theoretical Tg values, as seen
in Figure 5.4. The negative deviation could result from dominating drug-drug and/or
polymer-polymer homo-interactions or to an increase in free volume upon mixing.
Similar to the KET:PAA binary system, the largest deviation in Tg was observed for a
50:50 composition (ΔTg = -28.2 °C). Other systems like curcumin-HPMC and
felodipine-HPMC have also shown similar behavior.34,35
It is interesting to note in the Figure 5.4 that the ternary system of KET-PAAHPMC showed positive deviation between the experimental and theoretical Tg values,
similar to what was seen in the binary KET:PAA system. Again, the 50:50 composition
resulted in the maximum deviation between the experimental and theoretical Tg values
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(ΔTg = 16.0 °C), and more importantly, this value is almost half of what was seen in the
binary KET:PAA system. Additionally, the overall deviation for ternary system was
influenced by the positive deviation and the negative deviations effects of KET:PAA and
KET:HPMC binary systems respectively, resulting in the experimental Tg values to lie in
between the two curves. Although in ternary systems the amount of PAA is reduced to
half on weight basis, a strong positive deviation was observed, especially for
compositions < 80% KET, suggesting a similar interaction pattern existed, and probably
interactions between KET-PAA outweighed the others. It is possible to observe negative
deviations for ternary ASDs. Albadarin et al. observed negative deviation from the
theoretical values in ternary dispersions of itraconazole with Soluplus and HPMCP.36

Figure 5.3. DSC thermograms from second heating cycle for (A) KET:PAA binary
system (B) KET:HPMC binary system and (C) KET:PAA:HPMC ternary system. The
composition of the samples is indicated by drug:polymer ratio on a weight basis: black
for KET, gold for PAA and blue for HPMC.
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Figure 5.4. Mean experimental and theoretical Tg plotted as a function of weight fraction
of KET for KET: PAA dispersions (red color), KET:HPMC dispersions (blue color) and
KET:PAA:HPMC dispersions (green color). The dotted lines represent theoretical Tg
values obtained from the Gordon-Taylor equation.

5.3.3

FTIR Spectroscopy
FTIR spectroscopy was used to study the intermolecular interactions between

KET and each polymer in binary and ternary ASDs. FTIR plots for each system are
depicted in Figure 5.5. The carbonyl region of the KET:PAA in the binary dispersions is
shown in Figure 5.5 A. It has been already shown in the literature that pure PAA can self
associate through hydrogen bonding, and exists in two forms: free and dimer.37
Therefore, the spectrum of pure PAA is characterized by vibrations at 1737 cm -1 and
1695 cm-1, attributed to free (non-hydrogen bonded) and dimer (hydrogen bonded),
respectively. It has been suggested that KET is likely to interact with PAA via ionic
interactions.17 In the present study, this is supported by the appearance of one new
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specific peak at 1544 cm-1, assigned to asymmetric stretching vibration of the carboxylate
group. This new peak becomes more pronounced in samples with greater than or equal to
30% PAA. The formation of the carboxylate ion should also reveal a peak around 1400
cm-1 arising from symmetric stretching vibration of the carboxylate group. This peak was
hard to discern in the spectra due to strong absorption peaks of both KET and PAA. This
is in good agreement with the spectrum of the sodium salt of PAA, which shows two
prominent peaks corresponding to the carboxylate asymmetric stretching at 1549 cm-1
and carboxylate symmetric stretching at 1399 cm-1 (Figure 5.6). Nie et al. have reported
similar results for carboxylate group formation resulting from ionic interaction between
HPMCP and clofazimine.38 Additional evidence for proton transfer can be found in the
region of 2200-3400 cm-1 (Figure 5.5 B). Pure PAA displays a characteristic broad
absorption band at 3040 cm-1 for O-H stretching. A broad shoulder peak around 2530 cm1

appeared in KET:PAA dispersions samples assigned to +N-H stretch formed upon the

protonation of the imidazole group in KET. Furthermore, a hypsochromic shift of dimer
peak of PAA from 1695 cm-1 to 1716 cm-1 was observed in the dispersions indicating
disruption of dimers giving rise to new fraction of free carboxylic acid.
Another interesting finding can be seen in the 1300-1800 cm-1 region (Figure 5.5
A). The amorphous KET showed C=O stretching band at 1640 cm-1. In the presence of
PAA, a shoulder around 1607 cm-1 appeared in the dispersion samples with greater than
or equal to 20% PAA. The intensity of this extra vibration band at 1607 cm-1 increased
with increase in polymer loading. This phenomenon may be an indication of presence of
a new species of KET carbonyl group. Generally, hydrogen bonding results in a shift to
lower wave numbers. This shift to lower wavenumbers from 1640 cm-1 to 1607 cm-1 is
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possibly pointing to the formation of a hydrogen bond, where the carbonyl group of KET
can act as an acceptor and the carboxylic acid group of PAA as a donor. No changes
could be seen in the O-H stretching region of PAA due to overlapping bands. At this
stage, it is logical to hypothesize that the hydrogen bonding could also be a possible
mode of interaction between KET and PAA and more evidence is needed to support this
hypothesis.
In the case of KET: HPMC binary dispersions, no evidence of any interaction
could be derived from FTIR spectra. As shown in the Figure 5.5 C, HPMC caused no
change in the peak corresponding to the carbonyl group of KET in the region of 15501800 cm-1. Additionally, the O-H stretch region in KET:HPMC samples was difficult to
discern due to the presence of multiple overlapping absorption bands (Figure 5.5 D).
Basically, the FTIR spectra of this binary system were linear addition of the pure
amorphous components weighted by each component amount. This observation is
consistent with the findings from Chen et al.18 The authors pointed out that KET is poorly
miscible with HPMC based on the weak Flory-Huggins interaction parameter (positive χ
value), which collectively indicate the absence of any specific interactions between KET
and HPMC.
The results for FTIR spectra of ternary ASDs of KET:PAA:HPMC are shown in
Figure 5.5 (plots E and F). The ternary ASDs retain spectral features from binary
KET:PAA ASDs except for some minor differences. The dimer peak of PAA shifted to
higher wavenumbers similar to binary KET:PAA ASDs. The carboxylate peak around
1544 cm-1 became less intense in comparison to KET:PAA samples likely because of
less amount of PAA present in ternary samples. It is noteworthy to mention that the peak
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intensity of hydrogen bonded carbonyl group of KET (1607 cm-1) decreased in the
ternary ASDs. Likewise, the

+

N-H stretch peak around 2530 cm-1 became less

pronounced for ternary ASDs. In the case of ternary dispersions, the possibility of two
polymers interacting with each other needs to be taken into the account. In order to
explore this scenario, polymer blends with different weight ratios of PAA and HPMC
were studied via FTIR. From the Figure 5.7, it is clearly evident that in the presence of
HPMC there is loss of PAA dimers. At 80% HPMC weight ratio, the dimer peak
intensity is drastically reduced. The disruption of PAA dimer fraction could be a result of
intermolecular interactions between HPMC and PAA or simply due to a dilution effect.
If these two species were to interact on a molecular level via hydrogen bonding, a shift to
a lower wavenumbers is anticipated. The FTIR spectra of these polymer blends do not
seem to suggest such an occurrence. In fact, the dimer peak of PAA (1695 cm-1) moved
to higher wavenumbers as the weight fraction of HPMC is increased. For polymer blends
it is likely that PAA and HPMC are not involved in strong interactions, and therefore in
ternary ASDs there are no other competing interaction present. The interaction pattern in
the ternary ASDs seems to suggest that interaction between KET and PAA is still
favored in the presence of HPMC.
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Figure 5.5. FTIR spectra of pure KET, pure PAA and dispersions showing the carbonyl
stretching region and the single bond region for KET:PAA binary system (plots A and
B), KET:HPMC binary system (plots C and D) and KET:PAA:HPMC ternary system
(plots E and F).
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Figure 5.6. FTIR spectrum of PAA and its sodium salt. The peaks ~ 1549 cm-1 and 1399
cm-1 found in sodium salt of PAA are attributed to asymmetric and symmetric stretching
vibration of the carboxylate group respectively.

Figure 5.7. Comparison of FTIR spectra of PAA, HPMC and their spray dried blends. In
presence of HPMC, the intensity of dimer peak (~1695 cm-1) decreases and moves to
higher wavenumbers as the weight fraction of HPMC increases. Spectrum of 50:50
physical mixture of PAA and HPMC is shown as a reference.
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5.3.4
5.3.4.1

Solid-state NMR spectroscopy
13C

CP/MAS Experimental Results

In recent years, SSNMR has been used as a part of analysis for ASDs for its
unique capability to provide atomic level information on intermolecular interactions and
phase homogeneity.39-41 In order to understand holistically the system under study and to
complement routine analysis techniques, SSNMR experiments utilizing CP/MAS and
spin diffusion were included. Figure 5.8 shows 13C SSNMR spectra of the raw materials.
The spectrum of crystalline KET consisted of sharp resonances typical of crystalline
materials. The peaks were assigned according to the numbering scheme used in the
structure. There is one molecule in each asymmetric unit in the crystal structure based on
one peak for each carbon atom found in the spectrum. In contrast, amorphous KET
displayed broader peaks suggestive of a disordered state. The carbonyl carbon centered
around 169 ppm is of interest to probe any possible interactions with polymers for
hydrogen bonding. In addition, other potential sites of interest are the carbon signals in
the imidazole ring, which appear in the aromatic region (110-150 ppm), to investigate
any ionic interactions. The polymers exhibited amorphous nature as confirmed by
relatively broad signals in Figure 5.8. Pure HPMC does not have any carbonyl signal. It is
useful to note that the carbonyl region of PAA consisted of two peaks; one main peak of
182.6 ppm and the shoulder peak at 177.2 ppm. These two peaks corresponded to dimer
and free fractions. Upon deconvolution of the region, the respective contribution of the
peaks in terms of percentage was quantified. It was estimated that dimer and free
fractions were 44% and 56% respectively.
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It is important of compare the molar ratio of donor to acceptor groups with respect
to acidic and basic groups in both binary KET:PAA and ternary KET:PAA:HPMC
systems for the drug loadings under study. The molecular weights of KET (531.43 g/mol)
and monomer unit of PAA (72.06 g/mol) were used in Figure 5.9. For the composition
range between 50-80% drug loadings, the ratio of donor/acceptor functionalities
exceeded 1. Also, the theoretical composition of 1:1 molar ratio was calculated to be
88.11% KET on weight basis. In comparison to binary system, the molar ratios for
ternary system were half in values for each composition, considering PAA amount
reduced to half and there were no acidic groups in HPMC. The 78.71% weight fraction of
KET corresponded to 1:1 molar stoichiometry of KET:PAA in ternary compositions.
Thus, in theory below 88.11% and 78.71% weight of KET all imidazole groups should be
protonated in binary and ternary ASDs respectively, if there is no steric hindrance.
13

C CPMAS spectra of the binary KET-PAA dispersions at various drug loadings

are shown in Figure 5.10 A. The spectra displayed broader Gaussian resonances, which
confirmed their amorphous character. No significant changes were observed in the
spectra except in the carbonyl region. On analysis of the carbonyl region (160-190 ppm)
some interesting spectral features were noted. Firstly, there is a change in the intensity of
the dimer peak across the range of drug loadings as evident in Figure 5.11 A. This
suggests that there is loss of PAA dimers resulting from an interaction with KET. As
pointed by the FTIR analysis, KET and PAA can form ionic bonds, resulting in the
formation of carboxylate ion. In the carbonyl sub spectra given here, no apparent peaks
were observed which could be attributed to carboxylate ion formation. In order to
confirm the peak position of the carboxylate group, we compared the
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13

C spectrum of

sodium salt of PAA with pure PAA in Figure 5.12. It was shown that carboxylate ion
resonated further downfield around 186 ppm. Since this region in our samples did not
reveal any direct changes, an ionic interaction is likely to be hidden there. Very
interestingly, there is a new peak around 172 ppm, which is more resolved in dispersions
from 50 to 70 % and shifted further upfield as KET loading increased to 90% as seen in
Figure 5.11 A. This peak was found to be absent in the spectrum of 50:50 physical
mixture of amorphous KET and PAA (Figure 5.13). We hypothesize that this peak is due
to the hydrogen bonding of the carbonyl group of KET with PAA. From the molar ratio
calculations we know that there is an excess of PAA present for compositions ≤ 88.11%,
which most likely makes this hydrogen bond a possibility. In addition, this also supports
our earlier hypothesis for the 1607 cm-1 peak in FTIR analysis. It is clear from the
analysis of the carbonyl region that there are possibly two different fractions contributing
to the KET carbonyl intensities: hydrogen-bonded (H-bonded) and non-hydrogen bonded
(Non H-bonded) species.
13

C CP/MAS spectra of the binary KET:HPMC dispersions are displayed in

Figure 5.10 B. No change in chemical shift was observed in any region for the
dispersions samples in comparison with the pure components, and no evidence of any
interaction could be found. There was no spectral inference from HPMC in the carbonyl
region, and the respective peaks of KET and HPMC increased/decreased depending on
the composition. This is also in good agreement with the findings of FTIR analysis.
The possibility of PAA interacting with HPMC was again explored with SSNMR
as presented in Figure 5.14. The differences could be seen in the carbonyl region for
PAA:HPMC spray blends at various weight ratios. In presence of HPMC, the dimer
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fraction goes down and correspondingly the free fraction increases. For the 80:20
HPMC:PAA blend, the dimer fraction decreased to 7 % from 44% in pure PAA while
the free fraction increased form 56% to 93%. No change in the chemical shift was
observed. These changes confirm the absence of any strong interaction between PAA
and HPMC. This is consistent with the FTIR results reported earlier, and confirms that in
the ternary system these two polymers most likely do not interact.
From the spectra of ternary KET:PAA:HPMC dispersions, the followings
spectral features were noted from Figures 5.10 C and 5.11 B. As shown in Figure 5.10 C,
similar trends were seen in ternary samples as with the binary KET:PAA system, and
only the carbonyl region revealed some changes. Again, as depicted in Figure 5.11 B, the
peak attributed to hydrogen-bonded KET (~172 ppm) clearly existed and PAA dimer
peak (~182 ppm) intensity decreased with increasing drug load, implying the
disappearance of dimers due to the disruption of self-association of PAA. Meanwhile,
the peak associated with the free fraction of KET (~169 ppm) become more resolved in
spectra with higher drug loads. It was difficult to compare the carbonyl regions of binary
KET:PAA and ternary KET:PAA:HPMC systems in terms of quantification of various
species that existed because of an extensive peak overlap.
In order to understand the carbonyl region of binary KET:PAA and ternary
KET:PAA:HPMC systems, a detailed deconvolution exercise was performed. In the
present study, we fitted the respective sub spectra (160-190 ppm) with five peaks using
an iterative least-square peak fitting method with Gaussian-Lorentzian function (Figure
5.15). The five peaks criteria satisfied the existence of various species in KET and PAA.
The three out of five peaks belonged to PAA carbonyl portion: carboxylate (~186 ppm),
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dimer (~182 ppm) and free (~177 ppm) while the other two constituted the two carbonyl
species of KET: H-bonded (~172 ppm) and non H-bonded (~169 ppm). For the fitting
procedure, the chemical shift and line width were kept locked for all the samples. By
dividing the corresponding areas with the total area and multiplying with 100, we
obtained the respective area percentage of each species. The progression of the area
percentages

from

the

various

species

for

binary

KET:PAA

and

ternary

KET:PAA:HPPMC samples as the function of KET weight % is illustrated Figures 5.16.
We will first focus on the changes observed for PAA species for the both systems. It is
clear from Figure 5.16 that the area percentage of the PAA peaks decreased with
increasing drug load for both the systems. Also, the area percentages of all PAA peaks in
the binary samples (Plot A) were higher than those in the ternary samples (Plot B) for the
same KET weight percentage. This is expected because there is less PAA present in the
ternary samples. The decrease in the free PAA fraction was more gradual in the binary
system in comparison to the ternary system, where at 90% KET content the area reduced
to more than 50%. Interestingly, the dimer fraction reduced to almost the same
percentage in both the systems at the 90% drug load, even though the binary 50:50
composition had almost twice the amount present. Furthermore, the carboxylate peak did
not contribute significantly to the total area, which is suggestive of the fact that, for these
compositions, hydrogen bonding is the dominating interaction.
On the other hand, some interesting trends were observed for the area percentages
of the KET peaks as shown in Figure 5.16. First, the higher amount of non H-bonded
peak was found in the ternary systems for each composition (Plot B). Second, the area
percentages of non-H bonded peak increased when moving from 50 to 90 % KET content
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for both the systems. For the H-bonded peak in the binary system (Plot A), there was an
increase in the peak area when moving from 50 to 70% KET, reaching the maximum
value, after which it decreased. In contrast, in the ternary samples (Plot B) the area
percentage decreased gradually for compositions up to 80% KET content before an
abrupt reduction at 90% KET composition. The plots in Figure 5.16 compare the area
percentages obtained from the deconvolution procedure, but in order to make comparison
for the interaction patterns between the binary and ternary systems, it is necessary to
further treat the area percentages and normalize them based on the total area of either
groups: KET carbonyl group and PAA carbonyl group.
Figure 5.17 compares the percentages of the various species of PAA and KET for
both binary and ternary systems as computed on the basis of total KET/PAA carbonyl
area. These plots summaries the deconvolution exercise in a clearer fashion and a few
conclusions could be drawn. For total PAA carbonyl fraction (Plot A), contribution of
each species was in the given order: Free>Dimer>Carboxylate for both the systems.
Overall, higher percentages were seen for carboxylate and dimer fractions in the binary
system than in the ternary system. Meanwhile, more free PAA was present in the ternary
system. The ratio of free to dimer fractions increased with KET percent content in both
the systems. On the other hand, for total KET carbonyl fraction (Plot B), the higher
percentage of KET was H-bonded in binary system than in ternary system for each
composition. The ratio of non-H bonded to H-bonded fractions increased for both the
systems with increasing drug content, and a steeper increase was seen for the ternary
system. In summary, it can be concluded that the binary samples had more ionic and
hydrogen bonding interactions vs. ternary samples. Nevertheless, the ternary samples still
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had a similar interaction pattern with only half the amount of PAA present. This analysis
is also consistent with the results seen in the FTIR section. The low intensity of
carboxylate peak in the FTIR spectra could now be attributed to the less amount being
present. In addition, the peak attributed to H-bonded carbonyl of KET was more
pronounced for samples with lower drug loads, which is due to a higher fraction of KET
carbonyl being H-bonded for those compositions. We are not aware of any similar studies
being conduced earlier where comparison could be established between the molecular
interaction pattern for binary and ternary ASDs.

Figure 5.8. Comparison of

13

C CP/MAS spectra of (A) crystalline KET (B) amorphous

KET (C) PAA and (D) HPMC.
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Figure 5.9. Donor to acceptor molar ratio calculated for binary KET:PAA and ternary
KET:PAA:HPMC as a function of weight percent of KET. The cross point on the curve
represent the theoretical 1:1 molar ratio in each case.

Figure 5.10. Comparison of 13C CP/MAS spectra of (A) crystalline KET (B) amorphous
KET (C) PAA and (D) HPMC.
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Figure 5.11.

13

C CP/MAS sub spectra in the carbonyl region (160-190 ppm) for (A)

KET:PAA binary dispersions and (B) KET:PAA:HPMC ternary dispersions. The shaded
box shows how peak around 172 ppm shifts upfield with increase in drug loading.

Figure 5.12.

13

CP/MAS SSNMR spectra of PAA and sodium salt of PAA. The main

peak in the carbonyl region of sodium salt resonated around ~186 ppm.

161

Figure 5.13.

13

CP/MAS spectra of 50:50 KET:PAA binary dispersion (red) and 50:50

KET:PAA physical mixture (purple). The shoulder peak around 172 ppm is visible in
dispersion sample but absent in physical mixture. Spectra of PAA and amorphous KET is
included as a reference.
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Figure 5.14.

13

CP/MAS spectra of spray dried blends of PAA and HPMC at various

ratios.

Figure 5.15. Deconvolution of the carbonyl region of (A) binary KET:PAA samples and
(B) ternary KET:PAA:HPMC samples. The fitted peaks are shown in blue; the sum of the
fit is shown in yellow; the residual is shown in red.
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Figure 5.16. Plots of % peak area for various species as a function of KET weight %
obtained from deconvolution of the carbonyl region from SSNMR spectra for (A)
KET:PAA binary system and (B) KET:PAA:HPMC ternary system. The black and gold
curves belong to KET and PAA species respectively.
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Figure 5.17. Plots depicting comparison of various species in binary and ternary systems
calculated for total (A) PAA carbonyl fraction and (B) KET carbonyl fraction as a
function of KET weight%.
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5.3.4.2

15N

15

CP/MAS Spectra Analysis

N SSNMR experiments were performed in order to further understand the acid-

base interactions between KET and PAA.

15

N is known to have both a very low

magnetogyric ratio and natural abundance, which makes it very less sensitive and
therefore time consuming to analyze. Another challenge that comes with

15

N spectra of

amorphous materials is the presence of broader resonances, which makes detection more
complicated, and this becomes more aggravated in the presence of excipients, which can
further reduce the signal intensity due to dilution. However, even with these challenges,
15

N data collected in our study did reveal some important features regarding the local

nitrogen environment of KET. The 15N spectra of samples are compared in Figure 5.18.
Given the time it took to acquire each spectrum (~3-4 days), only one composition close
to the 1:1 molar ratio was selected (80:20 composition on weight basis for both the
systems). In the spectrum of amorphous KET, four resonances could be detected. The
peak at 259 ppm was attributed to the imidazole N34 nitrogen in KET. In the dispersion
samples, no variation in chemical shifts of other resonances was observed except for
nitrogen N34. The nitrogen N34 peak shifted upfield ~16 ppm and ~ 19 ppm in binary
and ternary samples, respectively, and this change in chemical shift is suggestive of
proton transfer or salt formation. Similar results have been reported by Lubach et al. for
indomethacin and eudragit system, where ~16 ppm shift relative to polymer was noted
for a 70% dispersion sample.42 In another study, similar change in chemical shift of
amorphous lapatinib was observed when formulated with HPMCP, resulting from
tionization of drug.43 This exercise supports the results obtained from FTIR and
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13

C

SSNMR experiments and further provides evidence for the presence of ionic interaction
between KET and PAA.
5.3.4.3 Investigation of Phase Homogeneity by SSNMR
In order to further understand the homogeneity of dispersions at a nanometric
level, 13C-detected proton relaxation experiments were performed. Two different kinds of
proton relaxation measurements were included: spin-lattice relaxation time in the
laboratory frame (1H T1), and in the rotating frame (1H T1ρ). The relaxation parameter 1H
T1 studies homogeneity on larger domain sizes than 1H T1ρ, since for solids 1H T1 >> 1H
T1ρ. Typically, for an intimately-mixed system, identical relaxation behavior is seen for
individual components due to spin diffusion. If not, different relaxation values are seen
for each component. A common 1H T1 value signifies mixing to a scale of about 20-50
nm, whereas a common 1H T1ρ value denotes mixing to a scale of about 2-5 nm. For
reference, the proton relaxation times for the individual components are given in Table
5.1. The relaxation times for the KET:PAA binary system are shown in Figure 5.19
(plots A and D). Each composition showed a single relaxation 1H T1 and T1ρ value within
the error of measurement, suggesting that dispersions are homogenous to a calculated
domain size of <2 nm. The plots of relaxation times for KET:HPMC binary system are
shown in Figure 5.19 (plots B and E). It can be found that near identical relaxation
values are obtained for 1H T1 and T1ρ for composition up to 80% drug load, indicating
phase homogeneity on a scale less than 3 nm. Whereas sample with 90% drug started to
show signs of nano heterogeneity as confirmed by slight differences seen for 1H T1 and
T1ρ relaxation times, with an estimated domain size of > 40 nm. The relaxation times for
ternary KET:PAA:HPMC system are shown in Figure 5.19 (plots C and F). A similar
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relaxation behavior was observed in the case of 1H T1 and T1ρ for all three components
up to 80% drug load, but some phase heterogeneity detected at 90% drug load with PAA.
Therefore, for ternary samples, a homogeneous domain size of < 3 nm and > 40 nm was
estimated for samples up to 80% drug load and 90% drug load respectively. To
summarize these results, no drastic differences were observed between the ternary and
binary systems in terms of phase homogeneity. In addition, the results provide further
insight into molecular level mixing on a smaller scale of resolution than DSC.

Figure 5.18. 15N CPMAS SSNMR spectra of (A) amorphous KET, (B) 80:20 KET:PAA
binary dispersion and (C) 80:10:10 KET:PAA:HPMC ternary dispersion.
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Figure 5.19. Comparison of 1HT1 (plots A, C, E) and 1HT1ρ (plots B, D and F) for drug
and polymer(s) components. The relaxation times for KET, PAA, HPMC are shown in
black, orange and blue bars respectively. Plots A, C and E belong to 1HT1 relaxation
times for binary KET:PAA system, binary KET:HPMC system and ternary
KET:PAA:HPMC system respectively. Plots B, D and F belong to 1HT1ρ relaxation times
for binary KET:PAA system, binary KET:HPMC system and ternary KET:PAA:HPMC
system respectively.

Table 5.1. Proton relaxation times of as received and amorphous KET along with
polymers PAA and HPMC.
Ketoconazole
Proton
Relaxation
Time

Polymers

As received

Amorphous

PAA

HPMC

T1 (s)

13.88±0.11

5.32±0.24

1.45±0.04

1.35±0.02

T1ρ (ms)

52.71±0.76

4.30±0.07

8.58±0.07

12.53±0.10
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5.3.5

Physical Stability
Physical stability of the 70:30 composition from each system was evaluated at

two different conditions, RT/94% RH and 40 °C/75% RH for up to six months. PXRD
was used to determine the point of initial crystallization. PXRD patterns of the binary and
ternary ASDs stored at RT/94% RH are shown in Figure 5.20 (plots A, B and C) for a
period of 6 months. The binary system with HPMC crystallized the fastest, displaying
signs of crystallization at the 1 week time point. In contrast, the binary system with PAA
remained physically stable at RT/94% RH over a period of 6 months with no signs of
crystallization. However, the composition of ternary system was shown to perform
robustly at these conditions for up to 2 months, when it started to show early signs of
crystallization, and crystallized thereafter.
The plots of PXRD data for binary and ternary ASDs at 40 °C/75% RH are
illustrated in Figure 5.20 (plots D, E and F). At 40 °C/75% RH, the binary dispersion
with HPMC again crystallized the fastest with crystallization being detected from 1 week
onwards. Very interestingly, the binary dispersion with PAA and the ternary dispersion
retained their amorphous state throughout the period of 6 months, with no diffraction
peaks being visible at this condition. This finding suggested that replacing 50% of
HPMC with PAA in the binary composition could significantly improve the physical
stability.
From the stability analysis, it was revealed that HPMC did not alone inhibit
crystallization at both conditions. This could be explained by lack of any specific
interactions within the system, which made this binary system the most susceptible to
crystallization. Also, we found that HPMC was not as effective as PAA in increasing the
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Tg of the ASDs, which also contributed towards poor stability of this binary system at
both conditions. As compared with the HPMC binary system, the PAA binary system did
outperform in terms of rendering the system physically stable at both conditions. This
behavior of PAA is consistent with the ability of PAA to form stronger interactions with
KET and higher enhancement in the Tg. Even though PAA is more hygroscopic than
HPMC, that did not result in crystallization. Similarly, Weuts et al. found that PAA
could maintain loperamide in the amorphous state and give a stable dissolution profile at
different storage conditions.31 In the case of ternary dispersions samples, adding HPMC
did not disrupt KET:PAA interactions drastically nor cause any significant reduction in
Tg as revealed from the DSC study. Our detailed SSNMR comparison of binary PAA
system and ternary system did reveal that there are some differences in how these two
systems interact on a molecular level. It is clear that the 70:30 ternary dispersion had less
ionic and H-bonding interactions than the counterpart binary system, and this explains
the somewhat poor performance, particularly at RT/94% RH. Otherwise, those
disparities still translated to better physical stability in comparison with binary HPMC
system.
Our results are very encouraging in a way that they provide support for the use of
binary polymer combinations to optimize the performance of ASDs. We have now shown
using HPMC alone as a matrix could result in poor physical stability but using a binary
combination of PAA and HPMC could help achieve a desired level of physical stability.
From dissolution point of view, we have seen from reports in literature that by
incorporating a cellulosic polymer in the system could help prolong supersaturation. 44
Hence, this combination of PAA and HPMC could potentially give a balanced dissolution
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profile with better physical stability. This aspect is something that we are currently
exploring. We also have to keep in mind that the approach of combining polymers might
not always works as shown by Meng et al.45 The authors reported that the ternary
dispersion of itraconazole with carbopol and povidone demonstrated poor physical
stability and drug release behavior when compared to individual polymer based binary
dispersions. Nonetheless, ternary ASDs require a detailed solid-state characterization
from a molecular perspective to select polymer combinations rationally in order to
optimize the overall performance.

Figure 5.20. PXRD patterns of stability binary and ternary dispersions for (A) KET:PAA
(B) KET:HPMC and (C) KET:PAA:HPMC stored at RT/94% RH. The plots of stability
samples stored at 40 °C/75% RH are shown in (D) KET:PAA (E) KET:HPMC and (F)
KET:PAA:HPMC. Crystalline KET is included as a reference.
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5.4

Conclusions
In current study, we have evaluated the molecular interaction patterns in binary

and ternary ASDs of KET using various solid-state characterization techniques. From
DSC analysis, a large positive deviation was observed for KET:PAA binary and
KET:PAA:HPMC ternary systems, whereas KET:HPMC binary system showed negative
deviation. Our spectroscopic data from FTIR and

13

C SSNMR showed that PAA

interacted with KET via ionic and hydrogen bonding interactions both in binary and
ternary ASDs. Moreover, spectral evidence can be found for lack of any specific
interactions between KET and HPMC. The results from

15

N SSNMR analysis further

provided evidence for an ionic interaction between KET and PAA. Through a detailed
13

C SSNMR deconvolution study, it was established that the binary KET:PAA system

had a higher prevalence of ionic and hydrogen bonds than the ternary KET:PAA:HPMC
system. This serves as one successful example of establishing a comparison between the
binary and ternary ASDs from a molecular perspective. ASDs were found to be
homogenous on a nanometric level using proton relaxation measurements for both the
binary and ternary systems. A stronger interaction in binary KET:PAA and ternary
KET:PAA:HPMC systems translated to better stability at different storage conditions. In
summary, this study also established a proof of concept for the approach of combining a
second interacting polymer to a non-interacting drug-polymer matrix to achieve better
physical stability. We believe our results are valuable contribution to the growing field of
ternary ASDs, and provide a better understanding of how to design ternary ASDs with
optimum performance.
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CHAPTER 6. IMPACT OF HPMCAS GRADE ON PHASE BEHAVIOR OF ITRACONAZOLE
SOLID DISPERSIONS: EFFECT OF PREPARATION METHOD
6.1

Introduction
In this chapter, we will discuss the role of different grades of hydroxypropyl

methylcellulose acetate succinate (HPMCAS) on the phase behavior of itraconazole
(ITZ) dispersions. In recent years, HPMCAS has been identified as one of the most
effective cellulose based polymers especially for manufacturing spray dried dispersions
(SDDs).1,2 HPMCAS has some unique characteristics that makes it amenable for spray
drying process.3 They are listed below:
(1) It possesses a high Tg in its unionized state. The high Tg reduces the drug mobility
and results in excellent physical stability of HPMCAS based dispersions.
(2) It has good solubility in volatile organic solvents like acetone and methanol,
thereby permitting economical and controllable processing for manufacturing
SDDs.
(3) At any pH above 5, the polymer becomes at least partially ionized, which causes
the charge to develop and minimizes the formation of large polymer aggregates
and stabilizes the drug-polymer colloids.
(4) Its amphiphilic nature permits poorly water-soluble drugs to interact with the
hydrophobic regions while the hydrophilic region allows these structures to
remain as stable colloids in aqueous medium.
Commercially, HPMCAS is available in three grades, designated as –L, -M, and
–H as listed in Table 6.1. These grades have different percentages of substituents:
methoxy, hydroxypropoxyl, acetate and succinate. Spray drying is a conventional
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method for the preparation of amorphous solid dispersions, but from a practical
standpoint, it is best to have techniques that can be used to predict the properties of the
spray-dried dispersion prior to the actual spray drying process.4 Recently, cast films have
been explored to anticipate the feasibility of samples prepared using methods such as
spray drying and hot melt extrusion.5,6 For instance, Durante et al. employed a predictive
model to estimate the miscibility of ITZ with different polymers for cast films and
SDDs.7 In this study, the authors could rank order the polymers (Eudragit
EPO<<PVP/VA< HPMCAS-MG) in terms of miscibility and their results reflected the
same trends between films and SDDs. In this study, the utility of films have been
investigated for a model system consisting of ITZ and different grades of HPMCAS in
order to anticipate the viability of large-scale processes such as spray drying. This study
was a collaborative effort between the Munson group and Prof. Polli’s group at
University of Maryland. The film and spray dried samples were prepared at University of
Maryland, whereas detailed solid-state characterization was performed at University of
Kentucky, with a special focus on SSNMR spectroscopy.
The first objective of this chapter was to assess the impact of different grades of
HPMCAS on the phase behavior of ITZ dispersions. Secondly, the role of preparation
method on the phase mixing of the drug with polymer was also evaluated. In addition,
long-term accelerated stability studies (40 °C/75 % RH) were conducted to evaluate the
physical stability of film and spray dried samples. Only the results gathered at University
of Kentucky are presented here. Chemical structures are shown in Figure 6.1.
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6.2
6.2.1

Experimental
Preparation Method
Preparation of Amorphous Itraconazole. Amorphous ITZ was prepared by in

situ by melt quenching inside the spinning NMR rotor. Sample was packed into 7.5 mm
zirconia rotors with Teflon or Kel-F end caps (Revolution NMR, LLC., Fort Collins,
CO). The rotor was heated in the NMR probe equipped with a variable-temperature
accessory stack (Varian, Palo Alto, CA) at 175 ˚C for approximately 10 min while
spinning at 4 kHz. The rotor was then rapidly cooled to room temperature to generate
amorphous ITZ.
Preparation of film samples. HPMCAS films were cast by dissolving each of
the three grades of HPMCAS in a 2:1 (w/w) mixture of dichloromethane and methanol.
ITZ was then added to the solutions to constitute 10, 20 and 30% (w/w) of the total solid
content in the solution. The total solid concentration in the final solutions was kept at
10% (w/w). Solutions were then poured into round 50 mL aluminum pans (121 mm
diameter x 5 mm height) at 50 g per pan and evaporated for 45 min. The pans were
transferred to a drying oven and dried at 40 °C for over 12 hr. The film samples were
then stored in a desiccating cabinet (RH < 5%) and subsequently milled into flakes by
trituration.
Preparation of Spray dried samples. Spray drying was performed using a
Buchi B-290 spray dryer (Buchi Corporation; New Castle, DE) in the closed-loop mode.
Solutions identical to those used for film casting were pumped into the atomizer at a rate
of 16 g/min. The inlet and outlet temperatures were 100 °C and 56 °C, respectively.
Spray drying process parameters (i.e. inlet temperature, percent solids, pump rate,
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atomizing gas pressure) had been previously examined to yield above methods. The
spray dried powder (i.e. SDDs) were collected and dried for an additional 12 hr at 40 °C
and stored in a desiccating cabinet (RH < 5%).
6.2.2

Solid-State NMR Spectroscopy
13

C SSNMR spectra were acquired using a Tecmag Redstone spectrometer

(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or KelF end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total
sideband suppression (TOSS)8 and SPINAL649 decoupling. The 1H 90˚ pulse width was
set to 4.5 μs and contact time of 1.5 ms was used in all the measurements. The pulse
delay for 1D experiments was 4 s and a total of 4096 scans were collected. The

13

C

chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which
was set to 18.84 ppm.10
The maximum peak intensity for the chemical shift regions selective to ITZ and
HPMCAS resonances were used to obtain relaxation times (details in Results and
Discussion section). The relaxation times were detected via 13C nucleus, which facilitates
identification of regions for respective components. Proton spin-lattice relaxation time in
the laboratory frame (1H T1) were measured using a

13

C-detected saturation recovery

pulse sequence with TOSS. Relaxation times were obtained by fitting intensity-recovery
time data by the following equation:
𝑀(𝑡) = 𝑀0 (1 − 𝑒

177

−

𝑡
𝑇1 )

(6.1)

where M(t) is the peak intensity at delay time t, M0 is an amplitude parameter from the
fit, and T1 is the obtained spin-lattice relaxation time. Proton relaxation times in the
rotating frame (1H T1ρ) were measured by varying the spin lock duration time after a 90˚
pulse. The T1ρ decay times were obtained by analyzing the integrated carbon signal
intensity exponentially according to the following equation:
𝑀(𝑡) = 𝑀0 𝑒

−

𝑡
𝑇1𝜌

(6.2)

where M(t) is the peak intensity and t is the spin-lock duration time. M0 is an amplitude
parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the rotating
frame. All data fitting was done using GraphPad Prism (GraphPad Software, Inc., La
Jolla, CA).
6.2.3

Powder X-ray Diffraction
PXRD patterns were collected on the Rigaku Miniflex 600 benchtop

diffractometer (Rigaku Corporation, Tokyo, Japan), with Cu Kα radiation (40 kV x 15
mA). The experiments were conducted at room temperature, between 2° to 50° 2θ at a
scan speed of 2.0 °/min and a step size of 0.02° 2θ under continuous mode.
6.2.4

Vapor Sorption
Moisture sorption isotherms of pure components and dispersions were measured

by an automated water sorption analyser (Q5000SA, TA instruments, New Castle, DE).
The neat samples were initially dried at 0% relative humidity (RH) at 25 °C for 180 min
with equilibrium criterion of < 0.001% w/w change for 15 min. The samples were then
exposed to different RH conditions from 10 to 90% at 25 °C with 10% step increase. The
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maximum dwell time of 180 min was used with the same equilibrium criterion. The
dispersion samples were subjected to constant RH of 75% at 40 °C until equilibrated
after initial drying at 0% RH with a dm/dt window of weight change % < 0.001 over 15
min.

6.3
6.3.1

Results and Discussion
13C

CP/MAS Solid-state NMR Spectra

The

13

C CP/MAS spectra of as-received ITZ and amorphous ITZ are shown in

Figure 6.2. The crystalline ITZ could be easily distinguished from amorphous ITZ based
on sharp and narrow resonances seen in the

13

C spectra. The amorphous form is

characterized by broader signals characteristic of disordered state. The peak at 152 ppm
corresponds to the carbonyl group (C=O) in the amorphous ITZ. The

13

C CP/MAS

spectra for the polymers are displayed in Figure 6.2. All the three grades of HPMCAS
were found to be amorphous. The HPMCAS grades were devoid of aromatic resonances
as shown in Figure 6.2. It is interesting to note the differences in peak shapes for
different grades of HPMCAS in the carbonyl region (160-180 ppm). Upon deconvolution
of the region, the area could be resolved into two peaks (~173 ppm and ~170 ppm).
These two peaks correspond to succinate and acetate ester functionalities, respectively,
although it should be noted that the succinate moiety has an equal contribution to
succinate and acetate peak, due to its partial ester structure. The analysis also yielded
respective percentages of these moieties as displayed in Figure 6.3. L grade has the
highest succinate to acetate ratio among three grades, which explains why the carbonyl
peak is apparently the most downfield in L grade. The other aliphatic resonances were
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measured to be similar in ppm in all the three grades, although the peak at ~28 ppm is
due to the succinate component, and its intensity changes with succinate concentration.
The dispersions samples were prepared via two approaches: rotary evaporation
and spray drying. The samples obtained from rotary evaporation were termed “film”
samples. The 13C CP/MAS spectra of film samples formulated with HPMCAS grades are
shown in Figure 6.4. For the spectra of dispersions with HPMCAS, samples up to 20%
drug loading were amorphous in nature whereas the samples with 30% ITZ showed the
presence of some amount of residual crystallinity. The degree of crystallinity could be
quantified for different grades of HPMCAS. The region between 90-115 ppm was
deconvoluted and the peak at 109 ppm was attributed to the crystalline ITZ fraction. The
degree of crystallinity was calculated using following equation:
∅𝐼𝑇𝑍 = 100 ∗

𝑃109
𝑃′109

(6.3)

where P109 is the peak intensity for 109 ppm signal in the sample and P’109 is the peak
intensity of 109 ppm signal of pure crystalline ITZ. The degree of crystallinity was rank
ordered as H>M>L (Table 6.3; initial condition). Thus, the highest crystallinity was
associated with H grade. And, the same trend was seen from DSC analysis (data not
shown). In the case of the spray-dried samples, it was evident from Figure 6.5 that
samples were completely amorphous for all the drug loadings. The spray-dried
dispersions were better than the film samples in this regard, as they were devoid of any
residual crystallinity. The spray drying process is generally regarded as more efficient in
rendering the samples amorphous than the rotary evaporation as it ensures better mixing
of the drug and polymer.
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Three regions between resonances 9-14 ppm, 45-55 ppm and 111-159 ppm were
selective for ITZ (shown in pink shaded boxes in Figures 6.4 and 6.5), while two regions
between peaks 80-90 ppm and 160-180 ppm served as non-overlapping areas for
HPMCAS (shown in green shaded boxes in Figures 6.4 and 6.5). These selective regions
were used in proton relaxation measurements to follow the relaxation behavior of ITZ
and HPMCAS in the samples (vide infra). In addition, any variation in chemical shift for
any peak in the spectra was also noted. HPMCAS has proton donors and acceptors in its
structure whereas ITZ has proton acceptors (Figure 6.1). Therefore, there is a likelihood
of hydrogen bond formation between the respective donors and acceptor functionalities
in the drug and polymer. It has been observed that any change in chemical shifts could
potentially result from H-bonding.11 The carbonyl region of HPMCAS did not show any
significant changes for both film and spray dried samples. In addition, any variation in
the carbonyl peak (~152 ppm) of ITZ was difficult to detect due to presence of multiple
peaks in the same region. Therefore, no direct evidence of hydrogen bonding or any
specific interaction could be obtained from the 13C CP/MAS spectra.
Table 6.1. Composition of different grades of HPMCAS (wt %).
Substituent

HPMCAS
L Grade

M Grade

H Grade

Methoxyl Content

20-24

21-25

22-26

Hydroxypropoxyl
Content

5-9

5-9

6-10

Acetyl Content

5-9

7-11

10-14

14-18

10-14

4-8

Succinoyl Content
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Figure 6.1. Chemical structures of itraconazole (left) and HPMCAS (right).

Figure 6.2. SSNMR spectra from bottom to top include crystalline ITZ, amorphous ITZ
and HPMCAS grades-H, L and M.

182

Figure 6.3. Deconvolution of the carbonyl region (160-180 ppm) in SSNMR spectra for
HPMCAS grades. The fitting of succinate and acetate peaks is shown in black and blue
respectively; the sum of the species is shown in magenta; the residual difference between
the experimental and fitted peaks is shown in orange.
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A)

B)

C)

Figure 6.4. Stacked

13

C CP/MAS spectra for ITZ film samples formulated with (A)

HPMCAS H grade, (B) HPMCAS L grade and (C) HPMCAS M grade. Green and pink
shaded boxes represent HPMCAS and ITZ specific regions respectively.
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A)

B)

C)

Figure 6.5. Stacked

13

C CP/MAS spectra for ITZ spray dried dispersion samples

formulated with (A) HPMCAS H grade, (B) HPMCAS L grade and (C) HPMCAS M
grade. Green and pink shaded boxes represent HPMCAS and ITZ specific regions
respectively.
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6.3.2

Phase Homogeneity Using Proton Relaxation Measurements
In order to understand phase mixing on a nanometric scale, proton relaxation

measurements were employed, which consisted of measuring spin-lattice relaxation
times in the laboratory frame 1H T1, and in the rotating frame 1H T1ρ. The relaxation
behavior of ITZ and HPMCAS was resolved via

13

C resonances. These parameters can

provide valuable insights regarding the phase mixing between the drug and the polymer
on two different length scales of mixing. The relaxation time constants 1H T1 and 1H T1ρ
are sensitive to motions in MHz range and kHz range, respectively. Because the 1H T1
times are 2-3 orders of magnitude longer than 1H T1ρ times, 1H T1 is averaged out to
larger distances (20-50 nm) than 1H T1ρ (2-5 nm). The relaxation times of pure materials
are shown in Table 6.2. Generally, amorphous materials show shorter 1H T1 and 1H T1ρ
relaxation times in comparison to their crystalline counterparts owing to greater mobility.
In the case of ITZ, the amorphous sample is characterized by shorter 1H T1 time whereas
the opposite behavior is seen for 1H T1ρ. For HPMCAS grades, 1H T1 times were
measured to be less than 2 s. It is interesting to note that 1H T1ρ time was measured
longest for the H grade. Meanwhile, both L and M grade showed almost identical 1H T1ρ
times. Greater differences were observed in 1H T1ρ times between amorphous ITZ and
HPMCAS.
Dispersion samples showed differences in relaxation time of ITZ and HPMCAS,
corresponding to some degree of phase heterogeneity between the drug and the polymer.
For a perfectly homogenous system, drug and polymer would show identical relaxation
times. Therefore, any differences observed in the relaxation behavior of the drug and
polymer would result from phase heterogeneity or non-uniform distribution of drug and
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polymer in the matrix. The plots of 1H T1 differential between ITZ and different grades
of HPMCAS are shown in Figure 6.6 for the film and spray dried samples. It is evident
from the Figure 6.6 (Plot A) that no significant differences were seen up to 20% ITZ
loading, whereas the sample with 30% loading started to show some differences,
resulting in a larger differential value for the film samples. The extent of phase
heterogeneity on 1H T1 scale of mixing could be ranked ordered as H>M>L. However,
for the spray-dried samples no such trend could be seen for any drug loading, and all the
samples were found to be homogenous on 1H T1 scale of mixing (Plot B). The plots of
1

H T1ρ differential between ITZ and different grades of HPMCAS are displayed in Figure

6.7 for film and spray dried samples. On smaller domains (Plot A), the film samples
were clearly phase non homogeneous at 30% drug loading, and same extent of phase
separation was observed (H>M>L). In contrast, the spray dried samples (Plot B) were
completely phase mixed showing no differences in differential values within 95%
confidence intervals.
In summary, the film samples were homogenous up to 20% drug loading,
whereas 30% sample showed signs of phase hetereogeneity on both the domains. In the
case of 30% ITZ sample, the extent of phase heterogeneity was found to be different for
different grades of HPMCAS (L grade being best). This is also supported from the
residual crystallinity analysis. It was shown that better mixing between ITZ and
HPMCAS could be established through spray drying. And, all the three grades exhibited
similar performance for spray dried samples and no phase heterogeneity was seen.

187

6.3.3

Determination of Domain Sizes
Proton relaxation measurements can also be used to estimate the upper limit of

the length scale of mixing because these processes are governed by spin diffusion. The
equation used to obtain semi quantitative information about domain size is given by:
𝐿2 = 6𝐷𝑇𝑖

(6.4)

where D is the spin diffusion coefficient, which depends on the average proton to proton
distance as well as a dipolar interaction. It has a typical value of 10-12 cm2/s.12,13 Ti is the
relaxation time, T1 or T1ρ. Using this approach, the domains sizes were estimated to be <
3 nm for all the samples except 30% ITZ film samples. In the case of 30% ITZ film
samples, domain sizes were estimated be >30 nm, 2-30 nm and >30 nm for H, L and M
grades respectively. These samples were known to show some degree of phase
heterogeneity and hence their larger domain sizes.

Table 6.2. 1H T1 and T1ρ values along with the standard errors associated with fit for ITZ
(as-received and amorphous) and HPMCAS grades measured via 13C resonances.
Proton
Relaxation
Time

Polymers

As received

Amorphous

H Grade

L Grade

M Grade

H T1 (s)

3.34±0.08

1.57±0.02

1.76±0.07

1.93±0.05

1.80±0.04

H T1ρ (ms)

2.88±0.07

3.65±0.05

7.63±0.19

5.99±0.10

5.97±0.25

1
1

Itraconazole
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Figure 6.6. Absolute difference in 1H T1 values between ITZ and HPMCAS grades for
A) film and B) spray dried samples as a function of ITZ weight percent. The error bars
represent the 95% confidence interval associated with the fit. The dashed line signifies
the zero difference line. The green, red and blue diamond symbols represent HPMCAS
H, L and M grades respectively.
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Figure 6.7. Absolute difference in 1H T1ρ values between ITZ and HPMCAS grades for
A) film and B) spray dried samples as a function of ITZ weight percent. The error bars
represent the 95% confidence interval associated with the fit. The dashed line signifies
the zero difference line. The green, red and blue diamond symbols represent HPMCAS
H, L and M grades respectively.
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6.3.4

Physical Stability
The physical stability of amorphous materials is very important because of their

propensity to crystallize. It is therefore common to study the behavior of ASDs at
accelerated stability conditions wherein the role of humidity and elevated temperature is
evaluated. The stability study was carried out for the 30% ITZ loading (film and spray
dried samples) at 40 °C/75% RH in open vials for a period of 6 months, and the samples
were examined via SSNMR and PXRD. PXRD data showed no change in spray-dried
samples over time (Figure 6.8). The spray-dried samples remained amorphous up to 6
months, with no detection of crystallinity for all of the grades of HPMCAS. It is also
noteworthy to point that SSNMR analysis of spray-dried samples revealed the same
trend. No changes were observed in the

13

C CPMAS spectra of the spray-dried samples

(Figure 6.9). The 1H T1 and 1H T1ρ relaxation data indicated that stability spray-dried
samples did not phase separate over time at these conditions, and there was no significant
change in the differential values of the relaxation times (Figure 6.10). In the case of film
stability samples, no further crystallization was observed by qualitative analysis from
PXRD (Figure 6.11). Also, 13C CP/MAS spectra of stability samples did not reveal any
new crystalline peaks except for the previously reported peak at ~109 ppm (Figure 6.12).
In addition, it is surprising to observe that there was reduction in measured apparent
crystallinity over time for these samples as calculated by SSNMR (Table 6.3). This kind
of behavior is counterintuitive, as it is known that moisture can promote phase separation
and/or crystallization in amorphous materials.14 At this point, we can speculate that this
trend can result from changes induced by RH equilibrated samples in SSNMR spectra.
Nonetheless, this needs further investigation to ascertain if this behavior is real or not.
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The relaxation data also suggest no further phase separation took place and the
differential values for both 1H T1 and 1H T1ρ did not change drastically over a period of 6
months (Figure 6.13). Both the systems were found to be robust at these conditions.
From the isothermal moisture sorption experiments, it can be seen that pure
HPMCAS grades did not absorb a significant amount of moisture, and maximum %
weight again was under 10% at the highest RH (Figure 6.14). The polymers could be
rank ordered for hygroscopicity from highest to lowest moisture being L>M>H. H grade
has highest acetate/succinate ratio, which makes it the most hydrophobic in the series. In
addition, amorphous ITZ was very hydrophobic, with less than 2% water absorbed at
90% RH. The moisture uptake by stability samples was under 3% from TGA analysis for
all the time points (data not shown). HPMCAS has a high Tg under dry conditions. The
Tg values of as prepared samples with 30% drug loading were measured to be above 100
°C (data not shown). When exposed to higher RH conditions, there is smaller decrease in
Tg of HPMCAS when compared to typical water-soluble polymers owning to its
hydrophobic nature and therefore less moisture uptake. As a result, the stability samples
still had Tg values well above the storage temperature of 40 °C (data not shown). Overall,
drug mobility remains low, which in part explains why the samples exhibited long-term
kinetic physical stability under standard accelerated stability conditions. Similar results
were observed in a study done by Chakravarty et al.15 Their results pointed out that the
long-term physical stability could be achieved using HPMCAS as the polymeric matrix
for spray dried dispersions.
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6.4

Conclusions
In this study, a detailed SSNMR characterization was conducted on ITZ film and

spray dried samples. SSNMR analysis revealed that spray drying resulted in intimate
mixing between ITZ and HPMCAS. The film samples were found to contain residual
crystallinity at 30% drug load. In addition, the extent of phase heterogeneity was found
to be HPMCAS grade dependent (H>M>L). The stability data suggested that the
components of both sets of dispersions remain phase mixed as studied by proton
relaxation times. Overall, this characterization study is important in understanding the
performance of different grades of HPMCAS and how the method of preparation can
dictate kinetic mixing between the components for rational development of ASDs.
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Figure 6.8. PXRD patterns of stability spray dried samples at 40 °C/75% RH for (A) H
Grade (B) L Grade and (C) M Grade.
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Figure 6.9. Stacked plots for SSNMR spectra of crystalline ITZ, amorphous ITZ and
spray dried stability samples at 40 °C/75 % RH for (A) H grade (B) L grade and (C) M
grade.
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Figure 6.10. Absolute difference in 1H T1 (plots (A-C); green bars) and 1H T1ρ (plots (DE); blue bars) values between ITZ and HPMCAS spray dried stability samples (40 °C/75
% RH) for a period of 6 months. The error bars represent the 95% confidence interval
associated with the fit.

Table 6.3. Comparison of percent crystallinity for different time periods for 30% ITZ
film stability sample (40 °C/75 %RH) as measured by SSNMR.
Time

H Grade

M Grade

L Grade

Initial

22.7

15.4

12.0

3 Months

15.1

11.2

9.2

6 Months

16.0

11.0

7.7

196

Figure 6.11. PXRD patterns of stability film samples at 40 °C/75% RH for (A) H Grade
(B) L Grade and (C) M Grade.
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Figure 6.12. Stacked plots for SSNMR spectra of crystalline ITZ, amorphous ITZ and
film samples at 40 °C/75 % RH for (A) H grade (B) L grade and (C) M grade.

198

Figure 6.13. Absolute difference in 1H T1 (plots (A-C); green bars) and 1H T1ρ (plots (DE); blue bars) values between ITZ and HPMCAS film stability samples (40 °C/75 % RH)
for a period of 6 months. The error bars represent the 95% confidence interval associated
with the fit.

Figure 6.14. Moisture sorption isotherms of ITZ, amorphous ITZ and HPMCAS grades.

199

CHAPTER 7. SUMMARY AND FUTURE DIRECTIONS
7.1

Summary
The central theme of this thesis research revolves around understanding the phase

homogeneity in ASDs. Throughout this thesis work, phase homogeneity and drugpolymer interactions were studied using SSNMR spectroscopy and other analytical
techniques. Various model systems were evaluated to gain molecular level understanding
of the factors controlling phase homogeneity and the physical stability of ASDs. As a
first step in Chapter 1, we provided the literature survey on the classification of ASDs,
the preparation methods, the solid-state characterization techniques, and the factors
affecting physical stability. Chapter 2 was aimed at providing the basic understanding of
SSNMR principles along with its advantages and limitations. Various experimental
features like cross polarization (CP), magic angle spinning (MAS) and high power
proton decoupling were presented. Special attention was given to the applications of
SSNMR spectroscopy in the field of ASDs. The applicability of proton relaxation times
(1H T1 and 1H T1ρ) in evaluating sub nanometric phase homogeneity and their advantages
over thermal analysis were highlighted. In addition, the usefulness of SSNMR for
understanding the type, extent and strength of intermolecular drug-polymer interactions
was discussed.
Chapter 3 presented a case study on the role of hydrogen bonding on the phase
homogeneity of felodipine melt quenched dispersions with three different polymers,
PVP, PVP/VA and PVAc. In the first part of the study, a comparative assessment of
phase homogeneity involving DSC and SSNMR analyses was conducted on the model
systems. In the second part of the study, the strength and extent hydrogen bonding
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interactions were quantified using SSNMR 13C CP/MAS spectra. Using a new approach,
it was possible to quantify various species present in amorphous felodipine and its
dispersions without the need of doing 15N SSNMR based experiments. More precisely, in
amorphous felodipine 40% and 60% of molecules were categorized as “dimer” and
“free” respectively. It was shown that polymers capable of forming hydrogen bonding
interactions disrupted the existing drug-drug interactions resulting in drug-polymer
hydrogen bonding interactions. The strength and extent of hydrogen bonding interactions
were rank ordered as PVP>PVP/VA>PVAc. Our results suggested that the phase
homogeneity was governed by the strength and extent of hydrogen bonding between the
drug-polymer. Moreover, it was demonstrated how SSNMR was useful in understanding
and characterizing the presence of nano heterogeneities.
It is crucial to understand the thermodynamic miscibility between the drug and
polymer to formulate a stable ASD system. We therefore thoroughly investigated and
compared the relationship between thermodynamic miscibility and phase homogeneity in
two structurally similar molecules, felodipine and nifedipine in Chapter 4. Soluplus was
selected as a model polymer. The melting point depression approach was used to
estimate the Flory-Huggins interaction parameter for the two systems understudy. Our
analysis revealed that nifedipine had higher miscibility with Soluplus, when compared to
felodipine. A similar analysis of hydrogen bonding interactions was performed on both
the systems, where tendencies of felodipine and nifedipine to interact with Soluplus were
compared. It was found that nifedipine was more extensively hydrogen bonded to
Soluplus than felodipine, while both the drugs had a similar strength of hydrogen
bonding interaction. Following the insight into the phase homogeneity of both the
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systems, it was shown that nano domains existed within both the systems with felodipine
dispersions slightly more heterogeneous.
Conventionally, ASDs have been formulated as a binary matrix but in recent
years a new class of ASDs have emerged, where generally a second polymer is added to
the formulation. Having the presence of a second polymer necessitates a comprehensive
solid-state characterization in order to study the intermolecular interactions and phase
behavior on a molecular level. With this goal in mind, ketoconazole was selected as a
model drug and hydroxypropyl methyl cellulose (HPMC) and polyacrylic acid (PAA)
were chosen as polymeric carriers. Binary ketoconazole dispersions with HPMC lacked
any specific interactions, whereas binary ketoconazole PAA dispersions and ternary
ketoconazole PAA and HPMC showed spectroscopic evidence for ionic and hydrogen
bonding interactions. The 13C SSNMR deconvolution study established a comparison for
molecular interactions between the binary and ternary dispersions, with the binary
ketoconazole PAA system showing higher prevalence of ionic and hydrogen bonds than
the ternary ketoconazole HPMC PAA system. Moreover, binary and ternary ASDs were
found to be homogenous on a nanometric level, implying the presence of a second
polymer did not impact the phase homogeneity. In addition, a stronger interaction in
binary ketoconazole PAA and ternary ketoconazole HPMC PAA system translated to
better physical stability at different storage conditions. Overall, this study provided a
detailed molecular level characterization of binary and ternary ASDs in order to design
ASDs formulation with optimum performance.
In Chapter 6, the impact of grade of hydroxypropyl methyl cellulose acetate
succinate (HPMCAS) on the phase behavior of itraconazole dispersions was
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investigated. The samples were prepared via different approaches: film casting versus
spray drying. SSNMR analysis revealed substantial differences in the phase behavior of
dispersions prepared by these two methods. For “film” samples, residual crystallinity
was detected at drug loadings of > 20 % and found to be dependent on the HPMCAS
grade, with H grade showing the highest crystallinity. Additionally, it was evident from
the proton relaxation measurements that “film” samples were homogenous up to 20%
itraconazole loading, whereas the sample with 30% itraconazole concentration started to
show the presence of phase heterogeneity and its extent could be rank ordered as
H>M>L. In contrast, the spray dried samples were amorphous and measured to be
homogenous for all the drug loadings. Both “film” and spray dried samples were
observed to be robust at accelerated stability conditions and did not show any further
changes in phase homogeneity, implying that HPMCAS was efficient in decreasing drug
mobility and keeping the drug kinetically stable. It was an important study to elucidate
the phase behavior of different grades of HPMCAS along with the effect of preparation
methods.

7.2

Future Directions
Throughout this dissertation, the proton relaxation measurements have been

employed to study the phase homogeneity of ASDs on different model systems. Though
such measurements have been proven to be quite useful, a detailed understanding and
appreciation of the differences seen for different model compounds and carriers is much
desired. Based on our experience working with different model systems, future studies
should involve studying the various factors, which can potentially influence such
measurements. It is worth giving a thought why do different APIs and polymers have
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such different proton relaxation times? Besides, is it possible to relate the differences
with some molecular properties? The proton relaxation measurements give a good
estimation of upper limit of domain sizes. In Chapter 3, we have seen how domain sizes
vary with the composition and polymer type. It was agreed that the extent of phase
homogeneity is governed on the nature of hydrogen bonding between the drug and
polymer. As a next logical step, it would be interesting to see some sort of correlation
between the domain sizes and the onset of crystallization. Moreover, the impact of
moisture on domain sizes could potentially be explored to predict the relative physical
stability of ASDs. Usually, the domain sizes are reported to indicate the extent of phase
homogeneity. Another relevant question is what is the real physical meaning of
“domains” and how do they impact the overall phase behavior of ASDs. Moreover, the
impact of moisture on domain sizes could potentially be explored to predict the relative
physical stability of ASDs.
Specific interactions like hydrogen bonding have been studied in depth through
13

C CP/MAS experiments in this thesis work. Some model systems showed the variation

in chemical shifts as a response to the changes induced by hydrogen bonding (Chapter 3
and 4), whereas systems involving HPMCAS didn’t directly reveal the presence of
hydrogen bonding as seen in Chapter 7. In order to collect more evidence for specific
interactions, two-dimensional experiments such as 1H-X CP/MAS HETCOR should also
be explored. As a next step for the quantification hydrogen bonding in ASDs systems, it
would be interesting to incorporate models like “Painter Coleman association model”
and compare the SSNMR data to FTIR and Raman spectroscopy. Additionally, as an
extension to the studies done in this thesis work, where compositions ranging from 50 %
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to 90 % w/w drug were studied, it would be helpful to explore the other compositions as
well.
Ternary ASDs are new emerging field in ASDs research, where more scientific
understanding is needed. Interestingly, we were able to present a detailed solid-state
characterization and compared the physical stability of binary and ternary ASDs.
However, the influence of a second polymer on dissolution characteristics needs further
exploration. Moreover, it would also be interesting to develop any correlation between
the phase homogeneity and dissolution characteristics. Finally, the study on ternary
ASDs could be extended on other model drugs and polymer combinations. Along those
lines, studying surfactants as a part of ternary ASDs could possibly open new avenues
for research.
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